









TRANSCRIPTIONAL REGULATION OF THE HUMAN ALPHA 2(1) 
PROCOLLAGEN GENE 
Thesis presented by 
VIRNA DRUCILLE LEANER 
in fu1fi11ment of the requirements for the degree of 




FACULTY OF MEDICINE 
UNIVERSITY OF CAPE TOWN 
September 1997 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 










Certificate of Supervisor I ii
CERTIFICATE OF SUPERVISOR 
In terms of paragraph eight of the "General regulations for the degree of Ph.D.", I, 
as supervisor of the candidate V.D. LEANER, certify that I approve of the 
incorporation into this thesis of material that has already been published or 
submitted for publication. 
Prof. M.I. Parker 
Department of Medical Biochemistry 
D.G. Murray Trust Chair of Cancer Research
Acknowledgements I iii 
ACKNOWLEDGEMENTS 
Thanks to the Almighty 
I wish to express my sincere thanks to the following individuals: 
• Prof M. Iqbal Parker, for excellent supervision, guidance, support and fostering a 
sense of scientific questioning in me. 
• Prof Wieland Gevers, Prof. Mario Ehlers, Prof. Lutz Thilo, Dr Cynthia Sikakana, 
Dept Med. Biochem, UCT, as role models for young scientists in all disciplines. 
• Malcolm Collins, Howard Donninger, Gael Fenhalls and Agatha Masemola for 
willingness to be of assistance at all times and useful and often entertaining discussion. 
• My other colleagues, past and present, E. Dietzsch, J. Davies, E. Joseph, S. Herman, 
'M. Ndlovu, Y. Giyose, H . Karjiker, Y.P. Goldberg, A. Smith, D . Bhoolia, M . Geyp 
and others in the Department of Medical Biochemistry for helpful discussion and for 
creating a stimulating work environment. 
• My family for their support and encouragement throughout the duration of my studies. 
• Zulaiga Rossouw, for friendship, motivation and providing me with opportunities to 
enjoy many an African sunset in the bush. 
• Chrismaur Oppelt, Portia and John Rodgers, for friendship, encouragement and 
sharing in both the good and bad times. 
• Graham Julies for his helpfulness, especially in supplying computer facilities. 
• My friends in Natsoc and Protec, for proving that together we can make a difference. 
• The Medical Research Council, Foundation for Research and Development (FRD), 
Duitsche Akademiese Ausl Dienste (DAAD) and the University of Cape Town for 
scholarships and bursaries in support of this work. 
Contents I iv 
CONTENTS 
Title Page 







1.1 THE COLLAGENS 
1.1.1 Introduction 
1.1.2 The fibrillar collagens - a brief ovetview 
1.2 REGULATION OF TYPE I COLLAGEN GENE EXPRESSION 
1.2.1 Preamble 
1.2.2 Co-ordinate expression of the type I collagen genes 
1.2.3 Type I collagen promoter elements and trans-acting factors 
1.2.3 .1 Transcription factors in co-ordinate expression 
1.2.3.1.1 The CCAAT-binding factor (CBF) 
1.2.3.1.2 Transcription factors IF-1 and IF-2 
1.2.3 .1.3 Transcription factor Sp 1 
1.2.3 .1. 4 Recently identified transcription factors 
1.2.3 .2 Additional DNA elements and trans-acting factors involved in 
constitutive activity of the type I collagen promoter 
1.2.3.3 Response of type I collagen genes to TGF-f3 stimulus 
1.2.4 Cell- and tissue-specific expression of the type I collagen genes 
1.2.4.1 The Alpha 2(1) procollagen gene 
























Contents I v 
1.3 REPRESSION OF THE TYPE I COLLAGEN GENES 
1.3 .1 Mechanisms of achieving repression 
1.3 .1.1 Repression by trans-acting factors 
1.3 .1.2 Repression via DNA methylation 
1.3.2 Events resulting in down-regulation of type I collagen synthesis 
1.3.2.1 Repression by exogenous factors 
1.3 .2.1 Repression by cellular transformation 
1.4 SIGNAL TRANSDUCTION AND COLLAGEN EXPRESSION 
1.4 .1 Effect of signalling pathways on collagen expression 
1.4.2 Effect of intact type I collagen on signal transduction pathways 
CHAPTER 2 ANALYSIS OF COLLAGEN SYNTHESIS IN 
DIFFERENTIATED CELL LINES 
2.1 INTRODUCTION 
2.2 RESULTS 
2.2.1 Analysis of type I collagen synthesis in different cell lines 
2 .2.2 Alpha 2(1) collagen mRNA levels in differentiated cell lines 
2.2.2 .1 Nortem Hybridisation Analysis 
2.2.2.2 Nuclear run-on transcription assays 
2 .2.3 Transcription factor binding to the human a.2(1) procollagen 
promoter 
2.2.4 DNA binding site analysis 
2.2.5 Binding kinetics of complexes I, II and ill 
2.4 DISCUSSION 
CHAPTER 3 SPECIES-SPECIFIC EXPRESSION OF THE a2(1) 
PROCOLLAGEN GENE AND SIGNALLING PATHWAYS 
3.1 INTRODUCTION 
3.2 RESULTS 

























Contents I vi 
3.2.2 Analysis of cross-species promoter-binding activities 62 
3.2.3 Human and rodent promoter activities 69 
3.2.4 Analysis of the human CCAAT-binding protein 70 
3.2.4.1 Competition experiments using known CCAA T 
binding sequences 70 
3.2.4.2 Supershift assays using mouse anti-CBF antibodies 72 
3.2.5 The role of phosphorylation in trans-acting factor binding to the 
a2( 1 )pro collagen promoter 77 
3.2.5.1 Phosphatase treatment of nuclear extracts 79 
3.2.5.2 Inhibition of protein kinases 79 
3.2.5.3 Effect of kinase inhibition on promoter activity and 
mRNAlevels 86 
3.2.5.4 Effect of PMA on a2(1) procollagen gene expression 89 
3.3 DISCUSSION 91 
CHAYfER4 CLONING THE GENES CODING FOR THE a2(1) 
PROCOLLAGEN PROMOTER-BINDING PROTEINS 
4.1 INTRODUCTION 99 
4.2 RESULTS 102 
4.2.1 Selection of probes for screening a Agt 11 expression library 102 
4.2.2 Screening of expression libraries 106 
4.2.2.1 Screening of a heart Agtl 1 expression library 106 
4.2.2.2 Controls for screening with the CME 109 
4.2.3 Detection oflysogens harboring Agtl 1 recombinant phages 111 
4.2.3.1 South-Western Blotting 111 
4.2.3.2 Western Blotting 113 
4.2.3.3 EMSA analysis of the A-2 fusion proteins 116 
4.2.4 Analysis of the A-2 cDNA inserts 118 
4.2.5 Expression of clone A-2 mRNA in different cell lines 124 
4.3 DISCUSSION 126 
CHAPTER 5 CONCLUSION 
5.1 Objectives 
5.2 Significant findings 
5.3 Novel aspects of this investigation 
5. 4 Extended model of trans-acting factor interactions with the -107 to +54 
a2(1) procollagen promoter 
CHAPTER6 MATERIALS AND METHODS 
6.1 CELL CULTURE 
6.1.1 Maintenance of cells in culture 
6.1.2 Treatment of cells with the kinase inhibitors; staurosporin or 
genistein and the phosphatase inhibitor; okadaic acid 
6.1.3 Collagen synthesis 









6.2 PREPARATION AND TRANSFORMATION OF COMPETENT E. Coli 
CELLS 146 
6.2.1 Preparation of competent cells 146 
6.2.2 Transformation of competent cells 147 
6.2.3 Preparation of plasmid DNA using a rapid plasmid extraction 
method 147 
6.2.4 Blunt end ligation 148 
6.2.5 In gel ligation 148 
6.3 PREPARATION OF DNA FRAGMENTS FOR EMSA 149 
6.3 .1 Preparation of plasmid DNA 149 
6.3.2 Isolation of DNA fragments 149 
6.3.2.1 Crush soak method 150 
6.3.2.2 QIAEX extraction method 150 
6.4 DNA-PROTEIN INTERACTIONS 150 
6.4.1 Preparation of nuclear proteins 150 
6.4.2 End-labelling of DNA 151 





6.5 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS 
6.5.1 Preparation gels and electrophoresis of gels 
6.5.2 Transfer of proteins to nitrocellulose membranses 
6.6 RNA EXTRACTION AND NORTHERN BLOT ANALYSIS 
6.6.1 Preparation ofRNA 
6.6.2 Northern blot analysis 
6.6.2.1 Electrophoresis of RNA on formaldehyde gels 
6.6.2.2 Random prime labelling of DNA probes 
6.6.2.3 Hybridisation of probes to Northern blots 
6. 7 NUCLEAR RUN-ON TRANSCRIPTION ASSAYS 
6. 7.1 Nuclear run-on transcription 
6.7.2 Hybridisation of RNA transcripts to cDNA 
6. 7 .2.1 Preparation of nitrocellulose filters 
6.7.2.2 Hybridisation reactions 
6.8 DNA SEQUENCING 
6.9 TRANSIENT TRANSFECTION EXPERIMENTS 
6.9.1 Preparation of cells 




Extraction of protein from transfected cells 
J3-galactosidase assay 
CAT assay 
6.10 SCREENING OF A.GTl 1 EXPRESSION LIBRARIES 
6 .10 .1 Concatemerisation of CME oligonucleotides 
6.10.2 PCR-generated probes for screening 
6.10.3 Screening of a A.gtll expression library 




























Contents I ix 
6.10.4 Purification of positive clones 165 
6.10.5 Controls for screening 166 
6.10.6 Rapid analysis of 1..gtl l fusion proteins 166 
6.10.7 Western Blots using an anti-J3-galactosidase antibody 167 
6.10.8 Recombinant lysogen detection 167 
6.10.9 Analysis of DNA from positive 1..gtl l clones 168 















































complementary deoxyribonucleic acid 
calf intestinal phosphatase 
collagen modulating element 










electrophoretic mobility shift assay 
GGAGG/CCAAT binding element 
GGAGG/CCAAT binding factor 
guanidine (aminomethanamide) thiocyanate salt 
guanosine triphosphate 





polyacrylamide gel electrophoresis 
phosphate-buffered saline 
polymerase chain reaction 








Abbreviations I x 
Dedication I xi 
TO MY PARENTS AND GRANDPARENTS 
the honest men and women who supported me in seizing opportunities not 
available to them in the past 
How? 
Why? 
I have six honest serving men 
They taught me all I knew 
When? 
1neir names are what, and where and when 





From: The Book of Projects, Derek John Gray, 1989. 
Abstract I xii 
ABSTRACT 
The objective of this study was to investigate the cell- and species-specific 
regulation of the a2( 1) pro collagen gene by analysing trans-acting factor 
interactions within the proximal promoter of the gene and to identify the genes 
coding for these trans-acting factors. 
a2( 1) procollagen gene expression was examined in a number of diff erentiate<;l cell 
lines and shown to differ significantly between normal fibroblasts (WI-38, FG0), 
transformed fibroblasts (CT-1, SVWI-38), HT1080 fibrosarcoma, HepG2 
hepatocellular carcinoma, L 77 lymphoblasts and breast cancer epithelial cells 
(MDA-MB-231, ZR-75-2). These differences were due to changes in transcription 
of the a2(1) procollagen gene as shown by Northern blot analysis and nuclear run-
on transcription experiments. Analysis of DNA-protein interactions with the 
proximal a2(1) procollagen promoter showed the presence of at least two DNA-
protein complexes ( complexes I and III) in collagen producing cell lines, while 
cells where collagen synthesis did not occur contained a third DNA-protein 
complex (complex Il). a2(1) procollagen gene expression was therefore shown to 
be associated with the presence of complexes I and III while repression of the gene 
was associated with the presence of complexes I and Il and the partial or complete 
absence of complex III. Complex I is a ubiquitous factor which binds the inverted 
CCAAT box located between -92 and -80 (G/CBE) with an apparent K<t of 2.9nM. 
Complexes Il and III both bind an adjacent DNA sequence between -78 and -67 
(the CME) with K<t values of 4.2 and 3.5nM respectively. 
While the CCAA T boxes in the human and mouse promoters are identical, a 3 bp 
mismatch was detected in the CME. This mismatch abolished the formation of 
complex Il and III on the mouse promoter, even though mouse cells contained 
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complex II proteins. The difference in the CME binding site between rodent and 
human promoters implied species-specific regulation of the cx.2(1) procollagen 
gene. Transfection of human and mouse proximal cx.2( 1) procollagen 
promoter/CAT constructs into human cells (CT-1) indicated that the human 
promoter had higher activity than the mouse promoter, whilst the two promoters 
had equivalent activities in rodent cells. These promoter activities may be 
accounted for by the differences in trans-acting factor binding to the two 
promoters. 
Complex I formation was competed out by the mouse CBF and NF-Y consensus 
oligonucleotides, while the mouse anti-CBF-B antibody resulted in a supershifted 
complex I. These results indicate that complex I is a member of the heterologous 
CCAAT-binding proteins and possibly related to or similar to the mouse CBF. 
The treatment of nuclear extracts with calf intestinal phosphatase resulted in a loss 
of complex I formation on the human and CBF binding to the mouse promoters. 
The Ser/Thr phosphatase, PP2A, specifically inhibited complexes II and ill 
formation. Nuclear extracts from CT-1 and U93 7 cell lines treated with the kinase 
inhibitor, staurosporin, was accompanied by a loss in DNA-protein interaction. 
This inhibition of DNA-binding activity was not observed using the tyrosine 
kinase inhibitor, genistein, and the PP2A phosphatase inhibitor, okadaic acid. 
Staurosporin also had a significant inhibitory effect on cx.2(1) procollagen promoter 
activity in CT-1 cells transfected with the human proximal a.2(1) procollagen 
promoter and on steady state collagen mRNA levels. These results indicate that 
phosphorylation is required for the binding of trans-acting factors to the proximal 
cx.2( 1) procollagen promoter and in transcriptional regulation of this gene. In 
support of the suggestion that phosphorylation events play a role in transcriptional 
regulation of the cx.2( 1) procollagen gene, CT-1 cells treated with the protein 
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kinase C activator, PMA, showed a significant reduction in a2(1) procollagen 
mRNA levels. 
A lambda gtll expression library was screened to obtain cDNA's encoding 
proteins that bind the CME in the human a2(1) proximal promoter. A cDNA clone 
of 958 bp with a predicted open reading frame of 116 amino acids (12.5kD) was 
obtained. No significant DNA or polypeptide sequence homologies existed in the 
databank, indicating the possibility of a novel trans-acting factor. Binding of this 
fusion protein was specific for the CME as observed in South Western blotting and 
gel shift assays using competitor DNA sequences. Northern blot analysis detected 
a mRNA transcript of approximately 4kb predominantly in cells where a2(1) 
procollagen expression is repressed. 
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CHAPTER 1: 
INTRODUCTION 
1.1 THE COLLAGENS 
The collagens are a superfamily of extracellular structural proteins with diverse 
biological functions, ranging from promotion of cell growth and differentiation, cell 
migration and tissue development. There are many excellent reviews on the structure 
/function and pathobiology of the different collagens (Bornstein and Sage, 1980; 
Burgeson, 1988; Ramirez et al, 1989; Ramirez et al, 1990; Vuorio and de 
Crombrugghe, 1990; van der Rest and Garrone, 1991; Prockop et al, 1993); hence this 
chapter will present a brief overview on the :fibrillar collagens, with specific reference 
to transcriptional regulatory mechanisms in type I collagen gene expression. 
1.1.1 Introduction 
At least 19 different collagen types have been characterised to date and their 
chromosomal location, tissue specificity and biological function vary considerably 
(Prockop and Kivirikko, 1995). The collagens are triple helical proteins consisting of 
three polypeptides forming molecular rod-like structures. The primary structure, is for 
the most part, a repeating Gly-X-Y amino acid triplet with positions X and Y 
frequently being occupied by prolyl and hydroxyprolyl residues respectively. This 
unique molecular structure and arrangement confers on the collagens the ability to 
polymerise and form highly ordered structures. Many of the collagens contain 
globular, non-collagenous domains which vary in size from 10 to 150 kD per 
polypeptide chain. These globular sequences are speculated to make the molecule 
more flexible although their exact function remains to be identified. Based on the 
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polymeric structures that the collagens form, they can be subdivided into different 
classes; (1) The fibrillar collagens, (2) collagens that form network-like structures, (3) 
the fibril-associated collagens (FACITS), (4) collagens forming beaded filaments, (5) 
anchoring collagen fibrils, ( 6) collagens containing transmembrane domains, (7) newly 
identified collagens and (8) non-collagen collagens (Prockop and Kivirikko, 1995). 
1.1.2 The fibrillar collagens - a brief oveniew 
This group of collagens are identified by their formation of highly organised fibers and 
fibrils which provide structural support in most connective tissues, blood vessels, 
bones and nerves. The structure of the genes encoding these collagens have common 
features in that the triple-helical domain is encoded by 42 exons varying in size usually 
in multiples of 54 bp (1 X 54 bp, 2 X 54 bp, 3 X 54 bp ). Exons of 45 bp and 99 bp are 
also found. The introns seperating the exons vmy in size from 100 to 3 000 bp 
(reviewed by Ramirez et al, 1990; Vuorio and de Crombrugghe, 1990 and Prockop 
and Kivirikko, 1995). Types I, II and ID (major fibrillar collagens) are the most 
abundant collagens in this group, with type V and XI constituting the minor fibrillar 
collagens. These collagens all consist of long triple-helical domains of approximately 
1000 amino acids, with short globular domains flanking the triple-helical portion. 
After post-translational modifications and assembly of the procollagen helix, specific 
N- and C-proteases remove the globular propeptides. Interestingly, such proteases 
have been demonstrated to have a potential role in the regulation of collagen 
biosynthesis. The cleavage of the C-propeptide by mast cell chymase is reported to 
initiate fibril formation (Kofford et al, 1997). A recent study also shows that type ID 
collagen, which is usually associated with type I collagen; is essential for type I 
collagen fibrillogenesis in the cardiovascular system and other organs (Liu et al, 1997). 
Similiarly, it has been shown that the interaction between types I and V collagen 
regulates fibril formation (Birk et al, 1990; Marchant et al, 1996). 
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Type I collagen synthesis varies significantly under different physiologic conditions, in 
different cellular tissues and in certain pathologic conditions. An understanding of the 
mechanisms underlying the expression of the type I collagen genes will contribute to 
our understanding of these conditions. 
1.2 REGULATION OF TYPE I COLLAGEN GENE EXPRESSION 
1.2.1 Preamble 
One of the earliest studies regarding the regulation of collagen biosynthesis in 
differentiated cell types was provided by Green et al, (1966). These authors classified 
differentiated cell types in terms of collagen expression in three levels at which 
synthesis may be maintained. These include cells of fibroblastic origin where the 
ability to synthesise collagen is highly developed, non-fibroblastic cell types which 
synthesize collagen at a rate of 2-3% compared to fibroblasts and cell types where the 
collagen genes are completely silenced. Interestingly, this paper concluded by stating 
that it was not possible to say whether any of these collagen states are produced by 
soluble regulatory factors . After more than thirty years of intensive investigation, a 
number of protein factors have been identified that have regulatory function in the 
expression of the collagens identified to date, and more are being discovered. The cell-
and tissue-specific transcription of the type I collagen genes is mainly attributed to 
complex interactions between cis-regulatory DNA elements and sequence specific 
trans-acting factors. These regulatory elements are located predominantly in the 
promoter region, 5' flanking region, the first intron and the 3' untranslated region of 
the genes. 
The following section will provide an overview of the factors influencing cell- and 
tissue-specific type I collagen synthesis as well as highlight some of the currently 
debated issues in the field. 
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1.2.2. Co-oordinate expression of the type I collagen genes 
It has generally been accepted that the expression of the al(l) and a2(1) procollagen 
genes are co-ordinately regulated (de Wet et al, 1983). The steady state levels of al(l) 
and a2(1) collagen mRNAs are in the ratio of 2:l(Vuust et al, 1985), and are reflected 
in the synthesis of pro al(l) and pro a2(1) chains (Bornstein and Sage, 1989). This 
ratio is, however, not maintained under varying culture conditions. While nuclei from 
sub-confluent cultures generally transcribe the two genes in a 2: 1 ratio, nuclei from 
post-confluent cultures transcribe the genes at a ratio of approximately 4: 1 (Olsen and 
Prockop, 1989). Steady state mRNA levels remain at a 2:1 ratio and it is likely that in 
addition to transcriptional regulation, post-transcriptional mechanisms also have a role 
in maintaining these levels. Co-ordinate expression of type I collagen genes has also 
been shown to occur during mouse development. Concommitant with this expression, 
co-ordinate al(l 11) collagen gene expression is also detected in fibroblast containing 
tissues (Niederreither et al, 1995). Transfections into human skin fibroblasts using 500 
bp of the proximal al(l) and a2(1) procollagen promoters fused to the luciferase gene 
provided additional evidence for the co-ordinate expression of these genes (Hata, 
1995). 
The mechanism by which the co-ordinate regulation of the al(l) and a2(1) collagen 
genes can be achieved is via common transcriptional factors that control both genes. A 
number of cis-elements and the transcription factors that interact with these regions 
have been identified in the promoters of the al(l) and a2(1) procollagen genes and 
are discussed below. 
1.2.3 Type I collagen promoter elements and trans-acting factors 
1.2.3.1 Transcription factors in co-ordinate regulation 
Both the al(l) and a 2(1) procollagen promoters contain the characteristic TATA box 
which is the binding site for the general transcription factors, a common CCAA T motif 
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and binding sites for other transcription factors. These factors have a key role in the 
co-ordinate regulation of the type I collagen genes. 
1.2.3.1.1 The CCAAT binding factor (CBF) 
The CCAA T consensus sequence is found in most eukaiyotic promoters and is 
involved in the tissue and cell-specific expression of a number of genes including the 
a-globin (Cohen et al, 1986; Bamhait et al, 1988), the liver specific aldolase B 
(Gregori et al, 1993), the rat albumin (Tronche et al, 1991; Wuarin et al, 1990), cell 
cycle-related genes eg thymidine kinase (Flemington et al, 1987; Pang and Chen, 
1993), the major histocompatability complex class II genes (Dom et al, 1987) and 
others (Gallinari et al, 1989). Recently the CCAAT binding factor, NF-Y has been 
reported to be modulated during monocyte-macrophage differentiation and it is 
required for the transcriptional regulation of the fenitin heavy-chain gene (Marzicialli 
et al, 1997). CCAAT binding proteins have also been implicated in the regulation of 
genes involved in stress responses, hsp70 (Wu et al, 1981; Lum et al, 1990) and in 
regulation of the grp78/BiP promoter under conditions of calcium stress (Roy and Lee, 
1996). 
Both the cx.2(1) and al(l) collagen promoters contain a common inverted CCAAT 
motif at positions -75 to -98 and -90 to -115 respectively. These inverted CCAAT 
motifs bind the transcriptional activator, the heterotrimeric CCAA T binding factor 
identified in NIH-3T3 cells (Hatamochi et al, 1986; Oikarinen et al, 1987; Maity et al, 
1988). Other members in the family ofheterotrimeric CCAAT-binding factors include 
NF-Y (Dom et al, 1987), CPI (Chodosh et al, 1988a), yeast Hap-2,3,4 (Forsbety and 
' 
Guarente, 1989) and a CP 1 (Kim & Sheffety, 1990). It has generally become accepted 
that CBF, NF-Y and CPI are the same or closely related factors. CBF was initially , 
identified as a heterodimeric factor (Hatamochi et al, 1988) but subsequent 
investigations proved it to be a heterotrimeric protein (Maity et al, 1992; Vuorio et al, 
1990). 
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The three subunits comprising CBF are CBF A, CBF B and CBF C, all of which are 
required for DNA binding activity. (Maity et al, 1992) and occur in a stoichiometric 
ratio of 1:1:1 (Sinha et al, 1996). CBF A and CBF B share a striking amino acid 
homology (99°/o) in humans, rats and mice. These identities were determined on the 
basis of their derived cDNA sequences (Li et al, 1992; Maity et al, 1990; Hooft van 
Huisjduijnen et al, 1990). While CBF A is a heat sensitive protein with a putative 
polypeptide size of 25 kD, CBF B is heat resistant and has a calculated molecular mass 
of 41 kD (Hatamochi et al, 1988, Vuorio et al, 1990). CBF A and CBF B have a high 
sequence identity with the yeast Hap-3 and Hap-2 proteins respectively. The C-
terminal domain of CBF B, which shares similarity with the yeast Hap-2 protein, 
consists of two separate segments, one domain which is required for DNA binding 
activity while the other for interaction with the other components of CBF (Maity and 
de Crombrugghe B, 1992). A similar interaction has also been observed for the yeast 
Hap2 protein with the other components in the yeast CCAAT binding factor, Hap2-3-4 
(Oleson et al, 1990; Xing et al, 1994). 
CBF C, the third component of the heterotrimeric CBF is required together with CBF 
A and CBF B for formation of the CBF-DNA complex (Sinha et al, 1995). These 
authors also showed that CBF A and CBF C initially interact with each other to form a 
CBF A-CBF C complex. This is followed by the interaction with CBF B and DNA 
binding of the complete complex is achieved. CBF C shares significant homology with 
the yeast Hap5 protein (McNabb et al, 1995) and its gene is located on chromosome 4 
in mouse with linkage data suggesting that the human NF-Y C (CBF C) will map to 
lp32 (Sinha et al, 1996). Using northern blot analysis, CBF C was shown to be 
ubiquitously expressed in several rat tissues and has a major mRNA species of 2kb 
(Sinha et al, 1996). 
CBF A contains three functional domains which are essential for, (i) interaction with 
CBF C to form the heterodimeric CBF AICBF C complex. (ii) interaction of CBF 
AICBF C complex with CBF B to form the CBF heterotrimer and (iii) binding of CBF 
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to DNA (Sihna et al, 1996). Interestingly, the segment of CBF A required for DNA 
binding of the CBF complex shows sequence similarity with a region of CBF C and 
these sequences in turn have similarity to the histone fold motifs of histones H2B and 
H2A (Baxevanis et al, 1995). These motifs are essential for the interaction between 
CBF A and CBF C and the subsequent binding of the CBF complex to DNA (Kim et 
al, 1996). 
In vivo transcriptional activation by CBF has been reported to require the glutamine 
rich domain of CBF B, but in an in vitro transcription reconstitution system, however, 
a truncated form of CBF B (lacking the glutamine and ser/thr rich domains) with 
purified CBF A and CBF C could activate transcription. This suggested that 
transcriptional activation of CBF may also be achieved via either or both CBF A and 
CBF C or via other transcription factors interacting with CBF (Coust:Iy et al, 1995). 
Indeed, a subsequent report showed that CBF transcriptional activity can be mediated 
by both CBF B and CBF C. Using a CBF deletion protein consisting of the full length 
CBF A and deleted forms of either CBF B or CBF C, it was shown that these mutant 
CBF proteins could stimulate transcription but at reduced levels compared to that of 
the wild type protein (Coust:Iy et al, 1996). 
For CBF to participate in cell-specific gene regulation it is thought that CBF functions 
in conjunction with other transcription factors. Evidence for this has been provided by 
studies on the CCAAT-binding NF-Y factor which is implicated in the in vivo 
recruitment of upstream DNA binding transcription factors in class II MH:C 
transcription. Constitutive expression of y-IFN-induced MHC class II DRA expression 
requires a functional NF-Y CCAAT element (the Y box) and adjacent elements, the S 
and X boxes (Vilen et al, 1990, 1992). Mutations in the Y box abolished binding of 
trans-acting factors at the Xl and X2 sites in the HLA-DRA promoters (Wright et al, 
1994). These findings suggest that NF-Y stabilises and interacts with X box factors 
and these interactions are required for gene activation. Sinha et al (1996) speculate that 
the CBF A/CBF C heterodimer could interact with the TATA binding protein-
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associated factors (TAFs) or other IBP-associated proteins to either activate or 
derepress transcription. Although the above has not been shown as yet, CCAA T 
binding factor interactions with a nwnber of other proteins have been reported. The B 
subunit of NF-Y can physically interact with the hwnan T-cell lymphotropic virus type 
I Tax protein to activate the NF-Y responsive DQB promoter. Tax, an activator of the 
human I-cell lymphotropic virus type I (RTL V-1) transcription and of many cellular 
genes, does not bind DNA directly, but regulates transcription via protein-protein 
interactions (Pise-Masison, 1997). The SV40 large T Antigen (SV40-LT) also 
trans activates the human cdc 2 promoter via induction of a CCAA T Box binding 
factor. Although physical interaction between the SV40-LT and CBF has not been 
shown, it is suggested that CCAA T box binding motifs in the human cdc 2 promoter 
are the major target for transaction by SV40-LT (Chen et al, 1996). A recent study 
showed that basal expression of the hwnan a2( 1) procollagen promoter may require 
the binding of a trans-acting factor to sequences adjacent to the CCAA T box which 
may, in combination with CBF, result in effective activation of the promoter. 
Mutations in the binding sequence of this factor drastically reduced promoter activity 
as observed in transient transfection assays (Collins et al, 1997). 
The CCAA T binding protein interactions and their role in transcriptional activation are 
therefore highly complex and involve the interaction of the different components of 
CBF with each other and the interaction of CBF with other trans-acting factors which 
may either activate or repress transcription. In terms of the type I collagen genes, 
sequences flanking the CCAA T motifs have been identified to interact with 
transcription factors possibly required in the co-ordinate regulation of the genes. 
1.2.3.1.2 Transcription factors IF-1 and IF-2 
Two DNA binding proteins, Inhibitory factor 1 (IF-1) and Inhibitory factor 2 (IF-2) 
interact with regions in the proximal al(l) collagen promoter. Both are proposed 
transcriptional repressors (Karsenty and de Crombrugghe, 1990). IF-1 binds two 
adjacent sites (-190 to -170 and -160 to -130) while IF-2 binds a 12bp repeat (5 '-
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TGGGGGCCGGGC-3 ') that brackets the proximal CCAA T motif. This 12bp 
sequence is a GC rich repeat and shows homology to Spl binding sites. Spl, however, 
appears to bind this region poorly (Brenner et al, 1989). Contrary to these 
observations, Nehls et al, (1991, 1992) demonstrated that Spl binds the 12bp repeat 
and that overexpression of Spl in NIH3T3 cells interferes with basal a.1(1) collagen 
promoter activity. IF-2 is a metallo-protein and mutually exclusive binding between 
IF-2 and CBF could have a significant role in the regulation of the a.1(1) collagen 
promoter (Karsenty and de Crombrugghe, 1990). The purification and functional 
characterisation ofIF-2 indicated that CBF effectively inhibits IF-2 binding while IF-2 
weakly inhibits CBF binding (Karsenty et al, 1991). 
The putative transcriptional repressor, IF-1, binds at least two upstream adjacent sites 
in the mouse a.1(1) collagen promoter, located at positions -190 to -170 (element A) 
and -160 to -130 (element B). EMSAs using a double-stranded oligonucleotide 
containing the B element indicated that less pronounced binding is detected to the B 
element than to the A element (Karsenty and de Crombrugghe, 1990). A similar B 
element is also present in the mouse a.2(1) collagen promoter between -173 and -143 
and shows a high degree of similarity (10 out of 11 bp) with the B element of the 
a.1(1) promoter. Mutations in this sequence abolish IF-1 binding and result in a 4 fold 
increase in a.2( 1) collagen promoter activity as compared to that of the wild type 
promoter construct (Karsenty and de Crombrugghe, 1991 ). These studies therefore 
propose that the IF-1 binding element may in part be involved in the co-ordinate 
regulation of the a.1(1) and a.2(1) collagen genes. A homologous IF-1 binding 
sequence is also present in the human a.2(1) collagen promoter at -164 to -159. 
Mutations in this region result in a 5-6 fold increase in promoter activity, suggesting a 
possible repressor binding site (Thn et al, 1996). 
In contrast to studies showing that mutations in the IF-1 binding site in the mouse 
a.2(1) collagen promoter (-173 to -143) results in a 4 fold increase in promoter activity 
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(Karsenty and de Crombrugghe, 1991 ), a recent study by Hasegawa et al, (1996) 
showed that deletion of the -170 to -130 region of the mouse a.2(1) promoter resulted 
in a significant reduction in promoter activity. Although this contradiction remains to 
be explained, the authors provide two possible explainations for how the -173 to -143 
region can function as a negative element; (i) that the protein binding this sequence is a 
true transcriptional repressor or (ii) that the protein binding this sequence is a weak 
activator and mutations in its binding site may allow the binding of a strong activator, 
hence the increase in promoter activity observed when the sequence is mutated. These 
explanations are certainly plausible and it is possible that the relative abundance of 
transcriptional activators and repressors may be important detenninants in the 
regulation of type I collagen genes. 
1.2.3.1.3 Transcription factor Spl 
In addition to the CCAAT elements in the al(l) and a.2(1) collagen promoters, a 
number of potential Spl binding sites have been identified (Rossouw et al, 1987). The 
same 12bp sequence reported to bind IF-2 (section 1.2.3.1.2) was reported by Nehls et 
al, (1991, 1992) to bind Spl, which is thought to bind the al(l) collagen promoter in a 
mutually exclusive manner with NF-1. This :finding is similar to that reported for IF-2 
and CBF (Karsenty et al, 1991), suggesting that IF-2 and Spl may be similar factors. 
Karsenty and de Combrugghe (1991), however, reported that IF-2 and Spl are distinct 
DNA binding factors and it may therefore be possible that sequences flanking the 
CCAA T sequence interact with Sp 1 and other GC-box binding proteins. The isolation 
of cDNA clones will allow for similarities between IF-2 and Spl to be evaluated. The 
IF-2 binding sequence has also been identified in the a.2(1) promoter, suggesting that 
Spl and IF-2 and other GC-rich binding proteins have the ability to bind both the 
mouse proximal al(l) and a.2(1) collagen promoters. A review by Karsenty and Park, 
(1995) speculate that Spl and other factors binding the sequences flanking the 
CCAAT motif in the mouse al(l) procollagen promoter act as activators of 
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transcription and somehow prevent the binding of a stronger transcriptional activator, 
the CCAAT binding factor. 
Hasegawa et al, (1996) reported that the -170 to -40 region of the mouse a.2(1) 
procollagen promoter contains binding sites (-176 to -152; -136 to -114 and -105 to -
65) for a number of nuclear proteins which include Sp 1, other proteins that bind to Sp 1 
consensus sites and proteins that bind to a Krox consensus site. Sp 1, however, appears 
to have a modest role in the activity of the mouse a.2( 1) collagen promoter, since anti-
Sp 1 antibodies had little effect on in vitro transcription of the WT -350 bp mouse 
promoter. In vitro transcription assays with deletion mutants encomposing the -170 to 
-40 bp region upstream of the start of transcription, indicated that this region is 
however essential for transcriptional activity (Hasegawa et al, 1996). 
While Sp 1 appears to have a modest role in activity of the mouse promoter, it is 
essential for binding and basal activity of the human a.2(1) procollagen promoter. 
Three short cis-acting GC rich elements between -303 and -274 in the human a.2(1) 
collagen promoter are capable of binding Sp 1 and mutations in these boxes abolished 
trans-acting factor interactions accompanied by a 90% loss in promoter activity in 
transient transfection assays (Tamaki et al, 1995). Spl has also been implicated in the 
TGF-P response of the human a.2(1) collagen promoter (Inagaki et al, 1994; Greenwel 
et al, 1997) and the debate around this observation will be discussed in section 1.2.3.3. 
In a recent report it was shown that purified Sp 1 can specifically interact with the 
human a.1(1) procollagen promoter (Poppleton and Raghow, 1997). Spl binding sites 
' 
are also located in the more distal region of the a.1(1) collagen promoter (-466 to -459) 
and in the first intron of the gene (Bornstein et al, 1987; Liska et al, 1992). It is 
possible that these Spl motifs can interact with each other, as it has been shown that 
Spl binding to a promoter can synergistically stimulate transcription via Spl/Spl 
protein interactions (Courey et al, 1989). 
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1.2.3.1.4 Recently identified trans-acting factors 
Previous reports showed that the sequences between-ISO and-136 of the mouse a.2(1) 
collagen promoter are essential for promoter activity and that this region binds a 
complex set of trans-acting factors. This region of the promoter was used by 
Hasegawa et al, (1997) to clone transcription factors that bind to specific sequences in 
the proximal promoter using the yeast one hybrid system. One such cDNA clone, 
designated BFCOLl, · encodes a polypeptide of 775 amino acids of which the N -
terminal 400 amino acids share 95% similarity with the human htJ3 protein. BFCOLl 
has four potential zinc fingers and binds the -180 to -152 region of the mouse a 2(1) 
collagen promoter. This binding site corresponds to that of the IF-1 binding site in the 
mouse al(l) and a.2(1) collagen promoter (section 1.2.3.1.2). The two IF-1 binding 
sites in the mouse al(l) collagen promoter also interact with BFCOLI. However, 
BFCOLI had a greater affinity for the -168 to -129 al(l) oligonucleotide (element B) 
than to the -194 to -168 al(l) oligonucleotide (element A). This is in contrast to IF-1 
in which the reverse is found. The C- terminal domain of BFCOLI functions as a 
potential transcription activator when tested as a GAL4 fusion polypeptide in 
transfection experiments (Hasegawa et al, 1997). 
In addition to BFCOLl, c-Krox also binds the same sequences in the al(l) and a.2(1) 
collagen promoters. c-Krox appears to bind the -194 to -168 region more effectively 
than the -168 to -129 region of the al(l) promoter. This binding correlates with 
transcriptional activity of a short al(l) collagen promoter in cotransfection 
experiments and expression of c-Krox mRNA is tissue-specific with the most 
abundant expression being in the skin (Galera et al, 1994; reviewed by Karsenty and 
Park, 1995). Three c-Krox binding sites are identified in the mouse a.2(1) collagen 
promoter, one of which is adjacent to the CCAAT motif in both promoters (Galera et 
al, 1996). c-Krox binding is the same as that reported for IF-I (Karsenty and de 
Crombrugghe, 1990). It is likely that IF-I and c-K.rox are similar, if not the same 
factor. 
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The aJ(l) and a2(1) procollagen proximal promoter regions therefore interact with a 
variety of common transcription factors, suggesting a role for these factors in the co-
ordinate regulation of the genes. The relationship between IF-I and c-Krox, IF-2 and 
Spl is not clear as yet, although the preference in recent literature is towards c-Krox 
and Spl as major transcription factors in regulation of the type I collagen genes. It has 
become increasingly apparent that a number of different transcription factors can 
interact with the same DNA sequence and the cell type and relative abundance of these 
proteins may determine which will interact. 
1.2.3.2 Additional DNA elements and trans-acting factors involved in 
constitutive activity of the type I collagen genes 
A number of other transcription factors and cis-elements in the al(l) and a2(1) 
collagen promoters have been identified as being important in the regulation of the 
genes. An NF-I binding site (-315 to -295) is located in the mouse a2(1) collagen 
promoter (Oikarinen et al, 1987). Point mutations which inhibit NF-1 binding 
exhibited a strong inhibitory effect on a2(1) promoter activity, suggesting that NF-I 
(or a protein with similar DNA binding properties) is an activator of a2(1) collagen 
gene expression. Support for this suggestion was provided in studies where the 
inclusion of this sequence in the SV40 early promoter resulted in a marked (10 fold) 
increase in promoter activity (Karsenty et al, 1988). Subsequent studies showed that 
this region of the promoter is required in TGF-P stimulation of the mouse a2(1) 
procollagen gene (see section 1.2.3.3). A factor, possibly histone Hl, has been purified 
and was also shown to bind the NF-1-like sequence in the mouse a2(1) procollagen 
promoter (Ristiniemi and Oikarinen, 1989). The sequences further upstream in the 
mouse a2(1) collagen promoter -(419 to -399) bind a factor designated as ColFl. 
Purification of this factor revealed two molecular weight species of 40 and 42 kD. 
ColF 1 binding appears to be distinct from that of CBF and it appears to be more 
abundant in NIH3T3 fibroblasts than in lymphoid and epithelial cells (Hatamochi et al, 
1993). The exact function of this trans-acting factor is unknown as yet. 
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The sequences -804 tO -675 in the mouse al(l) procollagen promoter contain an APl 
binding site and the reduced interaction of AP 1 to this sequence results in the 
increased expression of the al(l) procollagen gene in tight skin (TSK) mice 
myocardial fibroblast (Phillips et al, 1995). It would appear that AP 1 has a negative 
regulatory effect within this region of the gene. An AP 1 binding site has also been 
located within the -265 to -241 region of the human a2(1) procollagen gene and there 
is currently debate as to its involvement in conveying the response to TGF-P (see 
section 1.2.3.3). 
Although cis-elements and trans-acting factors which regulate the rodent type I 
collagen genes are reasonably well characterised, it is only of late that these elements 
in the human promoters have been identified. The region up to -376 of the human 
a2( 1) procollagen promoter is sufficient for high level expression of the gene (Boast et 
al, 1990). Closer analysis of this promoter segment revealed a TGF-P response 
element (-323 to -186) (Inagaki et al, 1994) and three additional regions involved in 
nuclear factor binding and transcriptional activity located at -173 to -155; -133 to -119 
and -101 to -72 (Ihn et al, 1996). The -101 to -72 region is the previously identified 
CCAAT motrt: -133 to -119 contains a TCCTCC motif which is required for 
activation of the promoter and -173 to -155 appears to be a repressor binding site. 
These cis-elements and the transcription factors that interact at these regions are 
fundamental in the regulation of the type I collagen genes. 
1.2.3.3 Response of the type I collagen genes to TGF-P 
Type I collagen synthesis can be regulated by a number of extracellular signalling 
molecules. One of these is TGF-P, a well documented regulator of cell cycle 
progression, cell differentiation and cell adhesion affecting the formation of 
extracellular matrices (Roberts et al, 1990; Massague,1990). Three ubiquitous cell 
membrane receptors mediate the effect ofTGF-f3. Two of these (types I and II) contain 
novel serine/threonine kinase activities and are responsible for the cellular signa11ing of 
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TGF-13 (reviewed by Brenner et al, 1994 and Massague and Weis-Garcia, 1996). 
TGF-13 has been shown to have a stimulatory effect on collagen production (Fine and 
Goldstein, 1989; Ignotz and Massague, 1986). Subcutaneous injections of TGF-P into 
transgenic mice containing 3.6 kb of the rat al(l) collagen promoter fused to a 
reporter CAT gene also resulted in increased CAT expression in the dermis of TGF-13 
treated animals (Agarwal et al, 1996). 
The mechanism underlying stimulation by TGF-13 has been extensively investigated. 
The steady state levels of al(l) and a2(1) collagen mRNA in 3T3 and Ito cells treated 
with TGF-13 were increased by 15-20 fold (Pentinnen et al, 1988; Weiner et al, 1990). 
Inhibition of RNA synthesis with actinomycin D showed that the upregulation of 
collagen gene expression in TGF-13 treated cells is due to increased transcriptional 
activity (Ignotz et al, 1986). 
A variety of transcription factors are thought to mediate the TGF-13 effect on both the 
al(l) and a2(1) collagen genes in rodents and humans. A TGF-13 activating element 
which contains an NF-1-like sequence is located 1.6 kb upstream of the transcriptional 
start site in the rat al(l) procollagen promoter (Ritzenhaler et al, 1991). Although this 
element resembles NF-1 and AP2 binding sites, a 82 kD protein different to both 
interacts with this region of the al(l) collagen gene (Ritzenhaler et al, 1993). 
TGF-13 stimulates the mouse a2(1) collagen gene 6-10 fold. The TGF-13 responsive 
element in this gene is located at position -300 and the transcription factor thought to 
mediate this response is CTF/NF-1. A 3bp mutation in the NF-1 binding site, which 
abolishes NF-1 binding, prevents stimulation of mouse a2( 1) procollagen expression 
by TGF-P (Rossi et al, 1988). NF-1 binding to the mouse a2(1) collagen promoter is, 
however, detected in both TGF-P treated and untreated cells and it is therefore 
proposed that TGF-13 may not neccessarily affect DNA binding, but rather the 
transcriptional activation function of NF-1 ( de Crombrugghe et al, 1990). The exact 
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role of CTF/NF-1 in the responsiveness of the mouse a2(1) gene to TGF-P could not 
be con.finned by Chang and Goldberg, (1995). These authors implicate APl since 
overexpression of jun-B induced transcription while jun-B antisense RNA interfered 
with TGF-P stimulation. This controversy has not been solved as yet, however, 
evidence for CTF as the factor involved in relaying the signal from TGF-P and tumor 
necrosis factor-a (TNF-a) on mouse a2(1) collagen gene expression is provided by 
Alevizopoulous et al, (1996). 
Similar controversy as to the transcription factors responsible for the TGF-P 
responsiveness of the human a2(1) collagen exists. The TGF-P-response element in 
the human a2(1) collagen gene was initially located between -376 and -108 upstream 
from the transcriptional start site (Kikuchi et al, 1992). Although an NF-1-like 
sequence is found at -311 to -298 it has been accepted that NF-1 appears not to be the 
transcription factor responsible for TGF-P stimulus of the human a2(1) collagen gene. 
The TGF-P-responsive element (TbRE) has subsequently been mapped to a 131 hp 
region (-323 to -186) of the COL1A2 promoter. This promoter region contains at least 
two cis-acting elements, one which has Sp 1 recognition sequences reported to be 
required for promoter inducibility. A nuclear protein complex, of which Spl is a 
component, showed increased binding to the TbRE upon TGF-P stimulation using 
electrophoretic mobility shift assays (EMSA) and tyrosine dephosphorylation of this 
complex may be required for transactivation (Inagaki et al, 1994; Greenwel et al, 
1995). This region of the promoter also regulates a2(1) collagen gene expression in fat 
storing cells and dermal fibroblast and this activity can be stimulated by TGF-P 
(Inagaki et al, 1995a). Three GC-boxes resembling Spl binding sites are located in the 
131 bp region (-323 to -186). These GC-boxes are located between -303 and -271 and 
are essential for a2(1) procollagen promoter activity (Tamaki et al, 1996). Contrary to 
the finding that an Spl-containing complex may be responsible for the TGF-P 
stimulus of the human a2(1) procollagen gene, Chung et al, (1996) report that an AP-I 
binding sequence overlapping the 3' end of the TbRE is essential for the TGF-P 
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stimulus. These authors show that deletion of the Sp 1 containing sequences does not 
interfere with TGF-P responsiveness, while deletion of sequences -265 to -241 
(including an AP-1 sequence and flanking NF-KB sequence) inhibits TGF-P stimulus. 
Neither NF-1 or NF-KB appear to be able to bind this region as NF-1 and NF-KB 
oligonucleotides failed to compete for complex formation in EMSAs (Chung et al, 
1996). As a counter arguement in support of Spl as the transcription factor responsible 
for TGF-P responsiveness, Greenwel et al, (1997) present evidence excluding AP-1 
participation and corrfinning Sp 1 requirement. This was achieved by using the 
pharmacological agents, mithramycin and curcumin, which inhibit the activity of Sp 1 
and AP-1 respectively. The inhibition of Spl activity inhibited TGF-P stimulation of 
a2( 1) procollagen gene expression, while AP-1 inhibition did not. Further exclusion of 
APl as the TGF-P responsive factor was provided by EMSA showing that JunB and 
c-Jun antibodies failed to recognise proteins in the TbRE-bound complex. AP-1 can, 
however, bind its recognition sequence in the absence of the Spl sequences, indicating 
that these two factors may bind the TbRE in a mutually exclusive manner, with Sp 1 
binding being favoured (Greenwel et al, 1997). Although the evidence in the case of 
Sp 1 is certainly very convincing, it is possible that within a given cell type and under 
differing experimental conditions, DNA elements can be used selectively by different 
transcription factors. 
The stimulation of type I collagen gene expression by TGF-P can also be suppressed 
by other exogenous factors. Tumour necrosis factor a (TNF-a) and interferon-y (IFN-
y) both suppress stimulation of the human type I collagen gene expression by TGF-p. 
TNF-a has a marked effect on suppression of a2(1) procollagen promoter activity, 
while IFN-y only has a minimal effect at a transcriptional level (Kahari et al, 1990). 
TNF-a treatment of cells has also been shown to result in the increased binding of a 
trans-acting factor which binds a negative element adjacent to the TGF-P-response 
element (TbRE) (Inagaki et al, 1995b ). It has therefore been postulated that TNF-a 
opposes TGF-P stimulation of the human a2(1) collagen gene via overlapping nuclear 
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signalling pathways. A recent study showed that TGF-P-induced a.2(1) collagen gene 
expression can also be inhibited by the basic fibroblast growth factor (bFGF). bFGF is 
capable of suppressing COL1A2 promoter activity in both normal and scleroderma 
fibroblast, suggesting a transcriptional inhibitory mechanism for bFGF (Ichiki et cl4 
1997). 
To summarise section 1.2.3; A complex set of transcription factors interact with the 
proximal promoters of the al(l) and a.2(1) procollagen genes. These factors and the 
cis-elements they interact with are essential in the regulation of these genes under 
different physiologic and pathologic conditions. A summary of the cis-elements and 
their corresponding trans-acting factors is shown in fig 1.1. 
mouse a1 (1) --~ 
-400 -300 -200 +1 
mouse a2(1) 
human a2(1) 
KEY TO TRANS-ACTING FACTORS : 









Fig 1 .1 Schematic representation indicating the approximate position of 
trans-acting factor interactions with the proximal promoters of the type I 
collagen genes. Note: IF-2 is reported to bind the mouse promoters. 
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1.2.4 Cell- and tissue-specific expression of the type I collagen genes 
1.2.4.1 The Alpha 2(1) procollagen gene 
Type I collagen gene expression is confined predominantly to fibroblast and 
osteoblastic cell lines in certain tissues, and is clearly maintained by cell- and tissue-
specific regulatory mechanisms. A number of cis-regulatory elements located in the 
proximal promoter, 5' flanking sequences, the first intron and far upstream sequences 
of the a.2(1) procollagen gene are thought to play a role in the tissue- and cell-specific 
expression of the gene. Early studies showed that tissue specific expression of the type 
I collagen genes can be determined at both transcriptional and post-transcriptional 
levels (Focht and Adams, 1984). Expression of the -2000 to +54 promoter of the 
mouse a2(1) promoter linked to a reporter gene in transgenic mice showed high levels 
of expression in many tissues. This expression was similar to that of the endogenous 
gene (Khillian et al, 1986). Using deletion constructs, Schmidt et al, (1986) also 
showed that the -2000 to +54 segment of the mouse a.2(1) procollagen gene is 
sufficient for the cell specific expression of the promoter and that two segments (-979 
to -502) and (-346 to -104) are required for optimal expression of the chimeric gene. 
Subsequently, the minimal sequences required for the cell and tissue-specific 
expression of the a.2(1) procollagen gene have been localised to the -350 to +54 
proximal promoter albeit at levels lower than that of the endogenous gene (Boast et al, 
1990, Niederreither et al, 1992). Although unique cell-specific promoter elements have 
not been defined as yet, a tandem repeat of the -315 and -284 sequence linked to the 
mininal a.2(1) collagen promoter (-41 to +54) showed considerably higher activity in 
type I collagen producing cell lines (Goldberg et al, 1990). Cell-specific expression of 
the human a.2(1) procollagen promoter has also been associated with trans-acting 
factor switching within the -107 to +54 region of the promoter (Parker et al, 1992). 
A transcriptional enhancer is located in the first intron of the mouse a.2(1) procollagen 
gene. The enhancer (+418 to +1524) functions in an orientation-independent manner 
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to stimulate both the a2( 1) procollagen promoter and a heterologous simian virus 40 
early promoter (Rossi and de Crombrugghe, 1987; de Crombrugghe et al, 1990). It 
should be noted that this intronic sequence has, however, not been shown to act as a 
transcriptional enhancer in transgenic mice (Goldberg et al, 1992). Two cis-elements 
have been located in the first intron and shown to bind a collagen intron binding factor 
(CIBF-1) and affinity purified Spl. CIBF-1 binding occurs at a 5'-TGTTTTAA-3' 
motif at +992, while the Spl binding sequence is located in a 'GT box' at +871 to 
+880 (Pogulis and Freytag, 1993). Contrary to the enhancing effect of the first intron 
in the mouse a.2(1) collagen gene, this region of the human a.2(1) procollagen gene, 
has an inhibitory effect. The human first intron contains two AP-1 motifs and a GT 
stretch. These sequences are absent in the mouse first intron and the low sequence 
similarity between the human and mouse a.2(1) first introns could account for the 
contradictary results (Sheiwood et al, 1990). A transcriptional enhancer is also located 
in the far upstream region of the mouse a2( 1) collagen promoter. Sequences between -
13.5 to -19.5 kb have been shown to stimulate the cell-specific expression of the 350 
bp a.2(1) proximal promoter. Interestingly, the same DNA segment was able to 
activate the cell-specific expression of the al(l) collagen promoter (Bou-Gharios et al, 
1996). A number of other collagen genes contain activator and repressor elements in 
intronic sequences. Examples of these include the a2(XI), al(Il), al(X), al(l) genes, 
where sequences within the first intron contain positive regulatory elements (Tsumaki 
et al, 1996, Krebsbach et al, 1996, Beier et al, 1997, section 1.2.4.2) and the a2(IV) 
gene, where sequences within the third intron has an inhibitory effect on gene 
expression (Haniel et al, 1995). 
1.2.4.2 The Alpha 1(1) collagen gene 
Tissue-specific expression of the human a.1(1) collagen gene is effectively achieved 
with the -300 to+ 100 proximal promoter region (Bornstein et al, 1987; Rossouw et al, 
1987; Sokolov et al, 1995). Similar experiments with the mouse a.1(1) collagen gene 
identified 220 bp of the proximal promoter as being sufficient to direct tissue-specific 
expression of the mouse gene (Rippe et al, 1989). In combination with the proximal 
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promoter, other 5' flanking regions in the al(l) promoter have also been identified as 
important in expression of the gene. One of these, a major tissue-specific enhancer, is 
located in the 5' flanking region of the human al(l) collagen promoter (-2300 to -444) 
and confers high-level, position-independent expression of the human al(l) collagen 
gene in bone, tail and skin (Slack et al, 1991). Subsequent investigations indicated that 
sequences up to -804 of the human al(l) collagen gene could drive expression of a 
CAT reporter gene (Thompson et al, 1991). Deletion of the sequences between -625 
and -442 resulted in significant decreased expression, while deletion of the -804 to -
609 region resulted in elevated activity indicating that tissue-specificity of the human 
gene is determined by both positive and negative cis-regulatory elements in the 
promoter (Simkevich et al, 1992). 
Bedalov et al, (1994) reported that 3.5 kb of the rat promoter fused to a CAT reporter 
gene had similar expression patterns as that of the endogenous gene. Sequences 
located upstream in the rat al(l) collagen promoter have potential osteoblast- and 
odontoblast-specific stimulatory elements (-3521 to -1672) (Pavlin et al, 1992). In 
support of this, the sequences between -2.3 and -1.7 kb have been shown to be 
required for COLlAl expression in bones and teeth, while sequences between -3.5 
and -1.7 are required for expression in tendon (Begdanovic, 1994). Seperate cis-
elements in the mouse al(l) collagen upstream promoter can also direct cell-specific 
expression in transgenic mice. Rossert et al, (1995) identified three cell-specific 
elements in the 3.2 kb mouse al(l) collagen promoter. Each of these elements confers 
al(l) expression in different collagen producing cell types. The minimal sequence 
required for high level expression in osteoblasts is a 117 bp segment (-1656 to -1540) 
fused to the proximal 220 bp promoter. A 28 bp region (-1656 to -1628) is proposed to 
bind cell-specific proteins for expression in osteoblasts while the -1575 to -1540 
region may bind ubiquitous proteins involved in high level expression of the gene 
(Rossert et al, 1996). A similar study showed that two different cis-regulatory elements 
direct cell-specific expression of the al(l) procollagen gene in stellate, skin and 
tendon cells. While the 0.44 kb 5' promoter region (including the first intron) was 
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sufficient for expression in stellate cells, high level expression in skin and tendon 
required the -2.3 to -0.44 kb region (Houglum et al, 1995). Recently it has been shown 
that a 1.9 kb fragment of the al(l) gene containing 0.48 kb of the promoter and most 
of the first intron and exon is sufficient to drive expression of both the COLlAl and 
COL1A2 gene in transgenic mice (Ala-Kokko et al, 1996). 
Certain evidence exists for the importance of the first intron in optimal tissue and cell-
specific expression of the al(l) collagen gene. Th.ere is, however, considerable 
controversy regarding the exact function of the first intron as the results obtained in 
transfection studies and transgenic mice are not consistent. Initial experiments 
indicating a role for the first intron stemmed from the development of Mov 13 mice in 
which retroviral insertion into the first intron resulted in the complete inhibition of the 
al(l) collagen gene, leading to the subsequent death of these mice (Schnieke et al, 
1983, Harbers et al, 1984). The exact mechanism of this inhibition remains unclear, 
and Chan et al, ( 1991) excluded DNA methylation as being responsible for the 
inhibition and proposed that alterations in chromatin structure may be responsible. 
Interestingly, Kratachwil et al, (1989) report that although the al(l) collagen gene is 
inhibited in the fibroblasts of Mov 13 mutants, expression of the gene is detected in 
odontoblasts This suggested that retroviral insertion in the first intron inteiferes with 
tissue-specific transcriptional control of the a 1 ( 1) gene. Both positive and negative cis-
elements are located in the first intron of the human gene (Bornstein et al, 1987, 1988; 
Bornstein and McKay, 1988; Liska et al, 1990; Boast et al, 1990; Simkevich et al, 
1992; Liska et al, 1992). A highly conserved AP-1 binding site has been identified in 
the first intron and is thought to play a role in al(l) collagen gene expression (Liska et 
al, 1990; Katia et al, 1992; Maata et al, 1993). The AP-1 element can act either as a 
positive or a negative element in a cell-specific manner (Katai et al, 1992). Although 
an initial study on the inhibition of human al(l) collagen gene expression by Ras 
indicated that the first intron had no role in this down-regulation (Slack et al, 1992), a 
later investigation showed that loss of AP-1 binding at the intronic site, could in part, 
account for the inhibition of al(l) collagen gene expression observed in these cells 
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(Slack et al, 1995). Additional cis-elements in the first intron include two Spl binding 
motifs (+820 to+ 1093), a viral core enhancer element (+999 to+ 1007) and a DNasel 
footprint (+951 to +978) (Bornstein et al, 1987; Rossouw et al, 1987; Liska et al, 
1992). 
While a number of studies emphasize the role of the first intron as that of a positive 
regulatory element (Bornstein et al, 1987, 1988; Slack et al, 1991; Simkevich et al, 
1992; Liska et al, 1994), others have found that intronic sequences are not essential for 
the tissue-specific expression of the gene (Olsen et al, 1991; Bornstein and McKay, 
1988; Sherwood and Bornstein, 1990; Boast et al, 1990; Sokolov et al, 1993, 1995; 
Houglum et al, 1995). A thorough attempt to assess the literature on the nature of the 
al(l) first intron has been made by Bornstein, (1996). The author proposes a number 
of possible causes for the conflicting data, one of particular interest to this thesis 
questions the placement of functionally equivalent regulatory elements in different 
species. Indeed, the results presented in section 3 of this thesis, suggest that subtle 
differences in the human and rodent a2( 1) procollagen promoters may result in 
significant differences in promoter activity. These observations therefore suggest that 
cross-species experiments should be viewed with care. 
It is also likely that co-operative interactions between ubiquitous promoter-binding 
factors and trans-acting factors and cis-elements not identified as yet are essential for 
the tissue- and cell-specific expression of the type I collagen genes. As such, the 
search for other regulatory sequences in the type I collagen genes are under way. A 
recent study reported that a region in the mouse al(l) collagen gene contains the 
binding sites for two upstream stimulating factors, USF-1 and USF-2 (Rippe et al, 
1997). 
1.3 REPRESSION OF THE TYPE I COLLAGEN GENES 
While transcriptional activation mechanisms are well documented for most genes, 
including the type I collagen genes, considerably less is known about the processes 
involved in transcriptional repression (see Johnson, 1995). There are, however, models 
that convincingly argue for the presence of proteins which inhibit gene transcription. 
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Certainly, transcriptional repression is as important an event as activation for a number 
of reasons, all which are pertinent to the type I collagen genes. These include; (a) 
negative regulation of genes may be required in certain cell and tissue types, (b) some 
genes are developmentally controlled, hence repressor mechanisms play a key role in 
developmental expression, ( c) genes which can be induced in response to a stimulus or 
stimuli need to be "turned off' when the stimulus is removed, eg collagen synthesis in 
wound healing. 
The following section will review repression of the type I collagen genes under two 
subsections; (1) Mechanisms by which repression can be achieved and (2) Events that 
down-regulate type I collagen gene expression by utilising the mechanisms described 
in (1). 
1.3.1 Mechanisms of achieving repression 
1.3.1.1 Repression by trans-acting factors 
Essentially three broad mechanisms of transcriptional repression involving trans-acting 
factors exist, these include the inhibition of binding of activator proteins, blocking of 
activation of the transcription initiation complex and direct binding of a trans-acting 
repressor which leads to silencing of genes (reviewed by Levine and Manley, 1989; 
Renkawitz, 1990; Clark and Docherty, 1993). Repressor mechanisms of the kind 
where activators and repressors compete for the same control element account for a 
diversity of transcriptional control. Examples of competition between transcription 
factors resulting in repression have been reported for several genes. These usually 
involve overlapping or closely linked sequences within the promoter of the gene. For 
example, a 91 kD protein which binds the GC rich sequences in the EGF-receptor and 
'3-actin promoters, inhibits transcription of these genes by preventing activators from 
binding (Kageyame and Pastan, 1989). A repressor of the sperm histone H2B-1 gene, 
the CCAAT-displacement protein (CDP) acts as a competitor for interaction between 
the CCAA T binding protein and DNA (Barberis et al, 1987). CDP is also implicated 
in blocking the binding of the CCAA T binding factor, CP-1, to the myelomonocytic 
specific gp9 l-phox promoter (Skalnik et al, 1991; Lievens et al, 1995). Similar results 
were obtained for the bZIP factor E4BP4 which overlaps in DNA binding-site 
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specificity with the transcriptional activators CREB and ATF (Cowell and Hurst, 
1994). 
It can be speculated that the inhibitozy factors, IF-1 and IF-2 identified as inhibitors of 
the type I collagen genes do so in a competitive manner in view of the fact that a 
number of other positive trans-acting factors bind to the same DNA element ( section 
1.2.3.1.3). Data presented by Parker et al, (1992) (and section 2 of this thesis), suggest 
that two trans-acting factors, complex II (potential repressor) and complex ill 
(potential activator) interact with the same DNA element in the human a.2(1) 
procollagen promoter. It is possible that competition for binding to the recognition 
sequence may occur in cell lines where both these factors are present. A negative DNA 
element located between -173 and -155 in the human a.2(1) collagen promoter also 
binds a potential transcriptional repressor (Thn et al, 1996). Negative regulatozy 
elements are also located in the al(l) procollagen promoter between -804 to -609 
(Simkevich et al, 1992). 
1.3.1.2 Repression via methylation 
Hypermethylation of genes are generally associated with the inactivation of these 
genes, while under-methylation is associated with transcriptionally active genes 
(reviewed by Boyes and Bird, 1991). A number of studies indicate that 
hypermethylation of the type I collagen genes may result in its inactivation (Parker et 
al, 1982, 1986; Smith and Marsilio, 1988). It was initially thought that retroviral 
insertion into the intronic sequence of the COLlAl gene in Mov13 mice resulting in 
hypermethylation of the gene was responsible for inactivation of the gene (Jahner and 
Jaenisch, 1985). Chan et al, (1992) however, reported that even in the absence of 
methylation, COLlAl promoter activity was suppressed in a cell-specific manner in 
Mov 13 cells, and speculated that the insertion of the retroviral DNA in the first intron 
probably prevented the formation of correct methylation patterns and chromatin 
structure resulting in inactivation of the gene. DNA methylation has also been 
implicated in the inhibition of a.2(1) collagen gene expression in W8 cells. 
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Hypermethylation within the promoter and first exon of the gene is obsetved in these 
cells and methylation of two sequences (-345 to +58 and -218 to +58) specifically 
inhibited expression of the gene (Guenette et al, 1992). The exact mechanism by 
which methylation inhibits transcription is still poorly understood. Chromatin 
structure, however, plays an important role in this process, since methylated DNA 
forms chromatin which is insensitive to DNasel treatment (Keshet et al, 1986). 
Several proteins which bind methylated DNA have been characterised and are thought 
to be involved in the repression of methylated genes (Lewis et al, 1992; Jost and 
Hofsteenge, 1992). Repression of the murine al(l) collagen promoter by DNA 
methylation, however, appears to occur by a mechanism independent of methyl C-
binding proteins (Rhodes et al, 1994). The inhibitory effect of DNA methylation in 
vertebrate cells therefore probably results from cooperativity between chromatin 
structure and methyl C-binding proteins. 
1.3.2 Events resulting in down-regulation of type I collagen synthesis 
1.3.2.1 Repression by exogenous factors 
The cytokines TNF-a and IFN-y can synergistically suppress the stimulatory effect of 
TGF-f3 on the type I collagen genes (section 1.1.3.3). TNF-a inhibits a2(1) collagen 
gene expression at a transcriptional levei while IFN-y inhibition is postulated to 
function at a post-transcriptional level (Kahari et al, 1990). Cytokines such as 
Interleukin-I and TNF-y may have both inhibitory and stimulatory effects on type I 
collagen gene expression (reviewed by Slack et al, 1993). The major negative regulator 
of type I collagen gene expression appears to be IFN-y. This inhibition occurs at a 
post-transcriptional level since no change in primary transcript formation is observed 
while steady state mRNA levels are reduced by 60-700/o by 48 hours after exposure of 
cells to IFN-y (Slack et al, 1993). Down-regulation of the types I and III collagen genes 
can also be achieved in a dose-dependent manner by the melanoma growth-stimulatory 
activity cytokine, [(MGSA)/GRO] (Unemori et al, 1993). Other exogenous factors 
such as 1,25-Dihydroxyvitamin D3 (vitamin D) has both stimulatory and inhibitory 
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effects on type I collagen gene expression. A 41 bp fragment in the al(l) procollagen 
promoter is reported to be involved in vitamin D mediated transcriptional repression in 
osteoblastic cells (-2256 to -2216). This sequence shares homology with vitamin D-
reponsive elements identified in the osteocalcin gene (Pavlin et al, 1994). 
1.3.2.2 Repression by transformation 
Collagen synthesis is markedly reduced upon transformation by several agents 
(Bornstein and Sage, 1989; Schreir et al, 1988). Both chemically and virally 
transformed fibroblasts exhibit reduced type I collagen synthesis (Parker and Fitschen, 
1980; Parker et al, 1989; Guenette et al, 1992). Transformation by oncogenes such as 
v-src, v-mos and v-fos all have an inhibitory effect on transcription of the type I 
collagen genes (Sandmeyer et al, 1981; Schmidt et al, 1985; Hoemann and Zarbl, 
1990). The c-Myc oncoprotein specifically inhibits the expression of al(l), a2(1) and 
a3(IV) collagen genes in mouse 3T3-Ll cells (Yang et al, 1991). Similarly, 
constitutive expression of the Fos oncoprotein inhibits the expression of al(l) 
collagen gene in MC3T3-El cells (Kuroki et al, 1992). Cells that have been 
immortalised by mutant p53 or the Ras oncogene have reduced levels of both al(l) 
and a2(1) collagen gene expression (Eizenberg and Oren, 1991; Slack et al, 1992). 
1.4 SIGNAL TRANSDUCTION AND COLLAGEN EXPRESSION 
1.4.1 The effect of signalling pathways on collagen gene expression 
The fact that type I collagen gene expression can be up or down regulated by a number 
of oncoproteins and cytokines implies that cytoplasmic kinase cascades are associated 
with the regulation of the collagen genes. These responses vary dramatically in a cell-
specific manner indicating that signal transduction by different stimuli may occur via 
cell-specific mechanisms. A stimulator of protein kinase C activity, phorbol 12-
myristate 13-acetate (PMA) causes a decrease in collagen synthesis in murine 
osteoblasts (Hrurison et al, 1990), mouse epidermal cells (Sobel et al, 1983), NIH3T3 
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mouse fibroblast (Rabin et al, 1986) and in human fetal skin fibroblast (Greenwel et al, 
1997). Contrary to these findings, PMA has a stimulat01y effect on a2(1) collagen 
gene expression in 3T3-Ll cells when compared to a PMA-non-responsive cell variant 
(Stuiver et al, 1991). Together these studies show that protein kinase C mediated 
signalling pathways have a regulatory effect on the expression of the type I collagen 
genes. 
The response of cells to TGFP is mediated via signal tranduction pathways which 
involve the activation of protein kinase C and other transmembrane serine/threonine 
kinases. These kinases in turn lead to the phosphorylation of other effector substrates 
such as Raf- I kinase, myristorylated alanine rich C kinase substrate (MARCKS) and 
cytoplasmic SOS (reviewed by Massague and Weis-Garcia, 1996; Mufson, 1997; 
Hunter, 1997). The action of protein kinase C has also been implicated in the down-
r~ation of type II collagen gene transcription in chondrocytes by TGF-P and 
fibroblast growth factor (FGF) (Bradham et al, 1994). 
It is thus possible that a cascade of events resulting from the activation of kinases such 
as protein kinase C may play a key role in the regulation of expression of the type I 
collagen genes via modification of transcription factors. Activated protein kinase C 
and other kinases such as mitogen-acitivated protein kinase (MAP kinase) can 
translocate to the nucleus where they phosphorylate a number of transcription factors 
(Boulikas, 1995). There are three main levels via which phosphorylation events can 
modulate transcription factor activity. These include entry of transcription factors into 
the nucleus, modulation of the DNA binding activity (positively or negatively) and, 
finally, phosphorylation can affect the transactivation activity of transcription factors 
(reviewed by Hunter and Karin, 1992; Sassone-Corsi, 1994; Karin and Hunter, 1995). 
A well characterised example where phosphorylation events lead to nuclear import is 
that of NF-ld3. Phosphorylation of the inhibitor of NF-ld3, Ild3, results in the 
dissociation of the NF-1d3-I1d3 complex followed by rapid translocation of NF-KB to 
the nucleus (Ghosh and Baltimore, 1990). The regulation of DNA binding activity by 
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phosphorylation has been reported for numerous transcription factors. Most reports, 
however, implicate inhibition of DNA binding in response to phosphorylation at 
specific sites in a transcription factor. These include c-Jun, Max, Oct-1 (Hunter and 
Karin, 1992), Ets, ERF (an Ets domain protein) (Sgouras et al, 1995) and CREB 
(Mahonety et al, 1992). While direct phosphorylation of the interferon consensus 
binding protein (ICSBP), a transcriptional repressor, prevents DNA binding, 
phosporylation of a specific tyrosine allows ICSBP to bind its' target DNA via 
association with other transcription factors (interferon regulator factors, IRF-1 and 2) 
(Sharf et al, 1997). One of the best documented examples of the role of protein 
phosphorylation in the regulation of transcription is that of the components of AP-1, 
Jun and F os. Phosphorylation causes an increase in the transcriptional activities of the 
c-fos and c-jun genes. The newly synthesised Jun and Fos proteins combine to form 
the AP-1 complex which on phosphorylation of the Jun activation domain enhances 
the transcriptional activity of AP-1 (reviewed by Hunter and Karin, 1992). 
Although well docwnented examples of stimulation of DNA binding activity by 
phosphorylation are rare, a recent report shows that phosphorylation of A TF-1 
enhances DNA binding and the subsequent activation of the Na,K-ATPase al subunit 
gene promoter. Dephosphorylation of nuclear extracts results in the loss of ATF-1 
DNA binding at a ATF/CRE binding site in the promoter (Kobayashi et al, 1997). In 
section 3 .2.5 of this thesis we report that dephosphorylation and inhibition of kinase 
activity also result in reduced binding of transcription factors to the hwnan a2( 1) 
procollagen promoter. Signal transduction pathways associated with Raf and MAP 
kinase have been implicated in the regulation of rat al(l) collagen expression. MAP 
kinase and Raf kinase activities are associated with the stimulation and inhibition of 
the al(l) collagen promoter respectively. These kinase activities are mapped to the 5'-
untranslated region of the gene, including the proximal Spl, NF-1 and the TGF-P 
activating element (Davis et al, 1996). 
The inhibition of protein phosphatases 1 and 2A result in suppression of type I 
collagen gene regulation. This implies that dephosphorylation events are also required 
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for the activation of the type I collagen genes (Westermarck et al, 1995; Wang and 
Raghow, 1996). It is possible that Spl may be one such factor, since 
dephosphorylation of Spl results in enhanced DNA binding and transcriptional 
activation of the acetyl-coA carboxylase gene (Daniel et al, 1996). This is in support of 
the proposal by Greenwel et al, (1995) that tyrosine dephosphorylation of nuclear 
proteins, possibly Spl mimic TGF-P stimulation of the human a.2(1) procollagen 
gene. It is therefore highly probable that signal transduction pathways resulting in both 
the phosphorylation and dephosphorylation of transcription factors have a significant 
effect on the regulation of type I collagen gene transcription. 
1.4.2 The effect of intact type I collagen on signalling pathways 
An intact type I collagen heterotrimer and other components of the extracellular matrix 
(ECM) are important for cell adhesion and anchorage dependent cell growth. Gross 
alterations in ECM components can result in the progression and metastasis of 
tumours (reviewed by Lochter and Bissel, 1995). In cell lines representative of a 
tumorigenic state, transfection of components of type I collagen results in partial 
reversion of these cells to a 'normal' state. Transfection of the full length a.2(1) 
collagen cDNA into chemically transformed cell line, W8, where no a.2(1) collagen 
chains are synthesised, resulted in a decrease in colony formation in soft agar and an 
increase in cell adhesion (Lim et al, 1994). Similarly, Travers et al, (1996) reported 
that restoration of the a2(1) collagen chain in Ras-transformed mouse fibroblasts result 
in the suppression of malignant properties. The restoration of type I collagen in these 
cells was correlated with the down-regulation of a Ras-responsive gene, suggesting 
that type I collagen has a functional role in oncoprotein signalling pathways associated 
with tumorigenicity. 
The mechanism by which type I collagen is involved in signal transduction occurs via 
the integrin family of proteins. ECM components such as type I collagen are ligands 
for members of the integrin family of heterodimers. The major integrin involved in 
type I collagen-mediated-signalling are alPl , a.2(31 and alP3 (Sonnenberg, 1993, 
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Haas and Plow, 1994). These integrins are responsible for regulating ECM 
remodulation and a 1 p 1 integrin receptor mediates signals which induce down 
regulation of type I collagen gene expression, while a2P 1 integrin is involved in the 
upregulation of collagenase (MMP-1) expression (Langholz et al, 1995). Type I 
collagen-integrin mediated signal transduction can involve both the stimulation and 
inhibition of protein kinases. Fibrillar collagens specifically regulate integrin signalling 
that lead to the stimulation of cdk2 inhibitors such as p27 and p21 resulting in the 
inhibition of smooth muscle cell proliferation (Koyama et al, 1996). 
Type I collagen itself may also have a feedback regulatory effect on its own 
expression. This proposal stems from experiments showing that the N-terminal 
propeptide of the al(l) collagen chain is associated with inhibition of endogenously 
produced type I collagen (Fouser et al, 1991). The exact mechanism by which this 
inhibition occurs is unknown, but down-regulation of type I collagen synthesis by 
fibroblasts grown in collagen lattices has been shown to involve both transcriptional 
and post-transcriptional mechanisms (Eckes et al, 1993). 
In conclusion, cellular control of and by type I collagen therefore involves a cascade of 
signal transduction pathways most of which still have to be identified. These signalling 
events may have an effect on transcription either in a direct manner by 
phosphorylation/dephosphorylation of specific transcription factors or in an indirect 
manner involving other kinase sensitive pathways. 
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CHAPTER 2: 
ANALYSIS OF COLLAGEN SYNTHESIS IN DIFFERENTIATED 
CELL LINES 
2.1 INTRODUCTION 
Cellular and tissue differentiation is characterised by the expression of a vast array 
of specialised genes encoding cell-specific proteins. One such protein is type I 
collagen, the synthesis of which varies widely in different tissues and cell types. 
These variations occur during processes such as embryogenesis, development, 
pathologic conditions and in the adult organism in a tissue and/or cell-specific 
manner (Parker et al, 1989; Ramirez et al, 1989; Slack et al, 1991; Sokolov et al, 
1995). The expression of type I collagen is confined mostly to cells of 
mesenchymal origin, while it is not produced by cells derived from the ectoderm, 
endoderm or hematopoetic cells (Bornstein and Sage, 1989; Ramirez et al, 1990; 
Prockop and Kivirikko, 1995). 
Studies to date have concentrated mostly on the transcriptional mechanisms 
involved in type I collagen synthesis and both transcriptional and post-
transcriptional mechanisms play a role in the cell and tissue-specific expression of 
the type I collagen genes (Focht and Adam, 1984; Simkevich et al, 1992; Slack et 
al, 1993). Trans-acting factors have been implicated in the regulation of both the 
al(l) and a2(1) collagen genes (Maity et al, 1988; Karsenty and de Crombrugghe, 
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1991; Hatamochi et al, 1988; 1993; Tamaki et al, 1995, Chen et al, 1997). The 
minimal promoter region (-350 to +54) has been found to be all that is required for 
the correct expression of the a2(1) collagen gene (Neiderreither et al, 1992). 
Subsequently, most of the transcription factors identified in the regulation of type I 
collagen gene expression were shown to bind within this region of the promoter. In 
the mouse a2( 1) procollagen promoter at least three sites within the minimal 
promoter have been identified as important for protein binding and promoter 
activity (de Crombrugghe et al, 1990 and Neiderreither et al, 1992). These sites 
include an inverted CCAAT-box between -84 and -80, a CAGA box between -250 
and -247 and an NF-1-like site between -312 and -300. The transcription factors 
which bind to these sites are the CCAAT binding factor (CBF), the CAGA-binding 
factor and possibly NF-1, respectively (Oikarinen et al, 1987 and Hatamochi et al, 
1988). NF-1 binding is thought to activate the mouse a2(1) collagen gene via a 
TGF-P response element. A reporter construct containing the -2000 to +54 region 
of the a2(1) procollagen promoter, displays increased expression upon TGF-P 
treatment. When the NF-1 binding site was included in a TGF-P unresponsive 
SV 40 promoter, inducibility of the promoter was observed (Rossi et al, 1988 and 
de Crombrugghe et al, 1990). Inagaki et al, (1995) however, have shown that 
although there is high sequence homology between the mouse and human a2( 1) 
procollagen promoters, TGF-P stimulation of the human a2(1) collagen gene 
promoter is thought to be achieved by the increased affinity of an Spl-DNA-
protein complex binding to the TbRE in the human a2(1) procollagen promoter. 
They implicated Spl in mediating the TGF-P effect and not NF-1 as thought to be 
the case in the mouse promoter reported by Rossi et al, (1988). Chung et al, 
(1 996), however, exclude Spl binding sites as a requirement for the TGF-P 
response in the human a2(1) procollagen promoter. They argue that TGF-P 
responsiveness in the COL1A2 promoter occurs via AP-1 binding between -265 
and -241. Subsequently, additional support for Sp 1 as the transcription factor 
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involved in TGF-f3 responsiveness in the human a2(1) procollagen promoter has 
been provided (Greenwel et al, 1997; section 1.2.3.3). 
The best characterised transcription factor involved in the regulation of the type I 
collagen gene is the mouse CCAAT binding protein (CBF). Hatamochi et al 
(1988), identified the mouse CBF as a member of a family of fairly ubiquitous 
proteins which bind CCAA T motifs in promoters of eukaryotic genes. The mouse 
CBF comprises three different components (A,B,and C) as previously described 
(Maity et al, 1992, Vuorio et al, 1995, section 1.2.3.1.1). 
Most of the studies on the a2( 1) procollagen gene have focused on the mouse 
proximal promoter (-350 to +54) while the factors binding within the 
corresponding region of the human a2( 1) promoter are poorly characterised. 
Recent studies by Inagaki et al, (1994, 1995) and Tamaki et al, (1995) propose 
GC-rich regions containing Sp 1 binding sites as regulatory elements in the human 
a2(1) procollagen promoter, while Chung et al (1996) reported that AP-1 binding 
is also essential for regulation of the gene. We have embarked on a study aimed at 
elucidating the factors which interact with the proximal COL1A2 promoter. A 
previous study has identified at least two factors binding within the region between 
-107 and -60 (including the inverted CCAAT box) of the COL1A2 promoter in a 
collagen producing cell line, CT-1 (Parker et al, 1992). An additional DNA-protein 
complex was observed in a cell line, SVWI-38, where no a2(1) collagen synthesis 
occurs. These differences implied negative regulation of the a2(1) procollagen 
gene in the SVWI-38 cell line .. 
Since type I collagen synthesis varied so widely in the two cell types, it was 
decided to explore the possibility of a correlation between a2(1) collagen 
synthesis and transcription factor binding to the proximal promoter of the gene in 
nine different cultured cell lines. To address this issue, a cross section of cell types 
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consisting of cells synthesising the a2( 1) chain of type I collagen and others where 
collagen synthesis is repressed was selected. The ability of these cells to produce 
type I collagen was examined by investigating collagen synthesis, steady state 
mRNA levels and primary transcript formation. This was followed by analysis of 
transcription factor binding to the proximal promoter of the a2( 1) procollagen 
gene in the different cell lines and seeking a correlation between transcription 
factor binding and the ability of the cell line to synthesise the a2( 1) chain of type I 
collagen. 
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2.2 RESULTS 
The findings by Parker et al, (1992) showed that a2(1) collagen synthesis is 
associated with differences in trans-acting factor binding to the proximal promoter 
of the gene. The collagen producing cell line (CT-1) contains predominantly 
complex I and III proteins, while the SVWI-38 cell line, where type I collagen 
expression is abolished, contains three DNA-protein complexes, I, II and III (fig 
2.1). The aim of this study was therefore to determine whether differential 
transcrtiption factor binding may be a more general cell-specific mechanism of 
control. Nine human cell lines displaying a wide range of type I collagen synthetic 
abilities were used in this investigation. The cells types ranged from normal lung 
fibroblasts, transformed lung fibroblasts, skin fibroblasts, fibrosarcoma, 
hepatocellular carcinoma, lymphoblastoid and breast epithelial cells. The 
experiments performed in this study included; (i) measuring type I collagen protein 
synthesis by labelling cells with 3H-proline and analysing secreted proteins; (ii) 
determining the steady state levels of a2(1) mRNA by Northern hybridisation 
analysis and (iii) determining primary transcript formation by nuclear run-on 
transcription assays. (iv) Nuclear proteins extracted from these cell lines were used 
in EMSA's using the -107 to -60 fragment of the COL1A2 promoter. 
2.2.1 Analysis of type I collagen synthesis 
Cells were labelled with 3H-proline, proteins secreted into the medium were 
extracted and the pepsin-resistant proteins analysed on SDS 7% polyacrylamide 
gels (section 6.5.1 ). The amount of pepsin-resistant collagenous material obtained 
from each cell line is shown in fig 2.2.A. As can be seen from the SDS-
polyacrylamide gels (fig 2.2.B) the cells of fibroblast origin; WI-38 (lung 
fibroblast), CT-1 (WI38 fibroblasts transformed by y-irradiation) and FG0 (skin 
fibroblasts), all synthesise both the a I (I) and a2( I) chains of type I collagen. 









Fig 2.1 Trancription factor· binding to the proximal promoter of the human 
a2(1) procollagen gene. (A) Wild type a2(1) promoter sequence between -107 to -60 
from transcription initiation site. The inverted CCAAT box is boxed. (B) Electrophoretic 
mobility shift assays using the radioactively labelled DNA fragment showed in (A) as a 
probe. DNA-protein complexes were analysed in duplicate using 4µg crude nuclear 
protein from CT-1 or SVWI-38 cells incubated with 1 ng of 
32P-labelled DNA (104 cpm) 
and electrophoresed on non-denaturing 5% polyacrylamide gels (section 6.4.3). Dried gels 
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Fig 2.2 Type I collagen synthesis in differentiated cell lines. (A) Cells were 
labelled with 3H-proline, secreted proteins were extracted and treated with pepsin (section 
6.1.3). Pepsin-resistant material was precipitated with TCA and radioactive counts 
determined. Pepsin-resisitant collagenous material were corrected for cell number and is 
shown for the various cell types. Results are of the mean ± S.D. (B) Radioactively 
labelled pepsin-resistant collagenous material, corrected for cell number was resolved on 
SDS 7% polyacrylamide gels. Dried gels were exposed to X-ray film for 48 hours. 
Molecular weight markers are indicated on the left and the position of the al(l) and cx.2(1) 
procollagen chains are indicated on the right hand side of the figure. 
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The HT1080 (fibrosarcoma), HepG2 (hepatocellular carcinoma), L-77 
(lymphoblasts), MDA-MB-231 and ZR-72-2 (breast cancer epithelial cells) 
contained no detectable a2(1) or al(l) collagen, while the SVWI-38 (WI-38 
transformed with simian virus-40) contained no a2(1) chains but reduced amounts 
of al(l) chains (fig 2.2.B). The al(l) chain in SVWI-38 cells had an altered 
electrophoretic mobility due to overmodification of these chains as observed by 
two-dimensional cyanogen bromide peptided analysis (Parker et al, 1989). Of 
note, is that the HT1080 cells (fibrosarcoma) did not synthesise any significant 
amounts of type I collagen. 
The cell lines included in this study, showed a varied degree of type I collagen 
synthesis and were thus suitable for assessing the cell-specific mechanisms of type 
I collagen synthesis. Since our interest was the elucidation of the transcriptional 
regulatory mechanism(s) responsible for the observed differences in a2(1) 
collagen synthesis in these cells, the a2( 1) collagen mRNA levels were 
determined. 
2.2.2 Alpha2(1) collagen mRNA levels in differentiated cell lines. 
2.2.2.1 Northern Hybridisation Analysis 
To determine steady-state mRNA levels, cytoplasmic RNA was isolated from the 
various cell lines as described by Chomczinsky and Sacchi, (1987). The purity of 
the RNA was determined spectrophotometrically and 5µg total RNA from each 
cell line was electrophoresed on 1 % agarose-formaldehyde gels (fig 2.3.A). The 
RNA was transfered to nylon membranes as described in section 6.6.2.1. and 
hybridised to radioactively labelled a2(1) collagen (Myers, et al 1981) and f3-actin 
probes (Gunning et al, 1983). Results obtained by Northern blot analysis (fig 
2.3 .B) followed the same trend as the results obtained in the collagen synthesis 
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experiments in the different cell lines (fig 2.2). This indicated that down-regulation 
of the a.2(1) collagen gene may occur at a transcriptional level in these cell lines. 
To obtain a direct correlation with transcription, the rate of newly formed type I 
collagen m.RNA transcripts in the different cell lines were examined using nuclear 
run-on transcription assays. 
2.2.2.2 Nuclear run-on transcription assays 
The nuclear run-on transcription assay was used to identify the formation of newly 
transcribed RNA and is therefore a direct indication of transcriptionally active 
genes. Radioactively labelled, newly transcribed RNA was hybridised to cloned 
gene fragments to assess the transcriptional activity of the type I collagen genes in 
the various cell types. The results indicate that differences in a.2(1) collagen 
synthesis occur at a transcriptional level (fig 2.4). Cells of fibroblast origin 
displayed considerable type I collagen transcripts, while the other cell types 
showed little to no transcripts. Although no a.2(1) collagen protein and m.RNA 
were detected in the HT1080 (fibrosarcoma) cell line (fig 2.3.B), high levels of 
nascent al(l) and a.2(1) collagen transcripts were detected in this cell line (fig 
2.4). A similar finding has been reported in HeLa cells, where type I collagen is 
transcribed but steady state mRNA or protein are not detected (Furth et al, 1991). 
The SVWI-38 cell line, which showed no a.2(1) chain synthesis or steady state 
m.RNA, contained very low levels of nascent a.2(1) run-on transcripts (fig 2.4.A 
and B). This result is not completely suprising, as it may be possible that the gene 
may not be entirely silenced in this cell line, but could be in a partially active ( or 
partially repressed) state. 
Analysis of type I collagen gene expression, in particular the a.2( I) chain, clearly 
indicated that the levels of type I collagen varied significantly in the different cell 
lines used in this study. A mechanism that could account for these variations in 
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Fig 2.3 Steady state mRNA levels in the different cell lines. (A) Cytoplasmic 
RNA was extracted from the different cell lines by the method of Chomzcinsky and 
Sacchi, (1987). After determining the purity of the RNA spectrophotometrically, 5µg of 
total RNA was loaded on 1% agarose formaldehyde gels. The position of the 28S and 18S 
RNA is indicated on the figure. (B) RNA from the gel shown in (A) was transfered to 
nylon membranes, UV cross-linked and the membranes hybridised to a.2(1) collagen 
specific and a f3-actin probes to correct for loading errors. Membranes were exposed to X-
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Fig 2.4 Nuclear run-on transcription assays of newly transcibed RNA from 
different cell lines. (A) 32P- labelled nuclear run-on transcripts were prepared as 
described in section 6.6.2.2 and hybridised to cloned al(l), a2(1) and f3-actin DNA 
immobilised onto nitrocellulose membranes. Membranes were exposed to X-ray film for 
16 hrs. The vector pUC-19 was used as a negative control and f3-actin was used as an 
internal control. (B) Bar graph showing a2(1) procollagen trancripts expressed relative to 
the amount of f3-actin transcripts. Although the SVWI-38 cell line, expresses a2(1) 
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the gene. It was therefore decided to determine if the transcription factors which 
bind the proximal promoter region of the human a2( 1) procollagen gene, do so in 
a cell-specific manner. The eventual aim being to correlate the data obtained thus 
far with transcription factor binding to the a2( 1) procollagen promoter in the 
different cell lines. 
2.2.3 Transcription factor binding to the human a.2(1) procollagen 
promoter. 
The results obtained in the nuclear run-on experiments indicated that the 
differences in collagen synthesis in these cell lines reside mainly at the level of 
transcription. Parker et al (1992), showed that the absence of a2(1) procollagen 
gene expression in SVWI-38 cells is associated with differential transcription 
factor binding to the -107 to -60 region of the human a2( 1) procollagen promoter 
(fig 2.1). This region of the promoter contains the binding site for the CCAAT 
binding factor (G/CBE) and the recently identified adjacent site, the CME 
(collagen modulating element). The CME is described by Collins, (1993) and 
Collins et al, (1997). These studies showed that the sequences within this region of 
the a2(1) procollagen promoter are critical for the expression and regulation of the 
gene. 
The G/CBE and CME are adjacent to each other (fig 2.5) and bind to distinct 
DNA-binding proteins. The G/CBE (GGAGG/CCAAT Binding Element) binds 
the ubiquitous CBF while the CME bind an as yet unidentified protein or proteins. 
These interactions appear to be responsible for differences in transcriptional 
activity of the a2(1) procollagen gene (Collins et al, 1997). 
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Fig 2.5 Transcription factor binding sites in the proximal promoter of the 
human a2(1) procollagen gene. The G/CBE contains an inverted CCAAT box and 
binds the complex I proteins. The adjacent element, the CME, binds both the complex II 
and III proteins (see fig 2.6). 
It was therefore logical to determine the presence of these transcription factors in 
the range of cell lines used above, in an attempt to explain the observed 
differences in a2(1) . collagen synthesis. Nuclear proteins were isolated from the 
different cell lines by the method of Dignam et al (1983). Binding of nuclear 
proteins to the -107 to -60 COL1A2 promoter fragment was analysed by 
electrophoretic mobility shift assays (EMSA) as described in section 6.4.3. Cells 
of fibroblast origin (WI-38, CT-1, FG0 , HT1080), where a2(1) collagen mRNA 
transcripts were detected, show predominantly two protein factors binding to this 
region of the promoter (complex I and complex III). In the cell lines where a2(1) 
collagen synthesis is not detected (SVWI-38, HepG2, L-77, MDA, ZR), a third 
DNA-protein complex, (complex II) is detected (fig 2.6.A). The complex I 
protein( s) are fairly ubiquitous, found in varying amounts in all the cell types and 
is thought to be a member of the CCAA T binding family of proteins ( evidence for 
this is provided in chapter 3). In the L-77, MDA and ZR cell lines, complex II 
completely replaced complex III, whereas in the SVWI-38 and HepG2 cell lines, 
both complexes II and III were present. 
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Fig 2.6 DNA-protein complex formation in differentiated cell lines. (A) 4µg of 
nuclear protein isolated from the indicated cell lines were incubated with 32P labelled -107 
to -60 a2(1) procollagen promoter fragment. 2µg poly dldC.poly dldC was included in 
the reaction. DNA-protein complexes were fractionated on 5% non-denaturing 
polyacrylamide gels, the gels dried and exposed to X-ray film for 16 hrs. The collagen 
producing cells showed predominantly complexes, I and ill. Cells where collagen 
synthesis is not detected, contains an additional DNA-protein complex, II. (B) The 
intensity of the complex II and ill bands was quantitated by densitometric scanning the 
autoradiographs of triplicate experiments and the relative intensity of these complexes in 
each cell line is shown in the bar chart. Cell lines are arranged such that the high collagen 
producers are on the left, progressing to the non-producers on the right. Results are the 
mean± S.D. of four independent expreriments. 
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Based on these results it was proposed that regulation of human a2( 1) collagen 
synthesis occurs via the following mechanisms: 
1. In a2(1) collagen expressing cells: DNA-protein complexes I and III are 
involved in the co-activation of the COL1A2 gene. 
2. In cell types not expressing a2(1) collagen: DNA-protein complex II is a 
potential repressor of COL1A2. The absence of complex ill may also be 
significant in the repression of the gene. 
The CT -1 cell line showed trace amounts of complex II binding to the a2( 1) 
promoter which is in line with the observed 20% reduction in collagen synthesis in 
this cell line, when compared to that of the parental WI-38 cell line. The presence 
of trace amounts of complex II proteins in CT-1 cells may be responsible for the 
slight reduction in transcription observed. In the fibrosarcoma cell line (HT1080), 
where RNA transcripts were detected, both complex I and ill proteins were 
present. This is consistent with other cells where type I collagen synthesis occurs 
and is in agreement with the hypothesis that complex I and ill binding is 
associated with a2( 1) collagen transcription. 
In SVWI-38 cells, all three complexes, I,II and ill were present. The presence of 
trace amounts of a2(1) procollagen RNA transcripts seen in nuclear run-on 
transcription assays in these cells may be as a result of the presence of complex I 
and some complex ill proteins. There is therefore a direct relationship between 
a2( 1) collagen expression and trans-acting factor interactions with the proximal 
promoter of the gene. 
The hepatocellular carcinoma derived cell line, HepG2, contains all three 
complexes. Complex III, however was found in reduced amounts compared to the 
amount present in the collagen producing cells. Since we have proposed that 
complex III proteins may in part be involved in the activation of a2(1) procollagen 
gene expression, the reasons as to the presence of this complex in HepG2 cells still 
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remains unclear at the moment since this cell line contains no detectable a2( 1) 
collagen transcripts. It is, however, possible that the abundant presence of complex 
II may mask any possible activation that complex ID may have. 
Quantitation of the complex II and ID proteins in the various cell lines shows a 
direct relationship between the levels of these complexes and collagen synthesis 
(fig 2.6.B). 
This relationship holds true for all the cell lines used in this study, with the 
possible exception of SVWI-38 where the ratio for complex II:ID proteins were 
1: 1. As explained in section 2.2.2.2, the a2( 1) collagen gene was not completely 
silenced in this cell line, hence the detection of both DNA-protein complexes. 
2.2.4 DNA binding site analysis 
Methylation interference assays and mutation analysis showed that the different 
complexes binding the proximal promoter of the a2(1) procollagen gene, bind to 
distinct but adjacent elements (Parker et al, 1992 and Collins et al, 1997). EMSA's 
using an excess of cold oligonucleotides of the G/CBE and CME as competitors 
for protein binding were performed as described in section 6.4.3.1. SVWI-38 
nuclear extracts were used as they contained all three DNA-protein complexes. 
The G/CBE oligonucleotide specifically competed out complex I formation (fig 
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2.7.A), while the CME oligonucleotide competed out both complex II and III 
formation (fig 2.7.B). These results showed that the complex II and III proteins 
bind the same DNA consensus sequence, (5'-GGAGGCCCTTTT-3'). Complex I 
formation is not affected by this oligonucleotide, showing distinct formation of 
complexes I, II and III. The binding of complex II and III proteins appeared to 
occur with similar affinity to the CME, since a densitometric scan of this 
competition shows that the competition for both complexes is virtually identical 
(fig 2.7.C). 
2.2.5 Binding Kinetics of complexes I, II and III. 
Since competition experiments indicated that complex II and III formation are 
similarly competed for by unlabelled CME oligonucleotide, an investigation into 
the binding kinetics of the proximal a2( 1) procollagen promoter binding proteins 
was performed. Increasing amounts of radioactively labelled proximal a2( 1) 
procollagen promoter fragment was incubated with a constant amount of nuclear 
extracts containing either partially purified complex I, II or III proteins. EMSA's 
were performed as described in section 6.4.3. The radioactivity in the DNA-
protein complexes was determined using a phosphorimager. Binding curves of 
bound counts vs DNA concentration were generated and the dissociation constants 
determined. Fifty percent maximal binding was taken as the apparent :Ki. Complex 
I bound the labelled probe with an apparent :Ki of 2.9nM (fig 2.8.A), while the 
apparent :Ki for complexes II and III were approximately 4.2 nM and 3.5 nM 
respectively (fig 2.8.B and C). These dissociation constants are within close range 
of each other, indicating that complexes II/III bind the CME with similar affinities, 
although complex III proteins has a slightly higher affinity for binding than 
complex II proteins. 
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Fig 2. 7 Competition of complexes I, II and ill binding by molar excess of 
double stranded G/CBE and CME oligonucleotides. (A) An increasing molar 
excess of concatermerised double stranded G/CBE oligonucleotide was incubated with 
4µg of SVWI-38 nuclear extract for 10 minutes prior to the addition of the -107 to -60 bp 
32P-labelled a2(1) procollagen promoter probe. DNA-protein complexes were analysed on 
non-denaturing 5% polyacrylamide gels, the gels dried and exposed to X-ray film for 16 
hrs. (B) Increasing molar excess of double stranded CME oligonucleotide was incubated 
with SVWI-38 nuclear extracts as indicated in (A). (C) Autoradiographs were scanned 
and the percentage binding of complexes II and ill with increase molar excess of 
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Fig 2.8 DNA binding affinity of complexes I, II and m. EMSA's were 
performed using increasing concentrations of labelled a.2(1) procollagen proximal 
promoter fragment (-107 to -60) with 4 µg of partially purified complex I (A), TI (B) or 
III (C) proteins (section 6.4.3). The reaction mixtures were fractionated on nondenaturing 
5% polyaarylamide gels. The dried gels were exposed to X-ray film for 16 hours. Bound 
counts were determined using a phosphorimager and plotted against the total DNA 
concentration. Fifty percent maximal binding was taken as the apparent K..i. 
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2.4 DISCUSSION 
Steady-state levels of type I collagen mRNA is a major factor in the determination 
of type I collagen synthesis. In this study we showed a clear correlation between 
the ability of different cell lines to synthesise collagen and transcription factor 
binding to the proximal promoter of the human a.2(1) procollagen gene. This 
correlation implies that cell-specific regulation of the human a.2(1) collagen gene 
is mediated via the interaction of transcription factor binding to the proximal 
promoter. A way in which this regulation could be achieved, may be cell-type 
dependent and be due to trans-acting factor switching or the relative abundance of 
these factors in vivo. Interestingly, a recent study reported that nuclear proteins 
found in both collagen expressing and non-expressing cell types, exhibit cell-
specific in vivo DNA-protein interactions at the mouse proximal a.1(1) and a.2(1) 
procollagen promoter (Chen et al, 1997). 
The DNA elements which play a role in tran-acting factor interactions at the 
human proximal a.2( 1) pro collagen gene have been characterised by Parker et al, 
(1989) and Collins et al, (1997) and are located at positon -92 to -67. The 
upstream element, the G/CBE, contains an inverted CCAA T box and forms a 
single DNA-protein complex, complex I. This element is identical to the CBF 
binding site in the mouse Col1A2 promoter (Hatamochi et al, 1988) and it is 
therefore likely that the complex I proteins are related to or identical to the mouse 
CBF. The second element, the collagen modulating element (CME), forms two 
different DNA-protein complexes, II and III. 
This investigation showed that complexes Il and ill were associated with 
differences in a.2(1) collagen gene transcriptional activity in a variety of cell 
lines. All the cell lines assayed contained equivalent amounts of complex I 
proteins, whereas the amount of complex Il and ill proteins varied from cell line 
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to cell line. It is proposed that complexes I and III are present in cells where the 
a2(1) procollagen gene is expressed and may be partly responsible for the 
activation of the a2(1) procollagen gene (fig 2.9.A). 
The complex I proteins appear to be fairly ubiquitous, possibly a CCAAT-
binding factor, while complex II and III proteins are as yet uncharacterised. 
Complex I and ill proteins could co-operate with each other and with the 
transcription initiation machinery to activate the COL1A2 gene in a cell-specific 
manner. The cell-specific expression of a number of genes has been attributed to 
co-operative interactions of transcription factors. Tronche, (1989) and Wuarin et 
al, (1990), showed that cell-specific expression of the albumin gene is associated 
with the co-operative interaction of the CCAAT-binding factor (NF-Y) and a 
cell-specific factor, HNF-1 to adjacent elements within the albumin promoter. 
Hernandez-Munain and Krangel, (1994) showed that intact and appropriately 
positioned (adjacent) binding sites for c-Myb and the T-cell-specific CBF are 
both necessary and sufficient for enhancer activity in the T-cell receptor (TCR) 
gene. These two factors co-operate functionally to mediate the T-cell- specific 
expression of the TCR8 gene. Although the HT1080 cell line used in our study 
contained no detectable type I collagen protein or steady-state mRNA, newly 
formed RNA transcripts were present as shown by nuclear run-on experiments. 
This cell line contained both the complex I and ill proteins in EMSA's, which is 
in agreement with the hypothesis that complex I and ill proteins are involved in 
the activation of the COL1A2 gene. It can therefore be predicted that the -107 to 
+54 COL1A2 promoter-CAT construct should have activity in HT1080 cells. 
Preliminary results indicated that the construct had activity in these cells, albeit 
at levels lower than that detected in CT-1 cells but higher than that in non-
collagen producing cell lines such as SVWI-38, HepG2, MDA-MB-231 and ZR-
75-2 (data not shown). Similar findings have been reported in HeLa cells by 
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Fig 2.9 Model for the regulation of the human a2(1) procollagen gene. (A) In 
collagen producing cells, the complex I and ill proteins interact with their binding sites, 
the G/CBE and CME respectively to activate gene transcription. (B) In some cases, the 
relative levels of complex II and m proteins may serve to modulate the extent to which 
the gene may be active. (C) In cells where collagen synthesis is not detected, complex III 
proteins may be completely replaced by complex II proteins, resulting in gene inactivation. 
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Furth et al, (1991) where the type I collagen genes are transcribed, but a post-
initiation block prevents the formation of mature type I collagen mRNA. 
In cells where very little or no a2(1) collagen is expressed, the presence of a 
different DNA-protein complex, complex II is detected. This complex is not 
detected in cells where the gene is active, and it is on the basis of this finding 
that it has been proposed that the complex II proteins may be involved in the 
cell-specific repression of the COL1A2 gene (fig 2.9.C). The complex II 
proteins could bind the CME to inactivate the expression of the COL1A2 gene in 
one of the following ways; (a) complex II proteins interact with the G/CBE 
binding proteins and in this way blocks activation of the gene, (b) The complex 
II proteins may be able to inactivate the gene independently, without any 
interaction with the G/CBE binding proteins. A repressor of the CCAAT binding 
factor, the CCAAT-displacement protein (CDP) has been shown to displace the 
CCAAT binding protein from the sea urchin histone H2B- l promoter (Barberis 
et al, 1987). Similar findings have been reported for the repressor activity of 
CDP in HL-60 myeloid cells (Lievens et al, 1995). Walsh and Schimmel (1987) 
showed that myoblast and myotube nuclear extracts form a DNA-protein 
complex on the a-actin promoter, which is specific for the myotube cell-type, 
while a different DNA-protein complex is detected in non-myocyte cell types. 
Although the SVWI-38 and HepG2 cell lines contained no a2(1) collagen, both 
cell lines had detectable levels of both complex II and III proteins. A study by 
Inagaki et al, (1987) also reported that type I collagen mRNA is not detected in 
HepG2 cells. Nuclear run-on transcription assays showed that SVWI-38 produced 
trace amounts of the COL1A2 transcripts which suggests that the relative ratios of 
complex II and III proteins may be important in the level of COL 1A2 expression. 
The CT-1 cell line, which produces 80% of the type I collagen produced by its 
parent cell line, WI-38, also showed trace amounts of the complex II proteins. The 
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presence of trace amounts of complex II could account for the partial inactivation 
of the gene in CT-1 cells. It would therefore appear that a given cell may have 
both complex II and III proteins, but that the relative abundance of the different 
complexes will detennine the transcriptional activity of the gene (fig 2.9.B) A 
similar situation exist in the control of the human a-globin gene where factors 
which may be functionally limiting in nuclear extracts have been shown to play a 
role in the regulation of the gene in that two adjacent sites (a-IRP and a-CPI) bind 
constitutively expressed transcription factors, while another factor ( a-CP2), 
binding upstream of these sites is present in functionally limiting amounts 
(Barnhart et al, 1988; Kim et al, 1990) . 
Our results show that the complex II and III proteins bind the same element (CME) 
in the COL1A2 promoter. The relationship between these proteins is unclear at the 
moment, but the possibility that complex III may be a degradation product of 
complex II has been excluded. It is possible that they are two distinct transcription 
factors with common DNA-binding domains or they may be products of the same 
gene arising by alternate splicing and each having a specific function. Examples of 
the latter are described by Foulkes and Sassone-Corsi, (1992). 
At the onset of this study, our aim was to detennine whether a correlation between 
cell-specific a2(1) collagen expression and trans-acting factor binding to the 
promoter of this gene existed. The results obtained in this study clearly showed 
that there is a direct relationship between expression of the gene and trans-acting 
factor binding to the -107 to -60 region of the promoter. This relationship appears 
to occur in a cell-specific manner, where the relative abundance of the trans-acting 
factors may be important in the regulation of the gene. The trans-acting factors 
described here may play a role in cell-specific expression of a2( 1) collagen in 
combination with other transcription factors, such as the transcription initiation 
machinery and factors which interact upstream of the CCAA T box. 
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CHAPTER 3: 
SPECIES-SPECIFIC EXPRESSION OF THE a2(1) PROCOLLAGEN 
GENE. 
3.1 INTRODUCTION 
The transcriptional mechanisms involved in the cell and tissue specific regulation 
of the mouse a.2( 1) procollagen gene are well documented. Chapter 2 reported that 
the cell-specific regulation of the human COL1A2 gene may in part be controlled 
by trans-acting factor switching. These factors bind to adjacent elements in the 
proximal promoter of the gene. Collins et al, (1997) defined the exact sequences 
required for binding of these factors, where at least one of the three protein factors 
that bind the promoter is a member of the CCAAT-binding family. This 
conclusion is drawn from the observation that this factor binds the inverted 
CCAAT box in the COL1A2 promoter. 
The CCAAT-binding proteins consist of a family of proteins (section 1.2.3.1.1) 
and methylation interference analysis showed that the DNA sequence interacting 
with the human CCAA T-binding protein includes an upstream GGAGG box as 
well as the inverted CCAAT sequence (G/CBE) (Parker et al, 1992). It would 
appear that the protein factor/s which interact with the human G/CBE and the 
mouse CBF are similar. Experiments aimed at determining the interaction of 
mouse nuclear proteins with the human -107 to -60 a.2( 1) collagen promoter 
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region led to an investigation of the species-specific regulation of the gene. 
Species specificity of the osteocalcin gene has been shown by Heinrichs et al, 
(1993) to involve trans-acting factor interactions with two proximal elements in 
the promoter of the gene. One of the elements involved in this species-specific 
regulation is the CCAAT sequence. These studies suggest that a single base 
mismatch between the human and rat osteocalcin gene around the CCAA T box 
could be responsible for species-specific regulation of the gene. 
As more data regarding the TGF-P response in type I collagen gene expression is 
being generated, it is becoming clear that the mechanism by which this response is 
mediated differs between the human and mouse. While Rossi et al, (1988) 
proposed NF-1 as the factor involved in the TGF-P response in the mouse 
promoter, Inagaki et al, ( 1994) proposed that Sp 1 may be the factor involved in the 
human promoter. Contrary to this, an additional study suggested AP-1 as the 
transcription factor responsible for the TGF-P response in the human promoter 
(Chung et al, 1996). This has subsequently been shown not to be the case by 
Greenwel et al, (1997), who provide data in support of their original claim that 
Spl is the TGF-P responsive factor. There is, however, general agreement that the 
TGF-P response is mediated in a species-specific manner, possibly due to 
sequence divergence between the human and mouse promoters, allowing the 
interaction of different trans-acting factors. Collectively, these results and those 
presented in this chapter suggest that subtle differences at a nucleotide level 
between the human and rodent a2( 1) procollagen promoters may in part be 
responsible for species-specific regulation of the gene. 
Protein phosphorylation is one of the most versatile post-translational modification 
events widely used by cells in the control of biological processes. Signal 
tranduction pathways are mediated via the activation of a variety of kinases 
including, MAP kinases and protein kinase C, which can translocate to the nucleus 
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where they phosphorylate transcription regulators in a cell cycle-dependent 
manner or in response to various stimuli. A number of transcription factors such as 
p53, c-Myc, Oct-1 and SV-40 T-antigen that stimulate DNA replication, are 
known to be controlled by phosphorylation which alters their DNA-binding 
activities and interactions with other transcription factors (reviewed by Boulikas, 
1995). Protein kinase C-dependent mechanisms have been implicated in the 
regulation of collagen gene expression (Harrison et al, 1990; Stuiver et al, 1991; 
Greenwel et al, 1997). This kind of regulation can be mediated via transcription 
factors such as AP-1, known to be under the control of phosphorylation events 
(Hunter and Karin, 1995) and recently proposed to have a possible regulatory role 
in a2(1) procollagen gene expression (Chung et al, 1996). Tyrosine 
deposhorylation of nuclear proteins (possibly that of Sp 1) has also been reported 
to mimic TGF-13 responsiveness of the human a2(1) procollagen gene (Greenwel 
et al, 1995). Collectively these findings prompted a study aimed at determining the 
effect of phosphorylation/dephosphorylation on transcription factor binding to the 
proximal a2(1) procollagen promoter and the ultimate expression of the gene. 
This chapter describes experiments which allowed the determination of species-
specific mechanisms and phosphorylation events in the expression of the human 
a2(1) procollagen gene. 
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3.2 RESULTS 
3.2.1 Binding of rodent nuclear proteins to the human a2(1) procollagen 
promoter. 
Nuclear extracts from rodent cells with differing collagen synthetic activities were 
prepared by the method of Dignam et al, (1983). The 3T3 and 3T6 fibroblasts are 
rodent cells where a.2( 1) collagen is produced. An oncogenic ras transformed rat 
cell line, Rasrat-1 had been shown by Slack et al, (1992) to express very little type 
1 collagen and a mouse macrophage cell line (p388D1) where no a.2(1) collagen 
was detected are representative of cells where the gene is inhibited. Nuclear 
proteins from these cell lines were incubated with the -107 to -60 fragment of the 
human promoter (fig 3.1). Surprisingly, all four cell lines contained DNA-protein 
complexes with migration patterns like that of complex I and II proteins. This is in 
contrast to the results obtained with human nuclear extracts, where a difference in 
trans-acting factor interactions between collagen expressing and non-expressing 
cells were observed (section 2.2.3). The proposal that complex II proteins are 
associated with the repression of the human a.2( 1) procollagen gene does not 
appear to hold true when using rodent nuclear extracts. This observation led to an 
investigation regarding the interaction of trans-acting factors with both the human 
and rodent a.2( 1) procollagen proximal promoters. 
3.2.2 Analysis of cross-species promoter-binding activities 
To determine whether the DNA-protein complexes on the rodent promoter occured 
on the same sequences as the human gene, the mouse a.2( 1) collagen promoter 
containing plasmid, pR40, (Rossi and de Crombrugghe, 1987) was digested with 
the restriction enzymes Hindlll and Smal to release a 160 bp fragment (fig 3.2.A). 
This 160 bp HindIIVSmal fragment was cloned in the vector pUC19 (fig 3.2.B and 
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Fig 3.1 Interactions of mouse nuclear proteins with the human proximal 
a2(1) procollagen promoter (-107 to -60). Nuclear proteins from collagen 
expressing rodent cells, 3T3, 3T6 and rodent cells not expressing cx2(1) collagen, Rasrat-1 
(RRat) and mouse macrophages, p388D1 were incubated with 1 ng oflabelled human -107 
to -60 a.2(1) collagen gene fragment. The DNA-protein complexes were electrophoresed 
on non-denaturing 5% polyacrylamide gels at 4°C in 0.5X TBE and 150 V for 2-3 hours. 
The dried gel was exposed to X-ray film for 16 hours. The positions of complexes I and IT 
are indicated. 
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Fig 3.2 Cloning of the mouse -107 to +54 a2(1) procollagen promoter 
fragment. (A) The 160 bp fragment spanning -107 to +54 of the mouse a2(1) collagen 
promoter was released from the plasmid pR40 (Rossi and de Crombrugghe, 1987). The 
digested DNA was electrophoresed on 7% polyacrylamide gels and the 160 bp fragment 
eluted from the gel slices as described in section 6.3 .2.1. (B) The released HindIIl/Smal 
fragment was cloned into HindIII/Smal digested pUC19. A diagramatic representation of 
the cloning events is depicted and the resultant plasmid pma2(1)160 is shown. (C) After 
cloning of the mouse promoter fragment, enzymatic digestion of pma2(1)160 was used to 
confirm the presence of the cloned fragment. Hindill and EcoRl double digest released 
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Fig 3.3 Comparison of the human and mouse a2(1) procollagen proximal 
promoter sequences. (A) DNA sequence analysis (section 6.8) was performed using 
the sequenase protocol (Amersham) to confirm the presence of the 3 bp difference 
between the human and rodent a.2(1) procollagen promoters in the region immediately 
downstream of the CCAAT box. (B) Alignment of the -90 to -60 region of the human 
and mouse a.2(1) procollagen promoters, indicating the 3 bp difference between the two 
promoters. The G/CBE and CME sequences are indicated. 
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Comparison of the equivalent region of the human a2(1) procollagen promoter 
revealed a three base pair mismatch between the human and mouse promoters in 
the region corresponding to the CME. The complex I binding site in the human 
and rodent a2(1) procollagen promoters, however, was conserved (fig 3.3B). Since 
the mismatch occured at the core of the CME, it is conceivable that complex II/III 
formation may not occur on the mouse a2(1) procollagen promoter. To test this 
theory, the rodent -107 to +54 fragment was used in EMSA's using nuclear 
extracts from collagen expressing and non-expressing rodent cells (fig 3.4). In all 
the cell lines tested, only one protein complex, the CCAAT-binding factor (CBF) 
was detected on the rodent promoter. This result together with the data in fig 3.1, 
indicated that although the complex II proteins were present in rodent nuclear 
extracts, it is unable to bind the Col1A2 promoter. 
In order to assess the binding of human factors to the mouse promoter, nuclear 
extracts from representative a2( 1) collagen expressing and non-expressing human 
and rodent cells were used in EMSA's to detect DNA binding activities of trans-
acting factors to equivalent regions of the human and rodent promoters. CT-1 and 
3 T3 nuclear extracts were used as representatives of cells which express the 
human and rodent a2(1) procollagen genes respectively, while SVWI-38 and 
mouse macrophages (p388D1), represent cells where the gene is not expressed. 
EMSA's were performed using either the human or mouse a2(1) procollagen 
proximal promoters as a probe. Human nuclear extracts from a2(1) collagen 
expressing cells, CT-1, showed binding of complex I and III proteins to the human 
probe. Extracts from SVWI-38 cells where a2(1) synthesis is inhibited contained 
the additional protein complex, complex II. Nuclear extracts from rodent cells 3T3 
and p388D1, contained both complex I and II proteins which bound the human 
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Fig 3.4 DNA-protein complex formation between rodent nuclear extracts and 
the mouse a2(1) procollagen proximal promoter. Nuclear ex.tracts from a.2(1) 
collagen expressing cells, 3T3 and 3T6 as well as that from non-expressing cells, rasrat-1 
(RRat) and p388D1 were incubated with 1 ng of labelled mouse promoter fragment (as 
described in fig 3.1). DNA-protein complexes were electrophoresed on non-denaturing 
5% polyacrylamide gels as described in section 6.4.3. Dried gels were exposed to X-ray 
film for 16 hours. The position of the mouse CCAAT binding factor, CBF is indicated. 
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Fig 3.5 Cross-species DNA-protein interactions on the human and mouse 
a2(1) procollagen promoters. (A) Nuclear extracts from representative human and 
rodent collagen expressing and non-expressing cells were isolated as described in section 
6.4.1. CT-I and 3T3 are representative of human and rodent collagen expressing cells 
respectively, while SVWI-38 and p388D1 represent the non-expressing cells. 4µg of 
nuclear proteins were incubated with the human -107 to +54 promoter fragment. DNA-
protein complexes were separated on non-denaturing 5% polyacrylamide gels and dried 
gels were exposed to X-ray film for 16 hours. The positions of complexes I, Il and ill are 
indicated. (B) The same of amount of nuclear proteins described in (A) were incubated 
with the mouse -107 to +54 promoter fragment. EMSA's were performed as described in 
(A). A single DNA-protein complex with a similar migration pattern to that of complex I 
was observed. 
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When the same nuclear extracts were incubated with the equivalent region of the 
mouse a2(1) procollagen promoter, complex I was the only complex observed in 
all the cell lines (fig 3.5.B). These results are in agreement with those shown in fig 
3.4 where the human complex II and III proteins were not detected on the rodent -
107 to +54 promoter fragment. The 3 bp mismatch is therefore sufficient to abolish 
the formation of complexes II and III with the mouse promoter although complex 
II proteins are present in these cells. 
Since the binding of complex II and III proteins appear to be affected by the 3 bp 
mismatch between the human and rodent a2( 1) pro collagen promoters in the CME 
region of the gene, it is possible that this mismatch may confer species-specific 
regulation of the gene. In order to determine whether this difference would be 
significant for species-specific regulation, this region of both human and mouse 
promoters were cloned into a CAT expression vector for measurement of promoter 
activities. 
3.2.3 Human and Rodent promoter activities 
The -107 to +54 a2(1) procollagen promoter-CAT constructs were co-transfected 
with CMV~gal as a control for transfection efficiency into CT-1 and 3T3 cells. 
The mouse ColCAT construct had a significantly lower activity than the human 
COLCAT construct in the CT-1 cell line (fig 3.6.A). This was a significant 
difference with p<0.01, Mann-Whitney U test. Similar results were obtained in 
four independent experiments. The difference between the human and mouse 
promoter activities in CT -1 cells varied from between 4 to 7 fold in different 
experiments. The only detectable difference between these two promoters in terms 
of trans-acting factor binding sites ( complexes I, II and III) is the 3 bp mismatch in 
the CME region. Although other differences between the human and mouse 
proximal promoters further downstream of -60 do exist, these appear not to 
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involve DNA-protein interactions ( except for the basal transcription factors which 
we do not detect in our assay system). It would therefore appear that the 3 bp 
mismatch in the CME is sufficient to confer not only species-specific binding of 
trans-acting factors, but also a species-specific difference in the activities of the 
a2(1) procollagen promoters. Interestingly, transfection of both promoter-CAT 
constructs into the mouse 3T3 cell line, showed no significant difference in 
activity between the two promoters. This may be an indication of basal expression 
of the gene in this cell line. Also, the activity of the human promoter-CAT 
construct is significantly lower in 3T3 cells than in CT-1 cells (fig 3.6.B). This 
result is consistent with the finding of Parker et al, (1992) that the human 
promoter-CAT construct has decreased activity in SVWI-38 cells which contain 
complex II proteins. It also supports the hypothesis that complex I, together with 
complex III enables a stronger activity. The presence of complex II and the 
absence of complex III proteins in 3 T3 cells could therefore result in the decreased 
activity of the human promoter-CAT construct in these cells. This is in agreement 
with the model that complex II proteins may be involved in the inhibition of a2(1) 
procollagen gene expression and that complex III proteins may, on the other hand, 
be involved in co-activation of the a2(1) procollagen gene. 
3.2.4 Analysis of the human CCAA T-binding factor 
3.2.4.1 Competition experiments using known CCAAT binding 
sequences 
Oligonucleotides containing known CCAAT binding motifs for different members 
of the CCAA T-binding protein family were used in EMSA' s to determine the 
nature of the complex I proteins and their relation to the mouse CBF. The 
competitor oligonucleotides used in EMSA' s with CT-1 nuclear extracts are 
shown in fig 3. 7 .A. Complex I formation was effectively competed out by the 
wildtype G/CBE, mouse CCAAT-binding element (CBE) and the NF-Y 
oligonucleotide while complex III formation was not affected (fig 3.7.B). 























~ ~ ~ ~ u u u u ,... ,... ,... ,... 
0 0 0 0 .... .... .... .... 
I . I I 
C a, C a, 
Ill II) Ill II) 
E :, E :, 0 0 :, 
E 
:, 
E .=. .=. 
cell lines: CT-1 3T3 
Fig 3.6 Transcriptional activities of the human and mouse proximal al(l) 
procollagen promoters. 10 µg of the indicated promoter constructs in the p8CAT 
vector was transfected into CT-l(A) and 3T3 (B) cells using the CaP04 precipitation 
method as described in section 6.9. The plasmid CMVJ3gal was included in the 
transfections as an internal control to measure DNA uptake into the cells. CAT activity 
relative to J3-galactosidase activity is indicated. Results are the mean ± S.D. of 3 
experiments. 
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Complex I formation was however not competed out by the CCAA T / enhancer 
binding consensus sequence (C/EBP) (fig 3.7.B). Similar results were obtained 
with SVWI-38 nuclear extracts, showing that complex I formation was competed 
out by the G/CBE, mouse CBE and to a marginally lesser extent by the NF-Y 
binding sequence The C/EBP oligonucleotide had no effect on complex I 
formation as previously observed (fig 3.8). Competition for complex I formation 
by these oligonucleotides resulted in an increase in the intensity of complex II 
binding. The reason for this is unclear, but it can be speculated that the loss of 
complex I binding to the labelled DNA fragment may decrease steric hindrance, 
allowing more effective binding of complex II. This may also be an in vitro artifact 
and in vivo binding may be of a different nature. The sequences immediately 
upstream of the G/CBE and the mouse CBE are conserved between the human and 
mouse a.2( 1) procollagen promoters. There are, however, differences between the 
nucleotides flanking the COL1A2 CCAAT box and the sequences flanking the 
CCAAT-binding sequence ofNF-Y (fig 3.9). Since it has previously been shown 
that sequences upstream of the CCAA T box in the G/CBE are essential for 
complex I formation (Collins, 1993, Collins et al, 1997), this could explain why 
the NF-Y binding sequence was a slightly weaker competitor. 
CBF binding on the mouse -107 to +54 promoter was also competed out by the 
human G/CBE in a manner similar to that observed by competition for complex I 
binding by the mouse CBF sequence. The human CCAA T-binding sequence, 
however was not as effective a competitor for CBF binding as was the wild type 
mouse CCAAT sequence (fig 3.10). These results indicate that the interaction of 
rodent and human CCAA T -binding proteins to each of the human and mouse 
promoters are similar, but not identical. 
3.2.4.2 Supershift assays using mouse anti-CBF antibodies 
Antibodies against the mouse CCAAT binding protein were used in EMSA's in 
order to gain more insight into the nature of the human complex I proteins. The 
mouse anti-CBF antibodies used were directed against the A and B-subunits of 
CBF ( a gift from H. Eberspaecher and B de Crombrugghe, University of Texas). 
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NF - Y 5 '- AACATTTTTCTGATTGGTTAAAAGTTG-3 ' 
3' -TTGTAAAAAGACTAACCAATTTTCAAC-5' 
C/EBP 5 ' -AATTCAATTGGGCAATCAGG-3' 
3 '- GTTAACCCGTTAGTCCTTAA-5 ' 
G/ CBE 5 ' -GATCCGCCCTCCCATTGGTG -3' 
3 '- GCGGGAGGGTAACCACCTAG-5 ' 
CBE -110 TO +54, murine Col1A2 gene 
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Fig 3. 7 Competition of CT-1 extracts with known CCAA T-binding motifs. 
(A) Double-stranded oligonucleotides with known CCAAT-binding motifs were prepared 
as described in section 6.4 .3 .1. (B) Increasing molar excess of double-stranded 
oligonucleotides were incubated with CT-1 nuclear extracts for 10 mins prior to the 
addition of labelled COL1A2 -107 to -60 promoter fragment. The DNA-protein 
complexes were electrophoresed on non-denaturing 5% polyacrylamide gels as described 
in section 6.4.3. Gels were dried and exposed to X-ray film for 16 hrs. The. positions of 
complexes I and III are indicated. 
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Fig 3.8 Competition of SVWJ38 nuclear extracts with known CCAAT-binding 
motifs. Increasing molar excess of double stranded oligonucleotides were incubated 
with SVWI-38 nuclear extracts for 10 mins prior to the addition oflabelled COL1A2 -107 
to -60 promoter fragment. The DNA-protein complexes were electrophoresed on non-
denaturing 5% polyacrylamide gels as described in section 6.4.3. Gels were dried and 
exposed to X-ray film for 16 hrs. The positions of complexes I, II and mare indicated. 
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• • •• GCCCTCCC TTG TGGAGGCCC 
CGGGAGGGT AAC ACCTCCGGG Human G/CBE 
0 0 0 e e e e e 
* * * 
GCCCTCCC TTG TGGAGACGT 
CGGGAGGGTAAC ACCTCTGCA 
• • • 
TTTTTCTG TTG TTAAAAGTT 
Mouse CBE 
NF-Y AAAAAGAC AACCAATTTTCAA 
0 • • • 
Fig 3.9 Comparison of sequences of known CCAA T box elements. Alignment of 
nucleotides -110 to -61 of the human CCAAT element with the mouse cx.2(1) collagen and 
NF-Y CCAAT elements. A high sequence homology is found between the human and 
mouse CCAAT box elements in the sequences 5' to the CCAAT box, while a 3 bp 
mismatch (indicated by asterisks) is found 3' of the CCAAT box. The inverted CCAAT 
boxes are boxed while the human CME is underlined. Full and partial methylation of 
purines in the G/CBE (Collins et al, 1997) and NF-Y (Chodosh et al, 1988) are indicated 
by(•) and {o) respectively. 
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Fig 3.10 Competition of mouse CBF binding by human G/CBE. Increasing 
molar excess of double-stranded oligonucleotides were incubated with 3T3 nuclear 
extracts for 10 mins prior to the addition of labelled mouse Col I A2 -107 to +54 promoter 
fragment. The DNA-protein complexes were electrophoresed on non-denaturing 5% 
polyacrylamide gels as described in section 6.4.3 . Gels were dried and exposed to X-ray 
film for 16 hrs. The position of the mouse CBF is indicated. 
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In EMSA's using increasing amounts of anti-CBF-B antibody, a supershifting of 
complex I proteins was observed, whereas complex III formation remained 
unaffected in CT- I cells (fig 3. I I.A). Complex II binding also remained 
unaffected with increasing amounts of antibody as observed with longer exposure 
of the gel to X-ray film (not shown). The supershifted complex is an indication 
that the anti-CBF-B antibody, although interacting with the B-subunit, does not 
interfere with complex I binding to its recognition sequence. Similar results were 
obtained when using the antibody in combination with mouse 3T3 nuclear extracts 
before addition of the mouse proximal promoter fragment (fig 3.Il.B). 
Experiments with the anti-CBF-A antibody produced no supershifted complexes in 
both CT-1 nuclear extracts with the human promoter fragment and 3T3 nuclear 
extracts with the mouse promoter fragment (fig 3.11.C and D). This antibody has, 
however, been reported to result in the supershift of the CBF-DNA complex 
(Hasegawa et al, 1996), and it is possible that the antibody dilution used by us was 
too low to detect the desired effect. 
The competition experiments and antibody studies collectively provide support for 
the suggestion that the G/CBE binding proteins ( complex I) and the mouse CBF 
are related to each other. 
3.2.5 The role of phosphorylation in trans-acting factor binding to the 
a.2(1) procollagen promoter. 
Different stimuli may affect gene expression due to the activation of protein 
kinases. It is highly probable that the binding activities and function of the 
proximal a2(1) procollagen promoter-binding proteins are regulated by 
phosphorylation. To determine whether protein phosphorylation is required in the 
binding of complex I, II and III proteins, EMSA's were performed using 
phosphatase treated nuclear extracts and nuclear proteins extracted from cells 
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Fig 3.11 Supershift assays with mouse anti-CBF antibodies. (A) Increasing 
amounts (1,5,10µ1) of a 1/100 dilution of rabbit anti-mouse CBF-B antibody was 
incubated with CT-I nuclear extracts for 30 minutes on ice before addition of labelled 
human -107 to -60 a2( 1) promoter fragment. The DNA-protein complexes were 
electrophoresed on non-denaturing 5% polyacrylamide gels as descnl>ed in section 6.4.3.2. 
Gels were dried and exposed to X-ray film for 16 hrs. The supershifted DNA-protein 
complex is indicated. (B) Incubation of the rabbit anti-mouse CBF-B antibody with 3T3 
nuclear extracts for 30 minutes prior to the addition of mouse -107 to +54 a2(1) promoter 
fragment. EMSA's were performed as descnl>ed in section 6.4.3.2. Supershifted CBF is 
indicated. (C) Incubation of rabbit anti-mouse CBF-A antibody with CT-I nuclear 
extracts and the human proximal a2(1) procollagen promoter as described above. No 
supershifted complexes are detected. (D) Incubation of rabbit anti-mouse CBF-A 
antibody with 3T3 nuclear extracts and the mouse proximal a2(1) procollagen promoter 
as described above. Supershifting of CBF is not observed. 
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3.2.6.1 Phosphatase treatment of nuclear extracts 
Two phosphatases, calf intestinal phosphatase (CIP) and the serine/threonine 
specific phosphatase PP2A, were used to dephosphorylate CT-1, U937 and mouse 
3T3 nuclear extracts. The phophatase treated nuclear extracts were then used in 
EMSA's to determine DNA binding activity. In all the cell lines, CIP treatment 
interferes with the binding of complex I and CBF (fig 3 .12). CIP treatment of 
U937 and CT-1 nuclear extracts resulted in a 70% and 67% decline in complex I 
binding respectively. Complex II and III formation remained largely unaffected by 
CIP treatment. The ser/thr phosphatase, PP2A, however had a significant effect on 
complex II and III formation. In U93 7 nuclear extracts, complex II formation is 
entirely abolished by PP2A treatment while in CT-1 nuclear extracts complex m 
formation is abolished (fig 3.12 A and B). It would therefore appear that complex 
II and III proteins require ser/thr phosphorylation to enable interaction with their 
recognition sequence, the CME. The binding of CBF to the mouse promoter was 
completely inhibited by treatment of 3T3 nuclear extracts with CIP, while PP2A 
had no effect (fig 3.12.C). These results are an indication that phosphorylation of 
these DNA binding proteins are required for DNA-protein interaction in both 
human and rodent nuclear extracts. In terms of its ' phosphorylation status, 
therefore, the human G/CBE proteins and mouse CBF behave similarly. 
3.2.5.2 Inhibition of protein kinases in cell culture 
The kinase inhibitor, staurosporin was used to inhibit intracellular kinase activity. 
U93 7 cells were treated with 1 µM staurosporin for 3 hours, nuclear proteins were 
extracted and incubated with labelled -107 to -60 human a2( I) procollagen 
promoter fragment in EMSA's (fig 3.13.A). No effect was observed in this 
instance. Cells were therefore treated with various concentrations of the drug for 
16 hours. At a concentration of 10 nM for 16 hours, a decline in interaction of all 
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Fig 3.12 The effect of protein dephosphorylation on DNA-protein complex 
formation. (A) I unit of calf intestinal phosphatase (CIP) or 0.4 units of phosphatase 
PP2A were incubated with 4 µg of U937 nuclear extracts for 30 mins at 37°C. Labelled 
COLIA2 -107 to -60 promoter fragment was then added and incubated with the protein 
mixture for 30 mins on ice. DNA-protein complexes were electrophoresed on non-
denaturing 5% polyacrylamide gels at 4°C in 0.5X TBE (section 6.4.3). Gels were dried 
and exposed to X-ray film for 16 hours. The positions of complexes I and Il are indicated. 
(B) 1 unit of calf intestinal phosphatase (CIP) or 0.4 units of phosphatase PP2A were 
incubated with 4 µg of CT-I nuclear extracts for 30 mins at 37°C. EMSA's with the 
human COLIA2 probe were performed as described in (A). The position of complexes I 
and Ill are indicated. (C) 1 unit of calf intestinal phosphatase (CIP) or 0.4 units of 
phosphatase, PP2A were incubated with 4 µg of3T3 nuclear extracts for 30 mins at 37°C. 
EMSA's were performed as described in (A) except that the labelled probe used was the 
mouse CollA2 -107 to +54 promoter fragment. 
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Fig 3.13 The effect of staurosporin on DNA-binding activity. (A) U937 cells 
were treated with 1 µM staurosporin for 3 hours before nuclear proteins were harvested as 
described in section 6.4.1. 4 µg of nuclear proteins from untreated or treated cells were 
incubated with the -107 to -60 COL1A2 promoter fragment. DNA-protein complexes 
were electrophoresed on non-denaturing 5% polyacrylamide gels. Gels were dried and 
exposed to X-ray film for 16 hours. (B) U937 cells were treated with the indicated 
concentrations of staurosporin for 16 hours. Nuclear proteins from untreated or treated 
cells were used in EMSA's as described in (A). The fastest migrating band (indicated by 
an arrow) are possible degradation products of complexes I and II and its migration 
pattern is distinct from that of complex ill. It is also not consistently observed. 
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complexes was observed, with no binding detected at 1000 nM (fig 3.13.B). This 
result was probably due to cell death, since a large percentage of dead cells were 
observed in culture at the higher concentrations (100 and 1000 nM) using the 
trypan blue exclusion test. 
The optimum treatment time which resulted in minimal cell death (<15% as 
observed by the trypan blue exclusion test) for the U937 cell line, was found to be 
8 hours. Cells were treated with varying concentrations of staurosporin for 8 hours 
and nuclear proteins extracted for use in EMSA's (fig 3.14.A). Binding studies 
showed that both complex I and II formation was significantly lower in nuclear 
extracts isolated from staurosporin treated U937 cells. The extent of the inhibition 
was similar for both complexes as determined by densitometric scanning of the 
autoradiographs (fig 3.14.B). These results are representative of three different 
experiments. Similar results were obtained with nuclear proteins extracted from 
CT -1 cells treated with staurosporin, albeit at concentrations lower than that used 
in the treatment of U93 7 cells. CT-1 cells showed a greater sensitivity to 
staurosporin treatment and concentrations greater than lnM resulted in cell death 
within 30 minutes. Staurosporin treatment resulted in a loss in the binding of both 
complex I and complex III, although complex ill binding was affected to a lesser 
extent (fig 3.15.A and B). 
Staurosporin predominantly affects protein kinase C activity as well as that of 
ser/thr kinases and some tyrosine kinases (Rosenshine et al, 1994). To determine 
whether phosporylation of tyrosine residues are required for DNA-protein 
complex formation, cells were incubated with the tyrosine kinase inhibitor, 
genistein. Nuclear proteins from genistein treated cells showed no change in DNA-
binding activities (fig 3.16.A). The finding that complex II/III binding is inhibited 
by treatment with the ser/thr phosphatase, PP2A and that the tyrosine kinase 
inhibitor, genistein had no effect on DNA binding activity, indicated that 
phosphorylation of these proteins more than likely occur at ser/thr residues. 
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Fig 3.14 Effect of staurosporin treatment of 0937 cells on DNA-binding 
activity. (A) U937 cells were treated with the indicated concentrations of staurosporin 
for 8 hours before extraction of nuclear proteins as described in section 6.4.1. 4 µg of 
nuclear proteins from untreated or treated cells were incubated with the -107 to -60 
COL1A2 promoter fragment. DNA-protein complexes were electrophoresed on non-
denaturing 5% polyacrylamide gels. Gels were dried and exposed to X-ray film for 16 
hours. (B) Bar graphs of densitometric scanning of autoradiographs in fig 3 .14 .A. 
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Fig 3.15 Effect of staurosporin treatment of CT-1 cells on DNA-binding 
activity. (A) CT-1 cells were treated with the indicated concentrations of staurosporin. 
Nuclear proteins were extracted as described in section 6.4.1 and 4µg protein was 
incubated with the -107 to -60 COL1A2 promoter fragment and DNA-protein complexes 
electrophoresed on non-denaturing 5% polyacylamide gels. Dried gels were exposed to X-
ray film for 16 hours. (B) Bar graphs of densitometric scanning of autoradiographs in fig. 
3.15.A. 
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Fig 3.16 Effect of genistein and okadaic acid on DNA-binding activity. (A) 
U937 cells were treated with the indicated concentrations of genistein for 8 hours before 
extraction of nuclear proteins (section 6.4.1). 4 µg of nuclear proteins from untreated or 
treated cells were incubated with the human -107 to -60 COL1A2 promoter fragment. 
DNA-protein complexes were electrophoresed on non-denaturing 5% polyacrylamide 
gels. Gels were dried and exposed to X-ray film for 16 hours. (B) U937 cells were 
treated with the PP2A phosphatase inhibitor, okadaic acid, as indicated. Nuclear proteins 
were extracted and EMSA's performed as described in (A). 
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the DNA-binding activities of any of the complexes (fig 3.16.B). There may even 
be a slight increase in complex formation with increasing okadaic acid 
concentration. This would be consistent with the idea that phosphorylation is 
required for DNA binding activity. It is clear from the above experiments that 
phosphorylation has a significant effect on the binding of proteins to the proximal 
promoter of the a2( 1) procollagen gene, since inhibiting with such events result in 
the loss of this activity. 
3.2.5.3 Effect of kinase inhibition on promoter activity and mRNA levels 
Since dephosphorylation of nuclear factors and inhibition of kinases by 
staurosporin resulted in a loss of complex formation at the -107 to -60 region of 
the a2( 1) procollagen promoter, the effect of kinase inhibition on the activity of 
the proximal promoter was investigated. Proximal a2( 1) procollagen promoter-
CAT constructs were transfected into CT-1 cells as described in section 3 .2.3. 
After transfection, the cells were treated with staurosporin at 0.5 and lnM for 16 
hours. The results obtained indicated a significant loss in a2( 1) procollagen 
promoter activity in the presence of both 0.5 and lnM staurosporin (fig 3.17). This 
therefore suggests that interference of kinase activation pathways result in the 
inhibition of the proximal a2(1) procollagen promoter activity. To determine the 
effect of kinase inhibition on the steady state a2(1) collagen mRNA levels, total 
RN A was extracted from CT-1 cells treated with staurosporin as described above 
(fig 3.18.A) and used in Northern blot analysis. Staurosporin treatment resulted in 
significant inhibition of endogenous a2( 1) procollagen gene expression when 
compared to cells that have not been treated (fig 3.18.B). The filters were stripped 
of the a2( 1) procollagen probe and reprobed with radioactively labelled P-actin 
cDNA. As observed with a2(1) procollagen, P-actin expression was also inhibited 
in CT-1 cells with increasing concentrations of staurosporin (fig 3.18.B). The 
inhibition is observed even though the loading of total RNA in lane 2 (0.5nM 
staurosporin) is more than that in lane 1 (no staurosporin). 
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Fig 3.17 Effect of staurosporin on the human proximal a2(1) procollagen 
promoter activity. 10 µg of the human -107COL-CAT construct was transfected into 
CT-I cells (as described in section 6.9), afterwhich the cells were treated for 16 hours 
with the indicated concentrations of staurosporin. Results are the mean ± S.D. of four 
independent experiments in which each construct was transfected onto triplicate 100 mm 
dishes of CT- I cells. The activity in the absence of staurosporin was set at 1. 0. Treatment 
with 0.5 nM and 1 nM staurosporin was significantly different from the control with 
p<0.05 and p<0.001 respectively (Mann-Whitney U test). 
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Fig 3.18 Effect of staurosporin on steady state a2(1) procollagen mRNA 
levels. (A) Total RNA from CT-I cells exposed to 0.5nM and lnM staurosporin were 
isolated and 5µg run on 1 % agarose-formaldehyde gels. The gels were stained with 
ethidium bromide (lµg/ml) to visualise the quantities of 18S and 28S rRNA. (B) 
Northern blot analysis of the levels of a.2(1) procollagen and J3-actin mRNA in the absence 
and presence of staurosporin. 
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The results presented indicate that kinase activity, possibly that of protein kinase 
C, has a role in the regulation of the a2(1) procollagen gene. It was therefore 
decided to investigate the effect of phorbol 12-myristate 13-acetate (PMA), an 
inducer of protein kinase C activity, on a2(1) procollagen gene expression. 
3.2.5.4 Effect of PMA on collagen gene expression in CT-1 cells 
CT-1 cells grown to confluency were growth arrested in serum free DMEM for 16 
hours, then treated with lOOng/ml PMA for 30 minutes and RNA isolated as 
described in section 6.6.1. The steady-state a2(1) procollagen mRNA levels were 
determined by Northern blot analysis (section 6.6.2) and found to differ 
significantly between PMA treated and untreated cells (fig 3.19.A). CT-1 cells 
treated with PMA showed a decrease in endogenous levels of a2(1) procollagen 
mRNA compared to expression in untreated cells. The decrease varied between 30 
and 60% relative to that of untreated controls in different experiments (fig 3.19.B). 
Interestingly, a recent study reported paradoxical responses of endogenous a2(1) 
procollagen gene expression and a transfected -378 COLIA2/CAT construct to 
PMA treatment in primary human fetal skin fibroblast. While PMA downregulated 
the expression of the endogenous gene, upregulation of the transfected promoter 
was observed (Greenwel et al, 1997). These results therefore confirm that protein 
kinase C and possibly other signal transduction pathways have a role in the 
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Fig 3.19 Effect of PMA on a2(1) procollagen gene expression in CT-1 cells. 
(A) CT-1 cells were exposed to PMA (lOOng/ml) for 30 minutes after which total RNA 
was extracted using the method of Chomczinsky and Sacchi, (1987). 5µg of total RNA 
from untreated(-) and PMA treated(+) cells was analysed for a.2(1) procollagen and J3-
actin mRNA by Northern Blotting (section 6.6.2). (B) Autoradiographs of four 
independent experiments were scanned using a densitometer and the ratio of a.2( 1) 
procollagen expression relative to that of J3-actin is shown in the bar chart. 
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3.3 DISCUSSION 
While DNA elements such as the CCAA T motif and a pyrimidine segment at -164 
and -159 are functionally conserved between the human and mouse a2(1) 
procollagen promoters, the TGF-P responsive elements differ extensively between 
the two species. TGF-P induces NF-1 binding activity in the mouse promoter at -
315 to -295 (Rossi et al, 1988), while Spl (Inagaki et al, 1994; Tamaki et al, 1995; 
Greenwel et al, 1997) or AP-1 (Chung et al, 1996) binding may be induced in the 
human promoter (section 1.2.3.3). Also, the Sp-1 binding sites at -300 and a 
TCCTCC motif (-133 to -118) appear to be specific for the human promoter (Ihn 
et al, 1996). These loci may in part be responsible for species-specific regulatory 
mechanisms of the human and mouse collagen genes. 
The findings reported in chapter 2 indicated that cell-specific regulation of the 
human COL1A2 gene is associated with differences in trans-acting factor binding 
to the proximal promoter. One of the objectives of this section was therefore to 
determine whether the same association existed within collagen expressing and 
non-expressing rodent cells. The surprising result was that the correlation between 
trans-acting factors and collagen gene expression observed in human cells was not 
observed in rodent cells. This observation prompted a study into to the species-
specific expression of the a2( 1) procollagen gene. A 3 bp mismatch in the binding 
site of the complex II/Ill proteins between the human and rodent promoters was 
confirmed. Both the mouse and rat promoters contained the mismatch which was 
sufficient to interfere with complexes II and III formation on the rodent promoter. 
Although complex II proteins were present in rodent nuclear extracts, they were 
unable to bind the rodent promoter. It is possible that these proteins are involved in 
the regulation of other genes in rodent cell lines. A Genebank search for the CME 
( complex II and III binding sequence) showed that several genes contained the 
binding sequence. GGAGG ( an integral part of the CME) boxes have been 
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reported to footprint in the promoters of a number of genes and often occur as 
repeats in these promoters (table 3.1). 
Table 3.1 Gene promoters containing functional GGAGG sequences. 
Gene Location of GGAGG box Reference 
human a.1(1) collagen -477 to -332 Liska et al, 1992 
human a.2(1) collagen -133 to -119 Ihn et al, 1996 
grp78/BiP -109 to -74 Roy and Lee, 1995 
c-myc -199 to -176 Suen and Hung, 1991 
Bossone et al, 1992 
EGF-r -290 to -331 Johnson et al, 1988 
a.1 (IV) collagen -107 to +10 Piccolo et al, 1995 
a.1 (XI) collagen -199 to -36 Yoshioka et al, 1995 
SP ARC/osteonectin -120 to -60 McVey et al, 1988 
a.-myosin heavy chain -111 to -129 Flink & Morkin, 1990 
bek/KGFR A vivi et al, 1992 
a.2A-adrenergic receptor -131 to -92 Handy &Gavras, 1992 
AP-2 Imagwa et al, 1987 
malT Raibaud et al, 1988 
JCV repeated sequence Martin et al, 1985 
The difference in trans-acting factor interaction in the human and mouse a.2( 1) 
procollagen promoters suggested species-specific transcriptional regulatory 
mechanisms. Measurement of promoter activity using human and mouse promoter-
CAT constructs transfected into CT -1 cells, indicated that the rodent promoter had 
a lower activity than the human promoter. This result can be explained by the 
absence in the binding site for complex III proteins (potential activators of 
transcription) in the rodent promoter. The lower activity of the human promoter in 
3T3 cells compared with CT-I cells, can be explained by the presence of complex 
II (potential repressor) and the absence of complex III (potential activator). These 
findings provide further evidence for the role of the CME in regulation of the 
human a.2(1) procollagen gene. Similar species-specific transcriptional regulation 
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has been reported for the Apolipoprotein A-I gene. A study by Sorci-Thomas and 
Kearns, (1991) reported that differences in apoA-1 expression in human and two 
nonhuman primate liver cell lines can be linked with sequence divergence within a 
494 bp region of the apoA-1 gene. A subsequent study identified nucleotide 
differences in three sites (-189, -144 and -48) that significantly alter the binding 
affinity of nuclear factors as well as determining the species-specific regulation of 
the apoA-1 gene (Sorci-Thomas and Kearns, 1995). The investigation presented in 
this chapter supports the idea that factors that regulate the expression of the a2( 1) 
procollagen gene may be important determinants in species-specific regulation. 
Competition experiments and antibody supershifted data suggest that the G/CBE 
binding proteins ( complex I) is a member of the structurally related CCAA T box 
binding factors which include CBF, (Karsenty, et al, 1988, Hatamochi et al, 1988, 
Maity et al, 1988,1992), NF-Y (Chodosh et al, 1988), a-CPl and CP-1 (Kim and 
Sheffery, 1990). Although the antibody recognised both the human complex I and 
mouse CBF, there is the possibility that these two factors may be different. 
Collins, (1993) proposed that complex I is a 120 kD protein, while the mouse CBF 
is a heterotrimeric protein. It is possible that some areas within the two proteins 
have been conserved and that these are recognised by the anti-CBF antibody while 
others have been changed during evolution. 
In an attempt to determine if phosphorylation is required for complex formation, 
phosphatase treatment of nuclear extracts resulted in the loss of DNA-binding 
activities. CIP affected complex I formation, while the ser/thr phosphatase, PP2A 
affected complexes II and ill formation. The loss of DNA binding activities of 
dephosphorylated protein complexes was observed in both human and rodent 
nuclear extracts. Phosphorylation of the CCAA T binding factor is therefore 
required for binding to its consensus sequence. This is in contrast to studies by 
Heinrichs et al, (1993;1995) which showed that CCAAT-specific DNA-protein 
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interactions on the rat osteocalcin gene promoter is insensitive to phosphatase 
treatment. It should be noted that the phosphatase used in their study as well as the 
time of incubation of nuclear proteins with phosphatase differs from that used in 
this investigation. While Heinrichs et al, ( 1993) showed that the CCAA T -specific 
DNA-protein interactions were heat stable, the complex I, II and III proteins have 
been shown to be heat labile (Smith, 1989). Hatamochi et al, (1988) also showed 
that the mouse CBF-A subunit is heat sensitive. Heating of CBF-A for 5 minutes at 
65°C resulted in a loss of CBF DNA binding activity. This provides more support 
that the human and rodent CCAA T-binding proteins are related. 
Treatment of cells with the kinase inhibitor, staurosporin, also exerted a negative 
effect on the binding of trans-acting factors to the proximal a2( 1) procollagen 
promoter, while a tyrosine kinase inhibitor had no effect. Staurosporin also had a 
significant inhibitory effect on a2( 1) procollagen promoter activity and steady 
state mRNA levels. This inhibition can be associated with the loss of trans-acting 
factor interactions with the proximal promoter of the gene. The data therefore 
indicate that both ser/thr kinase and protein kinase C activities may be required for 
the activities of these trans-acting factors (summarised in fig 3.20) and possibly 
other transcription factors which regulate a2( 1) pro collagen gene expression. 
Protein phosphorylation is required in the regulation of a number of other genes. 
Sudbeck et al, (1994) showed that collagen-stimulated induction of keratinocyte 
collagenase is mediated via tyrosine kinase and protein kinase C activities. Post-
translational modifications of the AP-I components, Fos and Jun are modulated by 
various kinases (Binetruy et al, 1991, de Groot and Sassone-Corsi,1992, Derijard 
et al, 1994). Activators of protein kinase C may influence transcription by 
increasing the activity of AP-I (Slack et al, 1993). This is of particular interest to 
the regulation of the human a2( 1) procollagen promoter since Chung et al, ( 1996) 
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Fig 3.20 Model depicting species-specific differences and phosphorylation in 
trans-acting factors binding the a2(1) procollagen promoter. Phosphorylation of 
complexes I, II, ill and CBF is required for binding to the proximal a2( 1) procollagen 
promoter. The thickness of the arrow indicate the degree of promoter activity. The 
asterisks depicts the three base pair difference between the human and rodent promoters. 
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The present study also shows that the phorbol ester, phorbol 12-myristate 13-
acetate (PMA), known to mediate mitogenic signal transduction, (Bell, 1986; 
Kikkawa and Nishizuka, 1986; Nishizuka, 1986) has a significant inhibitory effect 
on a2( 1) procollagen gene expression. This is in agreement with other studies 
reporting that phorbol esters inhibit type I collagen gene transcription (Harrison et 
al, 1990; Rabin et al, 1986; Sobel et al, 1983; Greenwel et al, 1997). Contrary to 
these studies, Stuiver et al, (1991) reported that PMA had a stimulatory effect on 
collagen expression in 3T3-Ll cells. Collagen gene expression may therefore be 
mediated through different signalling pathways in a cell-specific manner. It is also 
clear that phosphorylation/dephosphorylation events have an effect on the DNA-
binding activity of factors which interact both upstream and downstream of the 
CCAA T box in the a2( 1) procollagen promoter, as well as the CCAA T-binding 
factor itself. These interactions may mediate both negative and positive influences 
on a2( 1) procollagen gene transcription. 
In summary, the work presented in this study indicate that: 
1. Species-specific DNA-protein interactions in the proximal a2(1) procollagen 
promoter may be mediated via a 3 bp mismatch between the human and rodent 
promoter. The DNA sequences involved in this interaction includes the CCAAT 
box and an adjacent DNA element, the CME (in human). 
2. The protein( s) associated with binding to the human CCAA T consensus 
sequence (G/CBE) is similar or related to the mouse CBF. 
3. Phosphorylation via serine/threonine kinase and protein kinase C pathways 
are required for the binding of the CCAA T binding factor in both human and 
mouse nuclear extracts. Phosphorylation is also required for the binding of 
complex II and III proteins to the CME in the human a2(1) procollagen promoter 
and may induce conformational changes that would enable DNA-binding. 
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4. Inhibition of phosphorylation with staurosporin, a kinase inhibitor resulted in 
decreased activity of the proximal a.2(1) procollagen promoter and inhibition of 
gene transcription. 
5. Stimulation of protein kinase C activity resulted in a significant decrease in 
a.2(1) procollagen mRNA levels in PMA treated cells. Stimulation of kinase 
activity and subsequent phosphorylation of complexes I, Il and Ill are possibly 
terminal events in signalling pathways that result in either the activation or 
repression of the a.2(1) procollagen gene. 
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CHAPTER 4: 
CLONING THE GENES CODING FOR THE a2(1) PROCOLLAGEN 
PROMOTER-BINDING PROTEINS. 
4.1 INTRODUCTION 
The work presented in Chapters 2 and 3 identified DNA-binding proteins which 
bind the proximal promoter of the human a2( 1) procollagen gene in a sequence-
specific manner. At least two of these DNA-protein complexes ( complex II and 
ill) appear to be specific for the regulation of the human COL1A2 gene. Not only 
did this binding occur in a cell-specific manner, but regulation by these factors 
may also be species-specific. Both the species- and cell-specific trans-acting factor 
interactions are accompanied by differences in transcriptional activity of the a2( 1) 
procollagen gene. 
Since the complex II and ill proteins appear to be novel in their binding to the 
human a2(1) procollagen promoter, it was important to characterise the role of 
these factors in the regulation of the COL1A2 gene. The classica). way in which to 
identify transcription factors has been to purify the DNA-binding proteins using 
oligonucleotide affinity matrices. This approach was used successfully by a 
number of groups since it was first reported by Kadonaga and Tijian, (1986) in the 
purification of Sp 1. This technique was also used in combination with ion-
exchange chromatography in the identification of the mouse CCAA T binding 
proteins (Hatamochi et al, 1988 ). 
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Although the technique is highly successful, one of its limitations is the 
requirement for large amounts of starting material ( cells or tissue), which makes 
the purification of transcription factors on a preparative scale difficult. To 
circumvent this problem, the technique of screening an expression cDNA libnuy 
in E.coli with the recognition element of the DNA-binding protein has been 
developed by Singh et al, (1988). The strategy is modified from that developed for 
the isolation of genes using antibodies to screen recombinant libraries (Broome, 
1978). It was used to isolate a cDNA clone encoding a protein which has DNA 
recognition properties that overlap with those of H2TF 1 and NF-KB (Singh et al, 
1988). The technique is ideally suited for the isolation of clones encoding rare 
DNA-binding proteins and a number of other genes have subsequently been 
isolated (Table 4.1). The screening of A expression libraries with recognition-site 
DNA probes has become one of the prefered techniques in the isolation of genes 
coding for transcription factors. 
This technique has certain limitations, however, one of which is that the 
overexpression of P-galactosidase proteins in E.coli may lead to the formation of 
insoluble aggregates called inclusion bodies. A small proportion of DNA-binding 
proteins in an inclusion body may actually be in the correctly folded conformation 
suitable for binding to its ligand. As an improvement to the method, Vinson et al, 
(1988) showed that exposing protein immobilised on nitrocellulose filters to the 
denaturing agent, guanidine hydrochloride, enhances the presence of active 
molecules. 
This modified method was used to identify cDNA clones encoding trans-acting 
factors which are unique in their binding to the human a2(1) procollagen 
promoter. Since the complex II/III proteins may be novel to regulation of the 
human a2( 1) procollagen gene, efforts were concentrated on the identification of 
these proteins. 
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Table 4.1 
CLONES ENCODING SEQUENCE-SPECIFIC DNA BINDING PROTEINS 
ISOLATED BY SCREENING OF EXPRESSION LIBRARIES 
Clone Binding site Organism Reference 
MBP-1 GGGGATICCCC Human Singh et al, 1988 
Balwin et al, 1990 
Oct-2 ATGCAAAT Human Clerc et al, 1988 
Muller et al,1988 
Staudt et al, 1988 
Oct-1 ATGCAAAT Human Sturm et al, 1988 
El2 GGCAGGTG Human Murre et al, 1989 
XBP GCTGGCAACTGTGTGACGTCATCACAAGA Mouse Hsiou-Chi et al,1988 
RF-X CCCCCTAGCAACAG Human Reith et al, 1989 
IRF-1 AAGTGA Mouse Miyamoto et al, 1988 
Pit-1 GATIACATGAATATICATGA Rat Ingraham et al, 1988 
CREB TGACGTC Human Hoeftler et al, 1988 
CNBP GTGCGGTG Human Rajavashist et al, 1989 
HBP-1 ACGTCA Wheat Tabata et al, 1989 
ITF-1 , 2 AACACCTGCAGCAGCAGCTGGCAGG Human Henthorn et al, 1990 
Isl-1 TIAATAATCTAATIA Rat Karlsson et al, 1990 
PU.I GAGGAA Mouse Klemsz et al, 1990 
ICSBP AGTTICACTICT Mouse Driggers et al, 1990 
Ets-1 AGCCACATCCTCTGGAA Human Ho et al, 1990 
OBFl GATCCAAGTGCCGTGCATAATGATGTGGG Yeast Biswas et al, 1990 
FRG-Yl, Y2 CTGATIGGCCAA Xenopus Tafuri et al, 1990 
TEF-1 GTGGAATGT Human Xiao et al, 1991 
HTF4 CAGCTGG Human Zhang et al, 1991 
NF-El CCTCCATC Human Park et al, 1991 
AT-BPI GATCCCAGCCAGTGGACTIAGCCC Rat Mitchelmore et al, 1991 
AT-BP2 AACTGGGGTGACCTIGGTIAATATICACCAG Rat Mitchelmore et al, 1991 
ElA-F ACAGGAAGTGACACGGATGTGGC Human Higashino et al, 1993 
modified from Singh, 1993. 
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4.2 RESULTS 
4.2.1 Selection of probes for screening a A.gill expression library 
As previously described, the complex I, II and III proteins bind distinct elements 
within the proximal a2(1) procollagen promoter (-107 to -60). The element 
involved in binding complex I proteins is the G/CBE and the element binding both 
the complex II and III proteins is the CME (see chapter 2). These two elements are 
distinct protein binding sequences as observed by competition experiments using 
unlabelled double-stranded DNA oligonucleotides corresponding to these sites as 
well as mutated oligonucleotides in EMSA's (Collins et al, 1997). The complex II 
and III proteins bind the CME with similar affinity (section 2.2.6) and appear 
unique in their binding to the proximal human a2(1) procollagen promoter. 
Since the affinity of these protein complexes for the CME are similar, the use of 
the CME as a probe to screen an expression library, would allow the identification 
of genes encoding either of these factors. Oligonucleotides used in screening a 
Agtl 1 expression library were synthesised and tested for their ability to form 
DNA-protein complexes. Labelled G/CBE oligonucleotides specifically bound 
complex I proteins while CME specifically bound complex II and III proteins (fig 
4.1). This confirmed that the G/CBE and CME are distinct DNA elements. An 
expression library could therefore be screened effectively with the CME 
oligonucleotide to identify complex II or III proteins without the possibility of 
isolating genes encoding the CCAAT-binding proteins. 
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Fig 4.1 Checking of G/CBE and CME oligonucleotide probes in protein-
binding assays. SVWI-38 nuclear extracts were incubated with labelled probes; lane 1, 
-107 to -60 bp wild type (WT) fragment of the COL1A2 promoter (no nuclear proteins 
added), lane 2, nuclear proteins incubated with WT fragment, lane 3, 29bp G/CBE 
containing fragment released from plasmid pNJ-29 incubated with nuclear proteins and 
lane 4, 32bp CME containing fragment released from plasmid pNJ-32 incubated with 
nuclear proteins. 4µg of nuclear proteins were incubated with the probes, electrophoresed 
on non-denaturing 5% polyacrylarnide gels and exposed to X-ray film for 16 hours. 
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Since screening a phage libnuy with a concatemerised probe greatly improves the 
detection of positive clones (Vinson et al, 1988), a CME oligonucleotide that 
allowed for concatemerisation of the DNA-binding site was generated (fig 4.2.A). 
Annealed oligonucleotides were concatemerised as described in section 6 .10 .1 and 
observed as ladders on 1 % agarose gels (fig 4.2.B). The concatemerised 
oligonucleotides were radioactively labelled by nick translation for use in 
screening a Agtl 1 expression library. Initial results using nick translated probes 
were not successful and other labelling techniques were explored. The polymerase 
chain reaction (PCR) was subsequently used to prepare probes with high specific 
activities. Concatemerised CME was cloned into the vector pUC19 and used as a 
template in PCR. A Clontech human heart Agtl 1 library was screened with the 
radioactively labelled concatemerised probe. The choice of library is crucial in 
ensuring that the proteins of interest are expressed in the tissue/cell type used to 
make the library. The choice of screening a human heart library was based on the 
following; 
( 1) A human library had to be used since the proteins of interest are human a2( 1) 
procollagen promoter-binding proteins. 
(2) A previous study showed that although heart tissue contained type I collagen, 
it is expressed at intermediary levels. Heart tissue therefore contain cells that 
synthesise type I collagen and others that do not. 
Screening a heart cDNA expression library would therefore enable the 
identification of genes involved the possible inactivation or activation of the 
collagen genes (ie. complex II or III expressing). 
Chapter4 
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Fig 4.2 Concatemerisation of the CME oligonucleotides. (A) An oligonucleotide 
containing the complex Will binding site (CME) was generated. It contained 5'-AATT 
overhangs that allowed sticky end ligations ( section 6 .10 .1). (B) Detection of 
concatemerised CME oligonucletides by electrophoresis on 1 % agarose gels. The lane 
marked COL CME contain the 22bp COL CME oligomer shown in (A). 
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4.2.2 Screening of expression libraries 
4.2.2.1 Screening of a heart >..gtll expression library 
The heart 11.gtl l library was screened according to the modified method of Vinson 
et al, (1988). Near-confluent plates (150 mm diameter) were used in an initial 
screen to maximise the chance of detecting potential positives. Each plate in the 
initial screening contained approximately 25,000-30,000 plaques. A total of 10 
plates were screened at a time and the primary screening process was performed 
several times to allow for maximal positive detection. The plates containing 
plaques were overlayed with nitrocellulose membranes for 6-18 hours at 37°C. 
After marking, removing and drying the filters, the proteins bound to the filters 
were denatured/renatured as described in section 6 .10. 3. Filters were blocked with 
5% fat-free milk powder, after which they were probed with radioactively labelled 
concatemerised CME probe. To identify putative positive phage plaques, 
autoradiographs were aligned with the original plates. Few putative positive 
plaques were detected in the first screen (fig 4.3.A). This was expected, since 
nuclear proteins represent less than 0.01% of total cellular proteins. Putative 
positive plaques from an initial screen were cored out, the phage eluted and 
subjected to another round of screening so as to; (i) exclude false positives and (ii) 
to enrich for potential positive clones by several rounds of purification (fig 4.3.B). 
This purification procedure was repeated four times. In the third screening, all 
plaques from a single plaque in the second round provided positive signals (fig 
3.4.C). As confirmation, a fourth screen was done, showing 100% of the plaques 
expressing a protein that binds the CME (fig 4.3.D). The radioactive signals 
provided by these positives were vety strong and autoradiographs could usually be 
developed within one hour of exposing the filters to X-ray film. A number of 
initially positive clones proved to be false on subsequent screening and were 
discarded. Further analyisis was performed on clones that remained positive after 
four screens and two of these proved to be informative. The significance of the 
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Fig 4.3 Screening of a Agtll heart cDNA library. (A) Primary screen: 30,000 
pfu on 150 mm plates were overlayed with IPTG-treated nitrocellulose membranes for 6 
to 16 hours. Proteins immobilised on the membranes were screened with labelled 
concatemerised CME probes as described in section 6.10.3 . Membranes were washed and 
exposed to X-ray film for 16 hours. Potential positives are indicated by the arrows. 
Plaques at and in the vicinity of a positive signal were cored out, the phage eluted and 
subjected to a second screening procedure. (B) Secondary screen: Phage eluted after a 
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(C) Third screen: A single plaque from a secondary screen was cored out, the phage 
eluted and subjected to a third round of screening. At this stage all plaques were usually 
positive. (D) Fourth screen: A final round of plating and rescreening was included to 
confirm that a recombinant clone has been purified to homogeneity. 
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4.2.2.2 Controls for screening with the concatemerised CME 
Due to the likelihood of detecting false postives when screening expression 
libraries, suitable controls are required. One such control was to screen potential 
positives with an oligonucleotide that does not bind the protein of interest. The -57 
to -43 region (oligo A) of the a2(1) procollagen gene had been shown previously 
not to be involved in DNA-protein interactions (Smith, 1989). It was therefore 
used as a probe to detect non-specific binding. Putative positive phages were 
spotted in duplicate on a lawn of Y1090 cells immersed in top agarose on agar 
plates. After the appearance of plaques (about 3-4 hours at 42°C) the plates were 
overlayed with nitrocellulose membranes and incubated for a further 6 hours at 
37°C. Filters were removed, cut in half and processed as described in section 
6.10.5. No binding was detected with the non-specific DNA probe (oligo A), while 
the concatemerised CME probe bound all the potential positives spotted on the 
lawn of cells (fig 4.4.A). 
To confirm that the labelled concatemerised CME probe bound specifically to the 
positive clones and not non-specifically to any protein immobilised on the 
nitrocellulose membranes, the ability of the probe to bind clones expressing known 
proteins was assessed. These proteins included chicken ovalbumin and P-
galactosidase expressed by 11.ovalbumin and 11.gtl l respectively. A phage which on 
initial screening proved to be negative for binding to the CME probe (Meg) was 
also included. Phages expressing these proteins were spotted on a lawn of Y1090 
cells as previously described and filters probed with the concatemerised CME. 
While the probe bound putative positive clones, 11.2, 11.3 and 11.4, no binding was 
detected on chicken ovalbumin, J3-galactosidase and the A.neg expressing phages as 
observed by the unreacted zones of clearing. The clone marked 11.l reacted 
positively with the labelled probe in the first screen but on subsequent screening 
proved to be negative for CME binding activity (fig 4.4.B). These screening results 
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Fig 4.4 Controls for screening with the concatemerised CME. (A) Phage from 
putative positives were spotted in duplicate on a lawn of YI 090 cells on luria agar plates. 
After appearance of plaques, plates were overlayed with nitrocellulose membranes for 6 
hours at 37°C. The filters were cut in half, one half was probed with a labelled 
concatemerised CME probe and the other half was probed with oligo A (-57 to -43 of 
a.2(1) procollagen gene, (shown previously not to form any DNA-protein complexes). (B) 
Phages, Agt 11 ( expressing f3-galactosidase ), chicken Aovalbumin, )..negative and putative 
positives, A 1, A2, )..3 )..4 ( a and b represent duplicates) were spotted on a lawn of Y 1090 
cells on luria agar plates as described in (A). Filters containing immobilised proteins were 
screened with labelled concatemerised CME as described in section 6 .10. 5. Membranes 
were exposed to X-ray film for 16 hours. 
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therefore indentified three potential clones expressing recombinant proteins which 
interact with the CME in the human a2(1) procollagen promoter. Subsequent 
characterisation of the )..3 proved to be difficult as lysogens expressing the fusion 
protein could not be isolated, hence the experiments described below will 
concentrate on the characterisation of t..2 and t..4. 
4.2.3 Detection of lysogens harboring 1gtll recombinant phages. 
To obtain direct evidence that the positive recombinant phages isolated express 
CME-binding P-galactosidase fusion proteins, lysogens harboring the recombinant 
phage were prepared. Y 1090 cells containing the recombinant phages were 
streaked onto each of two plates. One plate was incubated at 32°C and the other at 
42°C. This was done to test for temperature-sensitive growth as clones growing at 
32°C but not at 42°C represent lysogens. Representitive recombinants incubated at 
these temperatures are depicted in fig 4.5. While all colonies grew at 32°C, eight 
failed to grow at 42°C. Crude proteins extracts were prepared from the lysogens as 
described in section 6.10.6. The protein extracts were stored at -70°C for 
subsequent use in characterisation of DNA-binding activity and SDS-
polyacrylamide gel elecrophoresis. 
4.2.3.1 South-Western Blotting 
Additional evidence that the recombinant proteins encoded by the putative positive 
clones had the capacity to bind the CME in a sequence-specific manner was 
provided by South-western blotting using the labelled concatemerised CME as a 
probe. Lysogens of the recombinant phages were induced with IPTG for 1, 2 or 3 
hours before fusion proteins were extracted. Proteins were fractionated on a 7% 
polyacrylamide SDS gel and transfered to nitrocellulose membranes. The 
immobilised proteins were denatured/renatured as described for the screening 
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32°C 42°C 
Fig 4.5 Detection of Iysogens harboring )..gtll recombinant phages. Putative 
positives were plated on duplicate luria agar plates. One plate was incubated at 32°C and 
the other at 42°C. Clones growing at 32°C but not at 42°C represent lysogens. Lysogens 
are indicated by the circles. 
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protocol (section 6.10.3). The processed filters were blocked and probed with 
labelled concatemerised CME. Crude extracts from the two positive clones, 'A2 and 
'A4, contained proteins which were IPTG inducible and able to bind to the probe 
(fig 4.6.A and B). Extracts from lysogens not induced with IPTG contained no 
detectable binding activity. An increase in binding of the probe to proteins was 
observed with increasing time of IPTG induction, indicating that these proteins 
were fusion products of the lac Z gene. The 'A2 extract contained a fusion protein 
with an apparent molecular size 139 ±8 kD (fig 4.6.A), while the 'A4 extract 
contained a fusion protein of approximately 153 ±10 kD (fig 4.6.B). Since the ~-
galactosidase segment of the fusion protein is approximately 116kD, the cDNAs 
encode proteins with molecular weights of approximately 23 ±8 kD and 37 ±10 kD 
respectively. Lysogens containing 'Agtl 1 and 'Anegative had no DNA binding 
activity even after IPTG induction. A SVWI-38 nuclear extract was used to check 
binding of the probe to the filter (fig 4.6, lane marked SV). The observed binding 
pattern in SVWI-38 nuclear extracts are similar to those presented by Collins, 
(1993). 
4.2.3.2 Wes tern Blotting 
The filters used in South-western blotting were stripped of radioacitivity and 
reprobed with an anti-~-galactosidase antibody (section 6.10.3). The anti-~-gal 
antibody detected a number of bands (fig 4.7). In 'A2 and 'A4 lysogen extracts, the 
slowest migrating proteins corresponded exactly in size to that seen in South-
western blots (fig 4.7A and B). This was observed by overlaying autoradiographs 
of South-western blots onto the Western blots. The appearance of several bands of 
lower molecular weight is probably due to degradation of the larger proteins. 
Similar degradation patterns of fusion proteins have been reported by Klemsz et al, 
(1990). The lanes containing proteins from the 'Agtl 1 and 'Aneg lysogens contained 
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Fig 4.6 South Western blots of proteins isolated from U and M lysogens. (A) 
A2 and A.gt 11 lysogens were induced with IPTG for the indicated times. After induction, 
crude proteins were seperated by SDS-P AGE and transfered to nitrocellulose membranes 
as described in section 6.5.2. Nitrocellulose filters were probed with labelled 
concatemerised CME probes. The lane marked SV represent crude nuclear proteins from 
SVWI-38 cells. (B) Proteins from A.4 and A.negative lysogens were separated on SDS-
PAGE and probed as described in (A). The approximate molecular weight of the A.2 fusion 
protein is 139 ±8 kDand that of A.4 is 153 ±10 kD. Standard deviations were obtained by 
calculating the approximate molecular weights from three seperate South Western blots. 
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Fig 4. 7 Western blot analysis using anti-JJ-galactosidase antibodies. The filters 
used in fig 4. 6 were stripped of radioactivities and reprobed with an anti P-galactosidase 
antibody . A secondary antibody was used to visualise P-galactosidase fusion proteins as 
described in section 6.10.7. (A) Anti P-galactosidase antibodies detected the presence of 
several cross reacting bands in A2 lysogen protein extracts. The slowest migrating band 
corresponding to that observed in South western blots is indicated by an arrow. Lysogens 
harboring Agtll , shows expression of the 116 kD P-galactosidase. (B) A4 and A.negative 
lysogen protein extracts probed in the same way as described in (A). The band 
corresponding to the fusion protein in A.4 extracts is indicated by a arrow. A.neg extracts 
also expressed P-galactosidase. 
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The results of the south-western and western blots provided additional evidence 
that at least two of the original putative positive phages, A2 and A4, express 
proteins which bind the CME of the human a2(1) procollagen promoter. To 
confirm this for one of the clones, A2 lysogen protein extracts were used in 
electrophoretic mobility shift assays. 
4.2.3.3 EMSA analysis of the U fusion proteins 
The COLIA2 proximal promoter fragment (-107 to -60) was used in EMSA's to 
confirm the binding activity of the j3-galactosidase fusion proteins. This probe 
contains a single binding site for the CME-binding proteins. 30 µg of crude 
lysogen protein extract was used in each reaction. A DNA-protein complex with 
was detected in both A2 protein extracts (fig 4.8.A). This migration pattern was 
slightly higher than that observed for complex I proteins and is as a result of the 
fusion of j3-galactosidase and the unknown protein segment expressed by the 
recombinant cDNA. It should also be noted that these DNA-protein complexes 
where detected after exposure of the gels for three days to X-ray film. The DNA-
binding activity detected in extracts from l2 lysogens was not found in protein 
extracts from uninfected Y1090 cells. 
Specificity for the DNA-binding activity was assayed by using an unlabelled CME 
oligonucleotide as a competitor for binding. Increasing amounts of the CME 
oligonucleotide specifically competed out binding of the DNA-binding protein 
complex found with A2 lysogen extracts. At 200 molar excess of unlabelled CME, 
practically all DNA-protein interaction was competed out (fig 4.8.B). EMSA's 
with the unlabelled G/CBE oligonucleotide had no effect on binding of the fusion 
protein (fig 4.8.C). These results therefore confirmed that the clone obtained in 
screening a human heart lgtl 1 expression library, expressed a fusion protein 
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Fig 4.8 DNA-binding specificity of the U fusion proteins. (A) 30µg of crude )..2 
lysogen proteins (in duplicate) and Y1090 proteins were incubated with a labelled 
COLIA2 proximal promoter fragment (-107 to -60). 2µg poly dldC.poly dldC was 
included in the reaction prior to the addition of the probe. DNA-protein complexes were 
fractionated on non-denaturing 5% polyacrylamide gels. Dried gels were exposed to X-ray 
film for 3-5 days. (B) Increasing molar excess of unlabelled CME was used as a 
competitor for formation of the DNA-protein complex in A.2 lysogen extracts. EMSA's 
were performed as previously described, except that competitor DNA was incubated with 
protein extracts prior to the addition of probe. Dried gels were exposed to X-ray film for 3 
days. (C) Increasing molar excess of unlabelled G/CBE used as a competitor as 
described in (B). 
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Having established that the clone, A.2 expressed a DNA-binding protein, further 
characterisation of the cDNA expressing the putative DNA-binding protein was 
performed. This included determining the size of the cDNA, followed by cloning 
into pUC 19 and subsequent sequence analysis. 
4.2.4 Analysis of the U cDNA inserts 
The polymerase chain reaction was used to determine the approximate cDNA 
insert size of clone A.2. A.gtl 1 primers flanking the cDNA inserts were used in the 
reactions. These primers were 24 mers and flanked the EcoRl site into which the 
cDNA's had been cloned (fig 4.9.A). A cDNA insert of approximately 1kb was 
obtained, while PCR of Agtl 1 and Meg DNA as negative controls provided no 
PCR products (fig 4.9.B). 
The A2 PCR product was blunt ended using klenow polymerase and cloned into 
pUC19 as described in section 6.2.4. Inserts were checked by digestion of the 
cloned plasmid with EcoRl or Kpnl/BamHl double digestion, both providing the 
correct size of approximately 1kb (fig 4.10). The cloned insert was sequenced 
using the M13 universal primers and internal primers designed to complete the 
sequencing by DNA automated sequencing. The complete sequence is shown in 
fig 4.11. Computer-assisted analysis of the sequence was performed using the 
University of Wisconsin Genetics Computer Group Sequence Analysis Software 
Package (Devereux et al, 1984, 1989). The FastA program was used to search the 
European Molecular Biology Laboratory (EMBL) and GenBank nucleic acid 
databases for similarity between A.2 and sequences in the databases. No similarity 
was obtained with any of the sequences in the database, indicating a possibility 
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Fig 4.9 Size analysis of l2 cDNA insert. Agtl 1 primers that flank cDNA inserts in 
A.gt 11 (A) were used in PCR reactions. PCR conditions for optimal product formation was 
set at 95°C, lmin; 60°C, lmin; 72°C, lmin for 30 cycles. (B) 1 Oµl of a 50µ1 PCR mix was 
loaded on 1 % agarose gels and products were separated at 45 mA constant current. The 
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Fig 4.10 Cloning of the Al cDNA insert in pUC19. The PCR product of clone )..2 
was blunt ended using Klenow polymerase. The blunt ended product was cloned in a Smal 
digested pUC19 vector, the resultant plasmid (pUC-2) was cut with the restriction 
enzymes, EcoRl, and a BamHl/Kpnl double digest and electrophoresed on 1 % agarose 
gels. A product of approximately 1 kb was detected. 
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5'-
GAATTCGGGGCCGGGACCAl 111 IAAATGTCAGTTGAAAATTATGGCTGTACTATTGCTT 60 
E FGA GT I FKCQL K IMAVL LL 
AAACAAAACTGGAACTGTTGTTCGAAATCCATAGCCAATACTTTTCACGCCAACCTGTGT 120 
K QNWNCC S KS IA NTFHA NLC 
ACTGAACATAGTAGATTGACATCTAATTCAAGATTACAACATCTGTTACATTCTAAGTGT 180 
T EHS R LTS NS R LQHLLHS KC 
GTTCAGGCTTCTGAAGGTAAAGGGACACTGGATCCAGAAGCTATGGAACCAGCAGTTGAT 240 
VQAS EGKGT LDP E AME PA VD 
TTCTTGTATTTCCTGATTAACCTACTTGTAAACTTGAAAGCAAGACCTTGATTGCACCAA 300 
F LYF LIN LTCKLE SK TL I AP 
CAGGTCCAGAGTATGAGTGCAAGCAAAGCAGAACTCTCATGCGTGACCTGAGCAGACAGG 360 











Fig 4.11 Nucleic acid and deduced amino acid sequence of clone A.2. The calculated 
size of the peptide encoded by the open reading frame is 12.5 kD. The peptide was also 
found to contain multiple consensus phosphorylation sites (see fig 4.12) for the cAMP-
dependent protein kinase and protein kinase C ( Kennely and Krebs, 1991). 
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Translation of the DNA sequence was performed and this showed an open reading 
frame of 116 amino acids with a calculated peptide molecular weight of 12.5kD. 
Discrepancies are often found between the calculated molecular weight of a 
protein and the apparent molecular weight observed by SDS-PAGE (23 ±8 kD, fig 
4.6.A). A search of the protein databank by computation at the National Centre for 
Biotechnology Information (NCBI) using the blast network service, provided very 
little similarities between the 116 amino acid peptide with other proteins. Some 
similarity however, was obtained with the sex-determining region Y (SRY) protein 
(fig 4.12.A). Although the similarity is minimal, it is interesting to note that SRY 
is a transcriptional activator which regulates the genetic switch in male 
development responsible for initiating male sex determination. It also contains a 
HMG box which recoginises DNA by partial interaction in the minor groove 
(Payen and Cori.not, 1993). The murine (m)SRY and human (h)SRY have 
differences in DNA binding activity in that (m)SR Y shows more extensive major-
groove contacts with DNA and it has a higher sequence specificity than (h)SR Y 
(Giese et al, 1994). 
The peptide also contains multiple potential consensus phosphorylation sites for 
the cAMP-dependent protein kinase and protein kinase C (fig 4.12.B). The 
consensus sequences recognised by these kinases are listed in table 4.2. 
Table 4.2 Consensus sequences most frequently recognised by cAMP-dependent 




Modified from Kennely and Krebs ( 1991) 
Consensus sequence 
R-R/K-X-S*/T* > R-X2-S*/T* = R-X-S*/T* 
(RIK1.3,X2.o)-S*/T*-(X2.o,RIK1.3) > 
S*/T*-(X2-o, RIK1-3) ~ (R/K.1-3, X2-o)-S*/T* 
Note: The phospho-acceptor group is denoted by an asterisk. 
Where two amino acids functions interchangeably, both are listed with a slash (/) separating them. Sequences judged to be neutral are denoted by an X. 
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Although these potential phosphorylation sites are found in the peptide, this does 
not imply that the protein is necessarily phosphorylated as secondary and tertiary 
structures can play a significant role in substrate recognition. These findings can 
only be confirmed when the protein has been purified and on secondary structure 
predictions. 
~ 27 CSKSIANTFHANLCTEHSRLTSNSRLQHLLHSKCVQASEGKGTLD 71 ><2.. 
C+K+ + + LC S + +NS LQ HS + TLD 
172 CAKTTHSQMESQLCRSQSLILTNSLLQKEHHSSWTNLGHDRVTLD 216 SRY 
Identities = 14/45 (35%) 
Positives = 21 /45 (46%) 
B 
* * EFGAGTIFKCQLKIMAVLLLKQNWNCCSKSI_ANTH 
* * * * * ANLCTEHSRLTSNSRLQHLLHSKCVQASEGKGTLD 
* * * PEAMEPAVDFLYFLINLTCKLESKTLIAPTGPDMS 
ASKAELSCVT 
Fig 4.12 Sequence similarities and potential phosphorylation . sites. (A) 
Computation performed using the NCBI blast network service provided similarities 
between the 116 amino acid peptide and the sex-determining region Y (SRY) protein. (B) 
Potential phosphorylation sites (indicated by the asterisks) using the phosphorylation 
consensus sequences listed in table 4.2. 
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4.2.5 Expression of U mRNA in different cell lines 
N orthem blot analysis was performed to assess the expression of the t..2 encoding 
gene in eukaryotic cell lines. Cytoplasmic RNA was extracted from cell lines 
which showed varying levels of a.2(1) collagen gene expression. The t..2 cDNA 
insert was released from pUC-2, radioactively labelled by random priming (section 
6.6.2.2) and used as a probe to detect the presence of t..2 message. A '3-actin probe 
was used as a control for RNA loading. A mRNA transcript of appoximately 4 kb 
was detected in varying amounts in the different cell lines (fig 4.13.A). The cell 
lines where a.2(1) collagen gene expression occurs (FG0 and HT1080) (section 
2.2.2.2), contained low amounts of the transcripts. In cell lines where a.2(1) 
collagen gene expression was not observed (MDA, MCF, ZR and LB), the amount 
of t..2 expression was enhanced by comparison to that in FG0 and HT 1080 cells. 
Bar graphs of the expression of t..2 relative to that of '3-actin in the different cell 
lines are shown in fig 4.13.B. 
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Fig 4.13 Expression of U transcript in different cell lines. (A) Total RNA was 
extracted from the cell lines by the method of Chomczinsky and Sacchi, (1987). Sµg of 
total RNA was separated on 1 % agarose formaldehyde gels, transferred to nylon 
membranes and probed with labelled A.2 and f3-actin probes as described in section 6.6.2. 
After washing, the filters were exposed to X-ray film for 16 hours. (B) Densitometric 
scans of the autoradiograph in (A) indicating the ratio of A.2 expression relative to that of 
P-actin. 
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4.3 DISCUSSION 
This study describes the isolation of cDNA clones coding for proteins which may 
in part be responsible for the cell- and species-specific expression of the human 
a2( 1) procollagen gene. Screening of a cDNA expression library with the CME 
provided two clones, A2 and A4. The proteins encoded by these clones showed 
weak binding to the CME in EMSA's using crude protein extracts from lysogens. 
This weak binding can be attributed to the following: (i) A limitation of the 
screening strategy used is that it can result in the isolation of fusion proteins in 
lysogen extracts that bind the recognition site with low affinity or no detectable 
affinity when assayed in soluble fractions (Singh, 1993). (ii) The technique also 
relies on the expression of a functional DNA-binding domain in E.coli where post-
translational modification of the fusion proteins does not occur as it would in 
eukaryotic cells. Chapter 3 reports that complex II and III proteins require 
phosphorylation for high affinity binding to their recognition site. This may 
explain the low affinity binding observed in EMSA's using E.coli lysogen protein 
extracts. The high affinity binding to the concatemerised CME probe detected on 
nitrocellulose membranes is as a result of denaturing and renaturing the proteins 
on the filters, and could allow the proteins to take up the correct conformation for 
DNA binding. 
Although low affinity binding of A2 fusion proteins was observed in EMSA's, 
competition experiments with unlabelled CME confirmed the presence of a 
sequence- specific DNA-binding protein in extracts from lysogens. The molecular 
size of the protein expressed by clone A2 was approximately 23 ±8 kD and the 
cDNA size of 1kb represented a segment of the coding region of the gene based on 
the findings by N orthem blot analysis indicating a transcript size of approximately 
4kb. 
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Since )...2 transcripts are found predominantly in cells where the a2( 1) procollagen 
gene is not expressed, the expression of these transcripts may be controlled in a 
cell-specific manner. This cell-specific expression is consistent with work 
presented in chapter 2, showing cell-specific detection of the complex IT proteins 
which bind the CME in the human a2(1) procollagen promoter. The implication of 
this is that )...2 expresses a peptide that could possibly be a component of the 
complex IT protein(s). Although the DNA-sequence used to screen the library was 
able to bind both complex IT and Ill proteins, it is more likely that the clone 
obtained encodes a component of complex IT since A.2 transcript detection in the 
different cell lines correlates with the presence of complex IT proteins and not that 
of complex Ill. 
Translation of the DNA sequence provided a 116 amino acid peptide which shares 
35% homology over 45 amino acids with the sex-determining region Y (SRY) 
protein, an activator of transcription (Payen and Cotinot, 1993). This is however 
not a significant similarity. Interestingly, recent work has shown that other 
members of the SR Y-related family of genes, the SOX genes, play a role in the 
regulation of the type IT collagen gene. SOX9, acts as an activator by interacting 
with an enhancer sequence located in the first intron of the al(II) gene (Lefebvre 
et al, 1997). Members of the SOX family of proteins may therefore have 
regulatory effects on the other collagen genes. It is possible that the clone isolated 
in this study represent an as yet undescribed DNA binding protein. Using the 
consensus sequences for phosphorylation sites published by Kennely and Krebs 
( 1991 ), a number of potential phosphorylation sites in the 116 amino acid peptide 
were noted. Identification of these phosphorylation sites are in agreement with a 
model depicting phosphorylation as a requirement for high affinity complex I, II 
and III DNA-protein interactions (section 3.2.5.2). 
In initial attempts to isolate clones expressing COL1A2 promoter binding proteins, 
the -107 and -60 region of the a2( 1) procollagen gene was used as a probe to 
screen a HepG2 A.gt! 1 expression library. This fragment includes the inverted 
CCAA T box and the CME. Sequence analysis of a potential positive and a 
database search indicated 85% homology between the clone and the bacteriophage 
lambda CI protein. It is interesting to note that the one of the DNA binding sites 
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for the lambda CI protein is highly homologous to that of the DNA probe used to 




Fig 4.14 Sequence homology between COL1A2 and )..03L. Sequence homology 
between the human a2(1) procollagen promoter and lambda operator 3 binding site. The 
bases not homologous or gaps are boxed. The CCAAT box is underlined. 
The A.CI protein binds three regions in the A left and right operator regions. The 
homology between the COL1A2 promoter and the CI protein DNA binding sites is 
found in the third lambda operator box, A03L. A comparison of the two sequences 
showed a 4 bp mismatch over a 19 bp region. It is therefore possible that the ACI 
proteins have the ability to bind this region in a2( 1) promoter, hence the detection 
of this clone. The manner in which t..CI DNA came about in the cloning region of 
the Agtl 1 expression vector remains unexplained. It is possible that this may have 
arisen due to a rearrangement of the Agtl 1 DNA. A rearrangement of this nature 
could have resulted in the placement of the t..CI gene in the vicinity of the lac Z 
promoter allowing the expression and subsequent detection of the protein. To 
substantiate the speculation of rearrangement events, several restriction enzymes 
were used to compare the digestion patterns of the clone isolated and wild type 
Agtl I cut with the same restriction enzymes. Digestion patterns between the clone 
( assuming it was Agt 11 containg an insert) and wild type Agt 11 were not consistent 
with the what was expected. These patterns implied differences in the cutting sites 
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between the clone and WT ).gtl 1. It should be noted that the HepG2 library used 
initially was a Clontech library. The purity of certain Cl on tech libraries had been 
questioned at the time and it is also possible that the initial choice of library may 
have been problematic. The subsequent screening of a heart ).gtl 1 library was 
therefore performed only after thorough checking of the library. Screening of this 
library revealed the clones discussed here. 
It should be noted that the results presented in this chapter are preliminary and a 
precise conclusion as to the exact role of the clone identified can only be made 
after extensive analysis with a recombinant protein using both wild type and 
mutant sequences. The detection of these clones will enable the to identification of 
full length DNAs encoding the proteins that bind the proximal a2(1) procollagen 
promoter. This will allow a detailed analysis of their precise role in a2( 1) 
procollagen gene expression. 
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CHAPTERS: 
CONCLUSION 
The regulation of a.2( 1) procollagen gene expression has been associated with 
different trans-acting factor interactions within the proximal promoter region (-107 
to -60). A a.2(1) collagen expressing cell line (CT-1), formed two major DNA-
protein complexes, complex I and ill, while a cell line in which the gene is 
inhibited (SVWI-38), contained an additional DNA-protein complex, II (Parker et 
al, 1989, 1992). Pr~liminary functional data also showed that the DNA binding 
sequences of these proteins were essential for the expression of a proximal 
COL1A2 promoter construct (Collins et al, 1997). The differences in trans-acting 
factor binding could explain the differences in a.2( 1) pro collagen promoter 
activities in the two cell lines and formed the basis of the investigation presented 
here. 
5.1 Objectives 
In an attempt to identify mechanisms in the transcriptional regulation of the human 
a.2(1) procollagen gene, the objectives of this investigation were as follows: 
1. To determine if the findings reported by Parker et al, (1992) were specific for 
the cell lines used in that particular study or whether cell differentiation in terms of 
procollagen gene expression could be associated with trans-acting factor 
interactions in a number of different cell lines. 
2. Having established the above; to determine if the model proposed for cell-
specific a.2( 1) procollagen gene expression, holds true in different species. 
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3. Since the human complex I proteins and the mouse CBF bound similar 
elements in their respective promoters; to determine their relationship with each 
other. 
4. To study the effect of dephosphorylation and kinase inhibitors on trans-acting 
factor interations at the proximal promoter and subsequent expression of the a2( 1) 
procollagen gene. 
5. To identify the gene(s) coding for a2(1) procollagen promoter-binding proteins 
and to correlate these findings with the cell and species-specific regulation of the 
a2(1) procollagen gene. 
5.2 Significant findings 
The present study provides evidence that the association between a2( 1) 
procollagen gene expression with trans-acting factor switching is a fairly general 
phenomenon. A range of cell lines was examined to determine a2( 1) collagen 
chain synthesis, steady state mRNA levels and new transcript formation. The 
different levels of a2( 1) collagen transcripts in the various cell lines was correlated 
with transcription factor interaction with the proximal a2(1) procollagen promoter. 
This clear correlation led to the proposal of a model for the cell-specific regulation 
of the a2(1) procollagen promoter. The model proposes that two DNA-protein 
complexes, I and III are associated with normal expression of the gene. Complex I 
proteins involves binding to the G/CBE (which includes the CCAAT box) and 
complex III proteins bind the CME. These two factors are possibly co-activators of 
a2( 1) procollagen gene expression. In cells where the gene is inhibited, two 
scenarios may be responsible for the down regulation of the gene, ( 1) the absence 
of complex III proteins and (2) the presence of a different DNA-protein complex, 
complex TI, is proposed as a repressor of a2( 1) collagen synthesis. Both these 
events may be required in the inhibition of the gene. The fact that the complex III 
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- proteins were not detected in cell extracts where the a2( 1) pro collagen gene is 
permanently inactive, could be due to the silencing of the gene( s) expressing 
complex ill protein( s) or modification of the protein( s) in such a manner that it is 
prevented from interacting with it's recognition sequence. In cells where the a2(1) 
procollagen gene is transiently silenced, the presence of all three DNA-protein 
complexes, I, II and ill were detected. It is possible that the relative amounts or the 
ratio of complex II to ill proteins may be important in regulating expression of the 
gene. Where the amounts of complex II proteins exceed that of complex ill, a2( 1) 
collagen synthesis is inhibited (eg SVWI-38) and vice versa (eg CT-I). 
Surprisingly, a cell line (HT1080) where no a2(1) collagen chains or steady state 
mRNA were detected, contained complex I and ill binding activity. Identification 
of newly formed RNA transcripts in this cell line by nuclear run-on transcription 
assays, showed that the gene was transcriptionally active and is therefore in line 
with the proposed model. This finding implies that post-trancriptional events are 
responsible for the absence of a2( 1) collagen mRNA and polypeptide synthesis in 
HT 1080 cells. A similar result was reported in HeLa cells, where the gene is 
active, but post-transcriptional modifications lead to absence of steady-state 
message and polypeptide synthesis (Furth et al, 1991). 
The use of a G/CBE oligonucleotide which exclude the downstream GGAGG box, 
( GCCCTCCCA TIGG) in competiton experiments, indicated that the two binding 
elements, G/CBE and CME, are distinct but adjacent binding sites. This sequence 
competed out binding of complex I as effectively as the proximal a2( 1) 
procollagen promoter sequence (-107 to -60). That these elements are distinct is 
supported by competition assays usmg the CME oligonucleotide 
(GGAGGCCCTTTT) which competed out complexes II and ill binding and not 
that of complex I. These factors also bind the proximal promoter with similar 
affinities. 
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The validity of the above model was tested in two species, human and mouse. The 
results indicated that the proposed model does not account for differences in a2( 1) 
procollagen gene expression in rodent cell lines. This may be due to a 3 bp 
mismatch within the CME motif between the human and rodent promoters. While 
the human promoter clearly forms two distinct DNA-protein complexes, the rodent 
promoter forms only one DNA-protein complex, the CCAAT-binding factor 
(CBF) in the -107 to -60 region. Interestingly, mouse nuclear extracts contained 
complex II proteins, but these however, are not able to interact with the mouse 
proximal a2( 1) procollagen promoter. It is possible that complex II protein may 
have DNA binding activity at distal sites or that it has a regulatory function in the 
expression of other genes. Since the CME binding proteins are proposed to have a 
regulatory function, this raises the possibility that the absence of this element in 
rodent promoters could lead to species-specific differences in the proximal a2( 1) 
procollagen promoter acitivity. Transfection assays of both the human and mouse 
proximal promoter-CAT constructs into CT-1 (human) and 3T3 (mouse) cells 
showed differences in transcriptional activities between two species. In CT-1 cells 
the human promoter-CAT construct was more active than the mouse promoter. 
Since the only difference in terms of trans-acting factor binding sites between the 
two promoters is the 3 bp mismatch in the CME, the observed transcriptional 
differences can be ascribed to differences in trans-acting factor binding. The 
inability of complex ill to bind the mouse promoter transfected into CT-1 cells 
may be responsible for the decreased transcriptional activity observed. Expression 
of the human and mouse promoter-CAT constructs in 3T3 cells showed no 
significant difference between the two, while a clear difference was observed 
when comparing the activity of the human promoter in the mouse and human cell 
lines. This difference is similar to that reported by Parker et al, (1992) showing a 
marked difference in a2(1) procollagen promoter activity in CT-1 and SVWI-38 
cells. 
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The DNA-protein complex which is common to both the human (COL1A2) and 
mouse (Col1A2) promoters, is the G/CBE ( complex I) binding proteins in human 
and CBF in mouse. This protein complex is ubiquitous and is found in all the cell 
lines used in this study. Similar findings reported by Vuorio et al, (1990) showed 
that the mouse CBF is a ubiquitous factor. Cross-species EMSA's using human 
nuclear extracts with the mouse proximal a2( 1) procollagen promoter produced a 
single DNA-protein complex, having the same migration pattern as that observed 
in the interaction of CBF with its consensus sequence. Further characterisation of 
the complex I proteins using consensus binding sites of other known CCAA T 
binding proteins as competitors showed that double stranded oligonucleotides of 
the mouse CCAA T binding element and the NF-Y binding sequence competed out 
complex I formation whereas a consensus oligonucleotide of the CCAAT/enhancer 
binding protein (C/EBP) did not. The use of a mouse anti-CBF-B antibody in 
EMSA's using human nuclear proteins resulted in the supershift of the complex I 
proteins, confirming that complex I and CBF are related or similar proteins. The 
same antibody also resulted in the supershifting of the mouse CBF. These results 
and those presented by Collins et al, (1997) confirm that complex I is a member of 
the heterologous CCAAT-binding proteins. 
Further analysis of the complex I, II an III proteins using phosphatase-treated 
nuclear proteins in EMSA's showed that all three proteins require phosphorylation 
for DNA binding activity. Dephosphorylation of nuclear proteins using calf 
intestinal phosphatase resulted in the loss of complex I formation on the COL1A2 
promoter and CBF binding to the Col 1A2 promoter. The serine/threonine 
phosphatase, PP2A resulted in the loss of complexes II and III formation. To 
confirm these findings, cells were incubated with the kinase inhibitor, 
staurosporin. This resulted in a decrease in all DNA-protein interactions with the 
proximal a2( 1) procollagen promoter. It is possible that phosphorylation leads to 
an altered protein conformation or to altered interaction with other proteins that 
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would allow for DNA binding activity (reviewed by Hunter and Karin, 1992). 
Well documented examples of transcription factors where DNA binding activity is 
stimulated by phosphorylation are rather limited. An extensively studied example 
is the serum response factor (SRF), which binds and activates the c-fos promoter 
through the serum response element (SRE). The mechanism whereby 
phosphorylation affects DNA binding is unknown, but phosphorylation induces a 
conformational change in SRF (Treisman, 1986 and Janknecht et al, 1992). It is 
likely that phosphorylation of the complex I, II and Ill proteins occur at ser/thr 
residues since a tyrosine kinase inhibitor had no effect on their DNA binding 
ability. The experiments performed in this study do not shed light on exactly how 
and where phosphorylation of complexes I, II, ill and CBF occur and whether it 
induces a conformational change in the proteins. These would be interesting 
questions to pursue once these proteins have been purified. 
The inhibition observed in a2( 1) procollagen promoter activity and gene 
expression (CT-1 cells) in the presence of the kinase inhibitor (staurosporin), 
correlates well with the loss of trans-acting factor interactions in the proximal 
promoter region and provides support for the proposal that phosphorylation events 
are important in the regulation of a2(1) procollagen gene expression. Sobel et al, 
(1983); Rabin et al, (1986) and Greenwel et al, (1997) reported that an activator of 
protein kinase C activity, PMA, resulted in inhibition of a2(1) procollagen gene 
expression. This is contradictory to findings by Stuiver et al, (1991) showing that 
PMA has a stimulatory effect on a2(1) procollagen expression in 3T3-Ll cells. It 
is possible that cell-specific signalling pathways are responsible for the differences 
observed and that a multitude of protein kinases play a role in expression of the 
collagen genes. 
In an attempt to identify the complex II and III proteins, a concatemerised CME 
probe was used to screen a human heart t..gtl 1 expression library. Two clones, t..2 
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and )...4, were identified. These clones expressed fusion proteins with approximate 
sizes of 139 kD and 153 kD as determined by south western blotting. They were 
also IPTG inducible, an indication that their expression was under the control of 
the lac Z promoter. When taking the size of ~-galactosidase into account, the size 
of )...2 corresponds to approximately 23 ±8 kD and )...4 to 37 ±10 kD. The fusion 
protein expressed by one of the clones, )...2, was shown to be sequence-specific 
since unlabelled wild type CME could compete out formation of the DNA-protein 
complex detected in EMSA's. It contained a cDNA insert of approximately 1 kb 
and a databank search for sequence similarities between )...2 and published 
sequences did not provide any significant homologies. Also, a search in the protein 
databank for similarities between the )...2 peptide and other proteins did not provide 
any significant homologies. It is therefore possible that )...2 is a product of an as yet 
unidentified gene that may have a role in the regulation of a2( 1) collagen 
synthesis. Northern blot analysis using )...2 as a probe showed that a 4 kb mRNA 
transcript is associated with cells where a2(1) collagen is not detected. This is 
similar to the association of complex II proteins with cells where a2( 1) collagen 
expression is inhibited. The identification of genes which express proteins that 
bind the a2(1) procollagen promoter will allow investigations that will lead to an 
improved understanding of the mechanisms by which the type I collagen genes are 
regulated. 
5.3 Novel aspects of this investigation 
Tissue and cell-specific expression of the mouse type I collagen genes has been 
shown by a number of groups (Rossi and de Crombrugghe, 1987; Slack et al, 
1991; Simkevich et al, 1992; Sokolov et al, 1995). These studies have focused on 
the identification of cis-regulatory elements and the trans-acting factors which 
bind to them. In this study, a clear correlation between trans-acting factor 
interaction and expression of the human a2( 1) procollagen gene was identified. A 
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study by Walsh and Schimmel (1987) showed a similar association of trans-acting 
factor binding in the muscle a-actin promoter during myocyte differentiation, 
where binding of a specific trans-acting factor is greatly diminished in non-
myocyte cells. The present study implicates cis-acting elements and their 
respective trans-acting factors with the expression of the a2( 1) pro collagen gene. 
Evidence that a 3 bp mismatch between the human and rodent a2( 1) procollagen 
promoters within the CME confers species-specific differences in promoter 
activities is provided. This finding is novel in that the mismatch prevents proposed 
activators and repressors ( complexes II and ill respectively) from binding to the 
rodent a2(1) procollagen promoter. The Col1A2 and COL1A2 promoters also 
respond to TGF-J3 via binding of different trans-acting factors to the individual 
promoters (Rossi et al, 1988; Inagaki et al, 1995; Chung et al, 1996; Greenwel et 
al, 1995, 1997). These studies showed that there are species-specific differences in 
the response of a2(1) procollagen promoter to cytokines like TGF-J3. Our 
investigation contributes to towards studies implying species-specific differences 
in a2( 1) procollagen gene expression, albeit in a different region of the a2( 1) 
procollagen promoter. The promoter region investigated in this study is located 
downstream of the TGF-J3 response element. 
Evidence for the requirement of phosphorylation for the DNA-binding activities of 
complex I, II, III and CBF is provided. This is of interest as no CCAA T-binding 
factor to date has been shown to require phosphorylation for DNA-binding 
activity. Although phosphorylation events are suggested to play a role in collagen 
gene expression (review by Slack et al, 1993), little direct evidence of its effect on 
trans-acting factor binding to the a2( 1) procollagen promoter has been reported. A 
study by Greenwell et al, (1995) however show that tyrosine dephosphorylation of 
nuclear proteins result in enhanced DNA-protein interaction with the human a2(1) 
procollagen TGF-J3 response element. There is much speculation as to exactly 
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which trans-acting factors bind to this region (section 1.). Chung et al, (1996) 
implicated AP-1 binding and the components of AP.-1, Fos and Jun are both 
influenced by phosphorylation. c-Jun DNA-binding activity is reversibly inhibited 
by phosphorylation of Ser-243, (Boyle et al, 1991). These findings may have a 
bearing on the study by Greenwel et al, (1995) which showed that 
dephosphorylation of nuclear proteins mimics TGF-f3 stimulation of a2(1) 
procollagen gene expression. The response observed may be due to 
dephosphorylation of proteins such as Spl (Greenwel et al, 1995; 1997) or Jun 
which can result in binding of Spl or AP-1 to the the TGF-f3 response element. It 
is possible that TGF-f3 stimulation results in the activation of a phosphatase(s) 
involved in dephosporylation of these proteins or other factors which affect trans-
acting factor binding to the a2(1) procollagen promoter. These ideas are 
speculative but shows that phosphorylation and dephosphorylation events have key 
roles in the regulation of a2( 1) procollagen gene expression. 
The isolation of a cDNA whose expression is associated with the inhibition of 
a2( 1) collagen synthesis will allow us to perform investigations that will lead to a 
. 
greater understanding of a2( 1) collagen gene expression. 
5.4 Extended model of trans-acting factor interactions with the -107 to 
+54 a2(1) promoter. 
The results of this study can be used to formulate a model which encomposes the 
major findings (fig 5.1). 
1. An external ligand leads to the activation of the protein kinase C pathway and 
other signalling pathways. 
2. Protein kinase C phosphorylates a serine/threonine kinase amongst other 
proteins. It may also phosphorylate nuclear factors directly. 
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3. The ser/thr kinase ( and possibly other kinases) phosphorylate proteins including 
the nuclear proteins forming complexes L II, ill in human and CBF in mouse. 
4. The phosphorylated proteins are stimulated to bind their recognition sequences 
leading to activation/inhibition of collagen gene expression in a cell and species-
specific manner. 
5. The interaction of complex I and ill proteins with the proximal a.2( 1) 
procollagen promoter leads to expression of the gene, while the interaction of 
complex II causes downregulation of the gene. The loss of complex ill binding 
may also account for decreased expression. 
6. Complex I and CBF are similar in their binding activities and are possibly 
members of the same family of proteins. 
. 
This study contributes towards our understanding of the mechanisms involved in 
the transcriptional regulation of the human a.2( 1) procollagen gene. The proximal 
promoter binding proteins discussed in this thesis are likely to interact with each 
other and the transcription initiation machinery to either activate or down regulate 
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Fig 5.1 Proposed model for the cell- and species-specific regulation of the 
a.2(1) procollagen promoters. An extracellular ligand initiates the activation of a 
mebrane bound receptor (R). This activated receptor results in the activation of 
phospholipase C, which cleaves PI 4,5-bisphosphate (PIP2) to generate diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3}. DAG stimulates the activation of protein 
kinase C (PKC) which in tum can activate a number of other protein kinases. Protein 
kinase C or other kinases (possibly ser/thr kinases) in tum phosphorylate the trans-acting 
factors which interact with the proximal a.2( 1) pro collagen promoter resulting in the 
binding of these factors to consensus sequences in the promoter and ultimate regulation of 
the gene. The thickness of the arrows indicate the degree of promoter activity. 
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CHAPTER 6: 
MATERIALS AND METHODS 
6.1 Cell Culture 
6.1.1 Maintenance of cells in culture 
Cells were grown in DMEM containing 10% fetal calf serum, lOOµg/ml 
streptomycin and 250u/ml penicillin. The cells were incubated at 37°C in a 
humidified 95% air, 5% CO2 incubator. Upon reaching confluence, cells were 
trypsinised with 0.05% trypsin in PBS containing lOmM EDTA, and split at a 
ratio of 1:4 for transformed cells and 1:2 for non-transformed cells. The mouse 
macrophage cell line, P388D1 and the human monocyte cell line, U937 were 
grown in suspension in RPMI medium containing lOOµg/ml streptomycin and 
250u/ml penicillin. 
The cell lines used in this study were: 
1. human skin fibroblasts, (FG0 ) (van der Westhuysen et al, 1984) 
2. human embryonic lung fibroblasts, (WI-38) (ATCC CCL-75) 
3. y-radiation-transformed WI-38 fibroblasts, (CT-1) (Namba et al, 1980) 
4. simian virus 40 transformed WI-38 fibroblast, (SVWI-38) (de Haan et al, 1986) 
5. human fibrosarcoma cells, HT1080 (ATCC CCL-121) 
6. normal human lymphoblastoid cells, L-77 
7. human hepatocellular carcinoma cells, HepG2 (ATCC HB 8065) 
Chapter 6 Materials and Methods I 145 
8. human mammary epithelial tumour cell lines, ZR-75-2 (ATCC CRL-1500) and 
MDA-MB-231 (ATCC HTB-26). 
9. human monocytic cell line (U937) (ATCC CRL 1593) 
10. Swiss mouse 3T3 fibroblasts (ATCC CCL 92) 
11. Swiss mouse 3T6 fibroblasts (ATCC CCL 96) 
12. Rat-1 lung fibroblast (Rat-1) (Slack et al, 1992) 
13. Ras-transformed Rat-1 fibroblasts, (Rasrat-1) (Sla,ck et al, 1992) 
14. mouse macrophages, (p388D1) (Koren et al, 1975) 
6.1.2 Treatment of cells with the kinase inhibitors, staurosporin or 
genistein and the phosphatase inhibitor, okadaic acid 
Cells in suspension were pelleted and resupended m RPMI medium. 
Approximately 5 X 106 cells in 10 ml of medium was treated with the required 
concentration of inhibitor (see section 3.2.5.2). Incubation was continued for 
between 3 and 17 hours and cell death observed by trypan blue exclusion. After 
incubation with inhibitors the cells were washed with PBS and nuclear proteins 
extracted as described below (section 6.4.1). 
6.1.3 Collagen synthesis 
For the determination of collagen synthesis , cells were plated at a density of 
2x105 cells per 30 mm diameter dish. The cells were grown at 37°C in a CO2 
incubator until approximately 80% confluent, and labelled for 18 hours in serum-
free medium containing 10 µCi/ml of 2,3-[3H]-proline, 50 µg/ml ascorbate and 50 
µg/ml of ~-aminopropionitrile (BAPN). 
The medium (2ml) from cells labelled with 2,3-[3H]-proline was added to 200 µl 
of a solution containing 1 mM PMSF and 0.8 mg/ml n-ethylmaleimide. To this 
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mix was added 50 µl of 1 mg/ml rat tail collagen in 0.5 M acetic acid. The cell 
layer was rinsed in 200 µl PBS which was added to the above and 600 µl of ice 
cold 96% ethanol was added to precipitate the collagen at -20°C for 16 hours. The 
collagen was pelleted at 10 000 rpm at 4°C for 30 min in a Beckman JA20 rotor. 
The ethanol was decanted and the pellet washed twice in 70% ethanol. All traces 
of ethanol was removed under vacuum and the collagen dissolved in 100 µl of 0.5 
M acetic acid. Non-collagenous proteins were digested by the addition of 5 µl of 1 
mg/ml pepsin and incubated overnight at 4 °C. 
Five µl of the protein sample was incubated with 5 µl of 20o/o TCA on ice for 1 
hour. This was followed by incubation at 90°C for 30 min, on ice for 30 min, the 
sample pippeted onto GF IC filters, washed three times in 5% TCA and a final 
wash with 70% ethanol. The filters were allowed to air dry and radioactivity 
counted in 10 ml scintillation fluid. 
6.2 Preparation and transformation of competent E. coli cells 
6.2.1 Preparation of competent cells 
Glycerol stocks of E.coli DH5a or DK-1 cells were used to prepare competent 
cells. Fifty µl of a glycerol stock was inoculated into 10 ml of luria broth and 
grown overnight at 37°C with shaking. Three ml of the overnight culture was 
inoculated into 300 ml of luria broth in a 2 litre conical flask and incubated at 
37°C with vigorous shaking until the cultures reached an OD6sonm of 0.2 to 0.4. 
The cells were pelleted by centrifugation at 5 000 rpm at 4°C in a Beckman JAlO 
rotor for 10 min. The pellet was resuspended in 40 ml of ice cold 60 mM CaCh, 
10 mM Pipes pH 7.2. This suspension was left on ice for 30 min, transferred to 
Corex glass centrifuge tubes and centrifuged at 5 000 rpm at 4 °C for 5 min in a 
Beckman JA20 rotor. Four ml of a solution of 60 mM CaCh, 10 mM Pipes and 
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15% glycerol was added to the pellet and gently mixed. The cell suspension was 
stored in aliquots of 200 µl at -70°C. 
6.2.2 Transformation of competent cells 
The transformation efficiency of the cells were checked using the vector pUC19. 
An aliquot of competent cells were thawed on ice and 100 µl transferred to a 15 ml 
sterile plastic tube. To the cells was added 1 ng of pUC19 DNA, mixed gently and 
incubated on ice for 30 min, followed by heat shock at 42°C for 3 min before the 
addition of 1 ml of prewarmed (37°C) L-broth and incubation at 37°C for 1 hour. 
50, 100 and 200 µl aliquots were plated out on luria agar plates containing 
50µg/ml and incubated overnight at 37°C. A successful competent cell batch 
usually formed between 10
7 and 108 colonies per µg ofpUC19 DNA. 
6.2.3 Preparation of plasmid DNA using the rapid plasmid extraction 
method 
An alkaline lysis method (Birnboim and Doly, 1979; Birnboim, 1983) was used 
for small scale crude plasmid extracts. Ten ml of L-broth containing 50 µg/ml 
ampicillin was inoculated with 50 µl of a glycerol stock and incubated overnight at 
37°C with shaking. Before harvesting of the overnight culture, glycerol stocks 
were prepared. The cells were pelleted in a Beckman TJ-6 centrifuge at 2000 rpm 
for 10 min at 4°C. The cell pellet was resuspended in 200 µl of solution 1 (25 mM 
Tris-Cl pH 8.0, 10 mM EDTA and 50 mM glucose), and incubated at room 
temperature for 5 min. Cells were lysed by the addition of 400 µl of solution 2 
(lM NaOH, 1% SDS) and left on ice for 5 min. The genomic DNA and cell 
membranes were precipitated by the addition of 300 µl of 3M potassium acetate, 
pH 4.8 and incubation on ice for 10 min. The cell debris and chromosomal DNA 
was removed by centrifugation in a microfuge for 5 min. Supematants were 
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transferred to a fresh tube and plasmid DNA was precipitated by the addition of an 
equal volume of isopropanol and left for 30 min at -20°C. The plasmid DNA was 
pelleted by centrifugation in a microfuge, washed twice with 70% ethanol and 
dried under vacuum. The pellet was resuspended in 50-80 µl of TE. 
6.2.4 Blunt end ligation of DNA fragments into plasmid vectors 
DNA fragments with 5 '-overhanging ends were incubated with the klenow 
fragment of E. coli DNA polymerase in order to fill in recessed 3 '-ends of double 
stranded DNA (Sambrook et al, 1989). One unit of klenow polymerase in klenow 
buffer containing 0.5 mM each of dGTP, dATP, dTTP and dCTP was incubated 
with 100 -1000 ng of double stranded DNA in a final volume of 20 µl. The 
reaction was incubated at room temperature for 30 min, extracted with 
phenol:chloroform:isoamyl alcohol (25:24:1) and the DNA precipitated with 96% 
ethanol. DNA was washed, dried and resuspended in a small volume of sterile 
water. 
For blunt end ligation, plasmids were digested with the restriction enzyme Smal. A 
DNA insert : vector ratio of 5: 1 was the prefered ratio used in ligations. Ligation 
reactions were performed in a final volume of 10 µl as recommended by the 
manufacturers of the ligase or by in gel ligations (section 6.2.5). 
6.2.5 In gel ligation 
In gel ligations were performed as previously described (Struhl, 1985). DNA 
samples were digested with the appropriate restriction enzymes and 
electrophoresed on 0.8% low melting agarose gels in TAE buffer (section 6.11). 
The desired bands were cut out in a small volume using a razor blade and 
transferred to a microfuge tube. The gel slices were melted at 70°C for 10 min and 
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added to a ligation reaction containing insert and vector DNA in a volume of 9 µl. 
The tube was placed at 37°C and 11µ1 of a cocktail containing 2x T4 DNA ligase 
buffer (section 6.11), 1 mM ATP and lunit T4 DNA ligase was added and 
incubated overnight at room temperature. After the ligation was completed, the 
gelatenous mixture was remelted at 70°C for 5 min and 5 to 10 µl was added to 
100 to 200 µl of competent cells. 
Ligation of vector and inserts were detected by blue/white selection of DH5a 
competent cells on L-agar ampicillin (50 µg/ml) plates onto which 50 µl of 100 
mM IPTG and 20 µl of 2% X-gal had been spread. Plasmids with inserts were 
isolated as described in section 6.2.3. 
6.3 Preparation of DNA fragments for EMSA's 
6.3.1 Preparation of plasmid DNA 
A 500 ml overnight culture of E.coli containing the desired plasmid was harvested 
at 5000 rpm for 10 min in a Beckman JAlO rotor at 4°C. The Qiagen plasmid 
DNA extraction kit (Diagen GmbH, Dusseldorf, Germany) was used to prepare 
plasmid DNA as described by the manufacturers. After precipitation, the DNA was 
washed with 70% ethanol and resuspended at a concentration of 1 µg/µl in sterile 
TE (section 6.11) or sterile water depending on the final use of the DNA. 
6.3.2 Isolation of DNA fragments 
Plasmid DNA was digested with the required restriction enzymes for 2-16 hours 
and the digested material resolved on 7% non-denaturing polyacrylamide gels or 
1 % agarose gels. The band/s of interest was eluted from the gels using one of the 
following methods. 
Chapter 6 Materials and Methods I 150 
6.3.2.1 Crush soak method 
After fractionating the released DNA fragments DNA on non-denaturing 
polyacrylamide gels, the gels were stained with ethidium bromide. The band of 
interest was excised from the gel using a sharp blade, sliced into smaller pieces 
and transferred to a microfuge tube containing 500 µl of DNA extraction buffer 
(section 6.11). This was incubated overnight at 37°C with gentle agitation. The 
buffer was removed and transferred to a fresh microfuge tube. Remaining gel 
slices were washed with 100 µl of DNA extraction buffer which was added to the 
above buffer. The DNA was then precipitated by the addition of 1/10 volume of 
3M sodium acetate and 2.5 volumes of ice cold 96o/o ethanol. The DNA was 
pelleted by centrifugation, washed with 70% ethanol, dried under vacuum and 
resuspended in 1 x TE. Recovered DNA was stored for later use in ligation 
reactions or DNA-protein binding experiments. 
6.3.2.2 Qiaex extraction method 
DNA fragments were fractionated on 0.8% low melting agarose gels in 1 x TAE 
buffer (section 6.11). The required DNA fragment was cut out of the gel and the 
DNA was extracted using the Qiaex gel extraction kit. The method of extraction is 
as described by the manufacturers, (Diagen GmbH, Dusseldorf, Germany). DNA 
prepared using this method was used in ligation experiments only. 
6.4 DNA-protein interactions 
6.4.1 Preparation of nuclear proteins 
Nuclear proteins were extracted from cells using the method of Qignam et al, 
(1983). Briefly, cells grown in 150 mm diameter tissue culture dishes were 
harvested in ice cold PBS using a rubber policeman and pelleted in a Beckman TJ-
Chapter6 Materials and Methods I 151 
6 centrifuge at 2000 rpm at 4 cc for 10 min. Cells grown in suspension were 
centrifuged in a Beckman JAlO rotor. The cells were washed in ice cold PBS, 
pelleted and resuspended in 5 packed cell volumes of buffer A (section 6.11). The 
cells were allowed to swell on ice for 10 min, pelleted again and resuspended in 2 
original packed cell volumes of buffer A. The resuspended cells were lysed using 
10-15 strokes of a tight pestle in a Dounce homogeniser. Cell lysis was checked by 
microscopy. The nuclei were pelleted by centrifugation at 13 000 rpm at 4 cc in a 
Beckman JA20 rotor for 30 min. Pelleted nuclei were resuspended in 1-3 ml of 
buffer C (section 6.11) containing 0.5 mM PMSF, 1 µg/ml pepstatin and 1 µg/ml 
leupeptin and homogenised with 10-15 strokes with the tight pestle of a Dounce 
homogeniser. The homogenised nuclei were transferred to a sterile 50 ml tube and 
gently stirred on ice for 30 min. The salt soluble proteins were separated from 
nuclear debris by centrifugation in a Beckman JA20 rotor for 30 min and 13 000 
rpm at 4cc. The supernatant was dialysed against 50 volumes of buffer D (section 
6.11) for 5 hours at 4cc. The dialysate was centrifuged at 13 000 rpm for 30 min 
in a Beckman JA20 rotor at 4cc and the supernatant stored at -70cC in aliquots of 
20-100 µl. 
6.4.2 End-labelling of DNA 
DNA fragments were end-labelled using the klenow fragment of E. coli DNA 
polymerase. 3 '-recessed ends of double stranded DNA were labelled as described 
by Sambrook et al, (1989). One unit of Kienow DNA polymerase was incubated 
with approximately 200-500 ng of DNA in lX klenow buffer containing 3 .3 mM 
each of dGTP, dATP and dTTP and 20 µCi of [a-
32P]-dCTP. The reactions were 
incubated at room temperature for 3 0 min and stopped by the addition of an equal 
volume of chloroform:isoamylalcohol (24: 1 (v/v)). Unincorporated nucleotides 
were separated from the labelled DNA using sephadex G-50 chromatography. 
Fractions were collected in 150 µl of sterile water and the tubes containing the 
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initial peak of radioactivity were pooled. Ten µI of the pooled fractions were 
counted to calculate the specific activity of the labelled DNA. 
6.4.3 Electrophoretic mobility shift assays (EMSA) 
Four µg of crude nuclear extract was incubated with 2 µg of poly dldC/poly dldC 
and 4 µl of incubation buffer ( section 6.11) in a volume of 20µ1 for 10 min on ice 
prior to the addition of labelled probe. Labelled probe was added at 10
4cpm 
(approximately 1 ng DNA) and the incubation continued for a further 30 min on 
ice (Fried and Crothers, 1981). At the end of the incubation period, 2 µl of 0.25% 
bromophenol blue in 35% glycerol was added. The DNA-protein complexes were 
separated on non-denaturing 5% polyacylamide gels at 150 V for approximately 2 
hours at 4°C in 0.5X TBE. The gels were dried under a vacuum and exposed to X-
ray film for 16 hours. 
6.4.3.1 EMSA Competition experiments 
Competition experiments were performed by incubating the nuclear extracts with 
50 to 200 molar excess of double stranded oligonucleotides for 10 min before the 
addition of the labelled probe. EMSA' s were then completed as described above. 
Sense and anti.sense oligonucleotides were synthesised using a Beckman system 
1000A DNA synthesiser. Double stranded oligonucleotides were produced by 
incubating an equal concentration of complementary oligomers at 90°C for 5 min, 
65°C for 30 min and annealing at 37°C for 1 hour followed by slow cooling to 
room temperature. Annealed oligonucleotides were checked on 12% non-
denaturing polyacrylamide gels. 
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6.4.3.2 EMSA Supershift experiments 
One, 5 and 10 µl of a 1/100 dilution of antibodies against the CCAAT-binding 
factor (CBF) (a kind gift from Drs Heide Eberspaecher and Benoit de 
Crombrugghe, University of Texas) was incubated with nuclear extracts for 30 
min at 37°C in incubation buffer prior to the addition of probe. 2 µg of poly 
dldC/poly dldC was incubated with the antibody/nuclear extract mix for a further 
10 min on ice, followed by the addition of labelled probe as described above. 
DNA-protein complexes were analysed as described in section 3.2.4.2. 
6.5 SDS-Polyacrylamide gel electrophoresis 
6.5.1 Preparation and electrophoresis of gels 
7% Separating gel (for mini gels, final volume 10 ml) were made up as follows: 
distilled water 
1.5 M Tris-Cl (pH 8.8) 
10% sos 
30% acrylamide:bisacrylamide stock (29: 1) 








Chapter6 Materials and Methods I 154 
The gel was cast in a Biorad minigel system, covered with a thin layer of water 
and allowed to set before addition of the stacking gel. 
4% Stacking gel (final volume 5 ml): 
distilled water 
0.5 M Tris-Cl (pH 6.8) 
10%SDS 
30% acrylamide:bisacrylamide stock (29:1) 








The stacking gel was poured on top of the separating gel, a comb inserted and the 
gel left to set at room temperature. 
Protein samples were lyophilised, resuspended in 10-15 µ1 of 2x treatment buffer 
(section 6.11) and 2 µ1 of stop buffer (section 6.11). The samples were heated at 
95°C for 5 min and immediately loaded onto the gel. Gels were electrophoresed in 
approximately 300 ml lx SDS PAGE buffer (section 6.11) at 100 V for 1 hour. 
For collagen gels, protein samples corresponding to radioactivity from 10
6 cells 
were dried, resuspended in 10 µ1 2X treatment buffer, heated and electrophoresed 
as described above. The gels were soaked in EN
3HANCE autoradiography 
enhancer (Du Pont) for 1 hour, rinsed in water for 1 hour and dried. Dried gels 
were exposed to X-ray film for between 16 and 18 hours. 
6.5.2 Transfer of proteins to nitrocellulose membranes 
Transfer of proteins to Hybond C nitrocellulose membranes was done using the 
Biorad minigel transfer system. Transfer buffer (section 6.11) was prepared and 
cooled to 4°C. Nitrocellulose membrane and Whatman 3M paper was cut to the 
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size of the gel, and soaked in transfer buffer for 15 min. A sandwich of filter 
paper, nitrocellulose membrane, gel and filter paper was prepared and placed in 
the transfer apparatus for transfer at 100 V for 1,5 hours at room temperature. 
6.6 RNA extraction and Northern blot analysis 
6.6.1 Preparation of RNA 
RNA was prepared using the method of Chomczynski and Sacchi, (1987). Cells 
were grown to near confluence as described in section 6.1 .1 and fresh meduim was 
added 24 hours before harvesting. The medium was removed and the cell surface 
rinsed with ice cold PBS. Cells growing in suspension were centrifuged at 5 000 
rpm in a Beckman JA20 rotor for 5 min at 4°C. To adherent cells in petri dishes or 
the suspension cell pellet was added 1 ml of guanidinium isothiocyanate (GITC) 
solution D (section 6.11) per 100 mm dish and shaken by gentle oscillation. The 
mixture was transferred to a sterile 15 ml tube followed by the addition of 100 µl 
of 2 M sodium acetate (pH4) and gentle mixing by inversion. An equal volume of 
water saturated phenol was added and the mixture vortexed to disrupt any clumps. 
200 µl of chloroform:isoamylalcohol (49:1) was added to the mixture, vortexed 
and incubated on ice for 15 min. The final suspension was centrifuged at 10 000 
rpm in a Beckman JA20 rotor for 20 min. The aqueous phase was removed, mixed 
with an equal volume of isopropanol and the RNA precipitated overnight at -20°C. 
The RNA was pelleted by centrifugation and washed with 70% ethanol, dried 
under vacuum and dissolved in 20-50 µl of sterile distilled water. The 
concentration of RNA was determined spectrophotometrically and 2 µg of RNA 
was checked on 1 % agarose formaldehyde gels. Gels were stained with ethidium 
bromide and the integrity of the RNA was ascertained by the intactness of the 18S 
and 28S ribosomal RNA. 
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6.6.2 Northern Blot analysis 
6.6.2.1 Electrophoresis of RNA on formaldehyde agarose gels 
Agarose formaldehyde minigels were perpared by boiling 0.4g high-gelling 
agarose in 23 .3 ml distilled water. After the solution cooled down to 
approximately 65°C, 8.53 ml of formaldehyde and 4 ml of lOX RNA running 
buffer (section 6.11) was added. 
To 5 µg of cytoplasmic RNA in 3.3µ1 sterile distilled water was added 1.5µ1 lOX 
RNA running buffer, 7.5µ1 deionised formamide, 2.7µ1 formaldehyde and 1.5µ1 
RNA loading buffer (section 6.11) 
The samples were heated for 10 min at 55°C, before loading on 1% agarose 
formaldehyde gels. Gels were run at 30 mA in IX RNA running buffer (section 
6.11), with stiring of the buffer eve.ty 30 min. RNA was transferred overnight to 
nylon membranes (Amersham Hybond-N) using the sandwich method (Sambrook 
et al, 1989). The success of transfer was ascertained by staining the gel with 
ethidium bromide after transfer. The membranes were rinsed in 6X SSC and the 
RNA cross-linked using an ultraviolet cross-linker (Spectrolinker, XL-1000 UV 
crosslinker). 
6.6.2.2 Random prime labelling of DNA probes 
The labelling reaction was performed as described by the manufacturers 
(Boeringher Mannheim). 25 ng of DNA was heated at 95°C for 5 min and labelled 
in a reaction volume of 20 µI containing, 2 µI reaction buffer, 3.3 mM of dGTP, 
dATP, dTTP, 5 µI of [a.-32P]-dCTP and 1 unit of Kienow DNA polymerase for 1 
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hour at 37°C. Labelled DNA was seperated from unincorporated nucleotides by 
chromotography on sephadex G-50 columns. 
6.6.2.3 Hybridisation of probes to Northern blots 
UV Cross-linked membranes were prehybridised for 4 hours at 42°C m a 
hybridisation oven in 10 ml of hybridisation buffer (section 6.11). 
DNA was labelled with [a-32P]-dCTP using the random primed labelling system, 
heated at 99°C for 5 min, cooled on ice and added to the hybridisation mix at a 
concentration of 1-2 X 106 cpm/ml. Hybridisation was for 18-48 hours at 42°C in 
a Hybaid hybridisation oven. The membranes were washed twice at room temp for 
15 min in 2X SSC and 0.1 % SDS, followed by two stringent washes at 65°C in 
O.lX SSC and 0.1% SDS. Membranes were sealed in plastic bags and exposed to 
X-ray film for 16 hours. 
6. 7 Nuclear Run-on Transcription Assay 
One to five 150 mm culture dishes or 175 cm
2 tissue culture flasks containing 5 to 
50 X 106 cells were used for the isolation of nuclei as described in Current 
Protocols, (1990). Extracted nuclei were stored in 200 µl glycerol storage buffer at 
-70°C. 
6.7.1 Nuclear run-on transcription 
Nuclear run-on transcription assays were performed usmg the method of 
Greenberg and Ziff, (1984). 200 µl of nuclei was added to 200 µl of 2x reaction 
buffer (section 6.11) containing 1 mM of each, GTP, ATP, CTP and 5 µl [a-
32P]UTP (10 mCi/ml) for 30 min at 30°C. Six hundred µl of a solution containing 
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40µg RNase-free DNase in HSB buffer (section 6.11) was added to the labelled 
nuclei and incubated for a further 5 min at 30°C, followed by the addition of 200 
µl of SDS/fris buffer (section 6.11), 10 µl of 20 mg/ml proteinase Kand further 
incubation at 42°C for 30 min. The sample was mixed vigorously with an equal 
volume of phenol:chloroform:isoamyl alcohol (25:24: 1) and centrifuged at 2000 
rpm in a Beckman TJ-6 centrifuge at room termperature. The aqueous layer was 
removed and 2 ml of sterile water, 3 ml 10% TCN60 mM sodium pyrophosphate 
and 10 µl of 10 mg/ml E. coli tRNA was added to precipitate the RNA for 30 min 
on ice. The precipitate was filtered onto Millipore type HA filters (0.45-µm) and 
washed 3 times in 10 ml of 5% TCAf30 mM sodium pyrophosphate. The filters 
were transferred to a scintillation vial and incubated for 30 min at 37°C in 1.5 ml 
ofDNase I buffer (section 6.11) containing 37.5 µl of 1 mg/ml RNase-free DNase 
I. The reaction was quenched by the addition of 45µ1 of 0.5 M EDTA and 68µ1 of 
20% SDS, heated at 65°C for 10 min to elute the labelled RNA. The supernatant 
was removed and 1.5 ml elution buffer (section 6.11) was added to the filter, 
incubated for 10 min at 65°C and the two supernatants combined. 4.5 µl of 20 
mg/ml proteinase K was added to the combined supernatants and incubated at 
37°C for 30 mm followed by adding an equal volume of 
phenol:chloroform:isoamyl alcohol (25:24: 1), centrifugation and removal of the 
aqueous phase. 0.75 ml of lM NaOH was added to the solution and left on ice for 
10 min. The reaction was neutralised by the addition of 1.5 ml of lM HEPES (free 
acid). Labelled RNA was precipitated overnight at -20°C by the addition of 0.53 
ml (1/10 the volume) of 3M sodium acetate and 14.5 ml (2.5 volumes) absolute 
ethanol. The precipitant was pelleted by centrifugation at 10 000 rpm at 4°C in a 
Beckman JA20 rotor for 30 min and resuspended in 0.5 ml TES solution (section 
6.11 ). 5 µl RNA samples were counted in liquid scintillation fluid to check the 
incorporation of labelled UTP into RNA. To the balance of the RNA solution an 
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equal volume of TES/NaCl solution (section 6.11) was added for use m 
hybridisation reactions. 
6. 7.2 Hybridisation of RNA transcripts to cDNA 
6. 7.2.1 Preparation of nitrocellulose filters for nuclear run-on transcription 
assays 
200µg of plasmid was linearised by digestion with an appropriate restriction 
endonuclease. 49 µI of lM NaOH was added to the linearised DNA (in a volume 
of 440µ1) and incubated for 30 min at room temperature. After incubation, 4.9 ml 
of 6X SSC was added to neutralise the sample and the mixture placed on ice. The 
slot blot apparatus was set up with 0.45-µm nitrocellulose membrane and 125 µl of 
sample ( --5 µg cDNA plasmid) was added per slot under a low vacuum provided by 
a venturi apparatus. The slots were rinsed with 500 µI 6X SSC, the nitrocellulose 
filters dried overnight and baked for 2 hours in a vacuum oven at 80°C. 
6. 7.2.2 Hybridisation reactions 
cDNA plasmids immobilised on nitrocellulose membranes as described in section 
6.7.2.1 were hybridised with 1 x 10
6 cpm of RNA in 1ml of TES/NaCl solution 
(section 6.11) for 48 hours at 65°C in sealed vials. After hybridisation, the filters 
were washed twice in 2X SSC for 30 min at 65°C. The filters were removed from 
the vials and transferred to 8 ml of 2X SSC containing 80 µg of RNase A and 
incubated for 15 min at 37°C. A final wash with 2X SSC at 37°C for 10 min was 
performed, the filters were blotted on Whatman 3MM paper and exposed to X-ray 
fihn for 24-48 hours. 
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6.8 DNA sequencing 
Sequencing was performed by the method of Sanger et al, (1977), using the 
dideoxy chain termination reaction. The protocol was performed as described by 
the manufacturer of Sequenase™ (United States Biochemical Corporation, 
Cleveland, Ohio). 2-3 µg of double stranded plasmid DNA was denatured in 0.2M 
NaOH in 0.2 mM EDTA for 5 min at room temperature and neutralised by the 
addition of 1/10 the volume of 2M ammonium acetate (pH 4.6) and 2.5 to 3 
volumes of 96% ethanol to precipitate the DNA at -70°C for 15 min. The DNA 
was pelleted, washed in 70% ethanol, dried and redissolved in 7 µl of sterile 
distilled water. To this was added 1 µl of primer (50 ng/µl), 2 µl of sequenase 
buffer (section 6.11) and incubated at 65°C for 10 min for the primers to anneal. 
The reaction was slow cooled by incubation at 37°C for 30 min followed by 
cooling at room temperature for 1 hour. Labelling and termination reactions were 
carried out as described by the manufacturers and 3 µl of the final sample was 
analysed on 6% denaturing-polyacrylamide sequencing gels. 
Automated sequencmg were performed by a core facility usmg an Applied 
Biosynthesis Model 373A Version 2.10.lS automated sequencer. 
6.9 Transient Transfection Experiments 
6.9.1 Preparation of cells 
Cells were grown on 150 mm diameter tissue culture dishes as described in section 
6.1. Transient transfections were performed in triplicate using the calcium 
phosphate-DNA precipitation method (Graham and van der Eb, 1973). Confluent 
cells on a 150 mm tissue culture dish was trypsinised and seeded into ten 100 mm 
tissue culture dishes. These were grown to 30-40% confluency in the required 
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medium prior to the addition of the DNA-CaP04 precipitate. Four hours before 
addition of the DNA-CaP04 precipitate the medium was replaced with fresh 
growth medium containing 10% heat inactivated foetal calf serum. 
6.9.2 Preparation of the DNA-CaP04 precipitate 
CaCli, TTE and DNA cocktail was prepared in a clear 10 ml plastic tube as 




internal control plasmid, CMV-Pgal 
345 µl 
60 µl 
10 µl (lOµg) 
5 µl (5µg) 
This cocktail was added dropwise to 420 µl of 2X HBS with constant agitation. A 
fine precipitate formed and was left at room temperature for 30 min. The 
suspension was distributed dropwise onto the cells and was incubated for 24 hours 
in 5% CO2 at 37°C. The medium was aspirated, cells rinsed with PBS and fresh 
medium was added for an additional 24-48 hours. 
6.9.3 Extraction of protein from transfected cells 
The medium was removed, replaced with 5 ml of trypsin and incubated at 37°C for 
2 min. 5 ml of fresh medium was added and the cells dislodged from the 
substratum by a gentle pipetting motion. The mixture was transferred to a 10 ml 
tube on ice and centrifuged at 2000 rpm at 4°C in a Beckman JA20.1 rotor for 5 
min. The pellet was washed with ice cold PBS, centrifuged and resuspended in 
100 µl of 0.25 M Tris-HCl (pH 8) The cell extract was freeze/thawed for three 
cycles, by freezing in liquid nitrogen and immediate thawing in a 37°C waterbath. 
Released cellular proteins were separated from .cell debri by centrifugation in a 
Chapter 6 Materials and Methods I 162 
microfuge for 5 min. The supernatant was removed, frozen and stored at -20°C for 
P-galactosidase and CAT assays. 
Protein concentrations were determined using the Biorad reagent as described by 
the supplier. 
6.9.4 J3-galactosidase assay 
50 µg of cell extract was mixed with 50 µl of a 4 mg/ml 0-nitrophenyl-P-D-
galactopyranosidase (ONPG), 3 µl of IOOX Mg
2
+ buffer (section 6.11), adjusted to 
300 µl with 0.1 M NaP04 and incubated at 37°C for 1 hour by which time a 
yellow colour was clearly visible. The reaction was stopped by the addition of 500 
µl of IM Na2C03 and the optical density measured at 420 nm. Protein extracts 
from cells where no DNA was included in the transfection was used as a blank. 
6.9.5 CAT Assays 
CAT activity was measured using the protocol of Seed and Sheen, (1988). Briefly, 
50 µg of cell extract was incubated with 2 µl of 
14C-chloramphenicol, 5 µl of n-
butyryl CoA (5mg/ml) and the volume adjusted to 125µ1 with 0.25 M Tris/HCl pH 
8.0. After incubation at 37°C for 16 hours, 300 µl of xylene (this extracts the 
butyrylated chloramphenicol into the xylene phase while unbutyrylated 
chloramphenicol remains in the aqueous phase) was added, mixed by vortexing, 
followed by centrifugation and the xylene phase (upper) removed to a fresh 
microfuge tube. 100 µl of 0.25 M Tris pH '8 was added to the xylene phase , re-
extracted as above, and 200 µl of the xylene phase transferred to a scintillation 
vial. Label incorporation was determined by counting in a Packard Tri-carb 4640 
liquid scintillation counter. 
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The relative CAT activity was calculated as follows: 
(CAT activity in experimental sample) - (background CAT activity) 
(P-galactosidase activity of experimental sample) - (background P-gal activity) 
6.10 Screening of Agtll expression libraries 
6.10.1 Concatemerisation of CME oligomer 
Equal concentrations of CME oligonucleotides (a) and (b) (section 6.4.3 .1) were 
incubated with 20 µl of 10 x polynucleotide kinase buffer in a total volume of 130 
µland incubated for 2 min at 90°C, 10 min at 65°C, 10 min at 37°C and 5 min at 
room temp. 15 µl of a 20 mM ATP stock and 10 units ofT4 polynucleotide kinase 
was added and the reaction incubated for 2 hours at 37°C. The kinase reaction was 
stopped by the addition of 50 µl of 10 M ammonium acetate, 100 µl of water and 
heated for 15 min at 65°C. This was followed by cooling to room temperature, the 
phosphorylated oligonucleotides were precipitated with 2.5-3 volumes of 96% 
ethanol and ligated to form concatemers. 
6.10.2 PCR-generated probes for screening 1gtll expression libraries 
Harline et al, (1992) demonstrated that probes labelled by PCR are superior to 
probes prepared by conventional labelling methods in the successful screening of 
Agtl 1 cDNA expression libraries. Concatemerised CME oligonucleotides were 
cloned into pUC19 and the M13 universal primers were used to prepare labelled 
probes by PCR. 5 ng of plasmid DNA ( containing concatemerised CME), 50 ng of 
each of forward and reverse primers, 1 mM of dGTP, dATP and dTTP , 10 µl of 
[a-32P]-dCTP, 5 µl of lOx Taq polymerase reaction buffer and 2 units of 
Boeringher Mannheim Taq polymerase were prepared in a reaction volume of 50 
µl . The conditions for the PCR amplification were 30 cycles of 95°C for 1 min, 
58°C for 1 min and 72°C for 1 min for 30 cycles. 
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After PCR, the reaction volume was increased to 150 µl with sterile water and 
extracted with an equal volume of phenol:chloroform:isoamyl alcohol (25:24: 1). 
The labelled PCR products was separated by chromatography on a sephadex G-50 
column. 
6.10.3 Screening of a lgtll expression library 
50 µl of E. coli Y1090 from a glycerol stock was inoculated in 10 ml of L-broth 
containing 50 µglml ampicillin and 0.4% maltose. The culture was incubated 
overnight at 37°C with shaking. 50 µl of the overnight culture was inoculated into 
fresh L-broth and incubated at 37°C until an OD550 of between 0.6 and 0.9 was 
reached. The cells were pelleted by centrifugation at 2000 rpm in a Beckman TJ-6 
centrifuge for 10 min and resuspended in 10 ml of 10 mM MgS04. The cell 
suspension was stored at 4 °C and could be used for up to two weeks. 
11.gtll cDNA libraries, titre 1 x 109 pfu/ml, were serially diluted in SM buffer to · 
104, 103 and 102 pfu/ml. 600 µl of Y1090 cells were incubated with 400 µl of 
diluted phage in SM buffer, incubated at 37°C for 20 min followed by the addition 
of 8 ml of top agar (section 6.11) (at 45°C) and mixed by gentle inversion of the 
tube. The top agar mixture was poured onto 150 mm luria agar plates. Plates were 
left to set at room temperature and transferred to a 42°C incubator until pin-prick 
sized plaques were visible (usually 3-4 hours). They were then overlayed with 
nitrocellulose membranes (Hybond-C, Amersham) saturated in 10 mM IPTG and 
incubated overnight at 37°C. 
After overnight incubation, the position of the filters were marked with needle 
holes and the filters removed from the plates. The plates were stored at 4 °C and 
the filters dried with the protein side up on Whatman 3 MM paper for 20 min. The 
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filters were processed by denaturation/renaturation using 6.6 M guanidine HCl in 
lx binding buffer (Vinson et al, 1988). Denaturation/renaturation was performed 
by sequential dilution of the 6.6 M guanidine HCl as described below. The filters 
were washed in a solution containing 450 ml of 6.6 M guanidine HCl, 50 ml lOx 
binding buffer (section 6.11) and 0.5 ml lM DTT for 5 min. This was decanted, 
replaced with fresh 6 M guanidine HCl and the wash repeated. The used 6 M 
guanidine was diluted to 3M with lx binding buffer and the filters washed for 5 
min. Washes with diluted guanidine HCl were continued down to 1.5, 0.75, 0.375 
and 0.188 M guanidine HCI. The filters were rinsed twice in lx binding buffer and 
then blocked with 5% instant non-fat dry milk in lx binding buffer containing 
0.05% Tween-20 with gentle shaking for 2 hours. 
Binding of PCR labelled concatemerised CME probe (10
6 cpm/ml) to proteins on 
filters was performed in lx binding buffer, 0.25% milk powder, 5 µg/ml herring 
sperm DNA, 0.5% Tween-20 for 1-2 hours at 4°C. The filters were washed for 15 
min each in three changes of binding buffer containing 0.25% milk powder. 
Excess moisture was removed by blotting the filters on Whatman 3MM paper. The 
filters were sealed in plastic bags and exposed to X-ray film for 2-16 hours. 
6.10.4 Purification of positive clones 
Positive clones producing proteins that bound the radioactive probe were detected 
by autoradiography. The position of the filters were marked on the 
autoradiographs and aligned with the plates. The positive plaques were cored out 
using a sterile pasteur pipette and transferred to 500 µl of SM buffer in a 
microfuge tube. 5 µ1 of chloroform was added and the tube incubated overnight at 
4 °C. The titre of the eluted phage was determined and the phage plated at a low 
density for rescreening. The screening process (section 6.10.3) was repeated until 
all the plaques on the plates were positive. 
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6.10.5 Controls for screening 
In order to determine whether the CME probe may cross react with phages other 
than the potential positives, 600 µl of E. coli Y1090 cells in 10 mM MgS04 was 
added to 4 ml of top agar ( 45°C), inverted and poured on L-agar plates. The plates 
were allowed to set for 20 min and then incubated at 37°C for 2 hours. Purified 
phage stocks (including the negative controls; Agtl 1 chicken ovalbumin, Agtl 1 
only and negative clones isolated from primary screens) were spotted onto the 
lawn of cells in clearly marked positions and incubated at 42°C for 3 hours. At the 
appearance of tiny plaques, IPTG saturated filters were placed on the lawn and the 
plates incubated for 6 hours at 37°C. The filters were removed and processed as 
described in section 6.10.3. 
Positive clones were also spotted in duplicate and the filters prepared as described 
above. The filters were then divided into two for hybridisition with either the CME 
or an oligomer spanning -57 to -43 of the a2( 1) procollagen promoter previously 
shown not to bind any trans-acting factors. 
6.10.6 Rapid analysis of Agtll fusion proteins 
Liquid cultures of E. coli Y1090 infected with recombinant Agtll were induced 
directly to produce fusion proteins as described by Runge, (1992). 400µ1 of Y1090 
in 10 mM MgS04 was incubated for 2 hours at 37°C with 100µ1 phage dilution 
(1/100) in 8ml of L-broth containing 50µg/ml ampicillin. After 2 hours a 1ml 
aliquot was removed and processed as described below. To the rest of the culture 
(7ml), 70µ1 of lM IPTG was added and the incubation continued. One ml aliquots 
were collected on a hourly basis up 3 hour post-induction at 37°C. Processing of 
aliquots: The infected cells were pelleted by centrifugation in a microfuge for 1 
min at room temperature. The supernatant was removed and the pellet resuspended 
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in 100µ1 of lx SDS loading buffer containing lµl of lOOmM PMSF, lµg/ml each 
of leupeptin and pepstatin. The samples were boiled for 3 min and stored at -70°C 
for later analysis. 25 µl of sample were analysed on 7% polyacrylamide SDS gels 
and proteins transferred to nitrocellulose membranes as described in section 6.5.2. 
South western blotting was performed using- the same method described in 
screening of Agtl 1 expression libraries with labelled concatemerised probes 
(section 6.10.3) Membranes were exposed to X-ray film for 16 hours at -70°C. 
6.10.7 Western Blotting using an anti-13-galactosidase antibody 
p-galactosidase fusion proteins immobilised on nitrocellulose membranes were 
prepared as described in section 6.10.6. The membranes were blocked with Tris-
buffered saline (TBS) (section 6.11) containing 5% milk powder and 0.2% Tween 
20 for 1 hour at room temperature. The filters were incubated with 500µg/ml 
mouse anti-P-galactosidase antibody in incubation solution (TBS containing 2% 
milk powder and 0.2% Tween 20) for 45 min at room temperature, followed by 
repeated washing in incubation solution without antibody. A 1/750 dilution of 
sheep anti-mouse IgG-peroxidase in incubation solution was reacted with the 
membranes for 45 min at room temperature. The membranes were washed in 
incubation solution followed by a final wash in TBS. The membranes were 
immersed in 60mg of 4-chloro-naphthol dissolved in a solution containing 20ml 
ice cold methanol, 100ml TBS and 60µ130% hydrogen peroxide until bands were 
visualised. 
6.10.8. Recombinant lysogen detection 
E. coli Y1090 lysogens were isolated by picking colonies surrounding the plaques 
of positive phages. The colonies were steaked on L-agar plates and incubated 
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overnight at 32°C. A number of overnight colonies were selected and plated on 
duplicate L-agar plates. One plate was incubated at 32°C and its duplicate at 42°C. 
Colonies growing at 32°C but not at 42°C represent lysogens. Lysogens were 
inoculated in L-broth and grown overnight at 32°C for preparation of glycerol 
stocks. 
For protein assays, crude proteins were extracted as described by Singh et al, 
(1989). 2 ml ofL-broth containing 50µg/ml ampicillin was inoculated with 20µ1 of 
an overnight culture of lysogen and incubated at 32°C with good aeration until it 
reached an OD600 of 0.5. The cultures were moved to a 44°C waterbath and 
incubated for 20 min. IPTG was added to a final concentration of 10 mM to induce 
the ~-galactosidase promoter and incubated for a further 1 hour at 37°C. The 
induced cells were pelleted by centrifugation in a microfuge for 1 min and the 
pellet resuspended in 200 µl of extraction buff er ( section 6 .11). The resuspended 
cells were frozen in liquid nitrogen, thawed and incubated with 0.5mg/ml 
lysozyme for 15 min on ice. NaCl was added to a final concentration of IM and 
the suspension mixed on a rotator for 15 min at 4°C. The lysates were centrifuged 
for 30 min at 4°C and the supematants dialysed on Millipore filters (type VS, 
0.025µm) against 100ml extraction buffer for 1 hour at 4°C. The dialysed extract 
was frozen and stored at -70°C for later use. 
6.10.9 Analysis of DNA from positive 11.gtll clones 
5 µl of positive phage in SM buffer was heated at 95°C for 5 min followed by 
cooling on ice for 5 min. A PCR reaction mix was prepared consisting of 5 µl 
phage, 50ng each of Agtll forward and reverse primers, lmM dNTP mix, Taq 
polymerase buffer and 2 units of Taq polymerase in a final volume of 50µ1. The 
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PCR reaction procedure was as follows, 95°C for 1 min, 66°C for 1 min and 72°C 
for 1 min for 3 0 cycles. 
PCR products were phosphocylated using T4 polynucleotide kinase (Ausubel et al, 
1987). One unit of T4 polynucleotide kinase was added to 10µ1 of PCR product in 
polynucleotide kinase buffer containing lmM ATP in a final volume of 20µ1 for 1 
hour at 37°C. 
Phosphocylated PCR products were blunt-ended using Kienow DNA polymerase. 
One unit of Kienow, in lx klenow reaction bnff:er containing 0.5mM each of 
dGTP, dATP, dTTP and dCTP was incubated with 10µ1 of PCR product for 30 
min at room temp. The blunt-ended DNA was ligated to pUC19 digested with 
Smal and transformed into competent DH5a as described in section 6.2.2. 
Recombinant plasmids were isolated as described in section 6.2.3. 
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6.11 Buffers and Solutions 
Acrylamide Stock Solution (30%) (29:1) 
29% Accylamide 
1 % Bisaccylamide 
Acrylamide Stock Solution ( 40%) (38:2) 
3 8% Accylamide 
2% Bisaccylamide 
Dignam buffer A 




Dignam buffer C 






1 µg/ml leupeptin 
1 µg/ml pepstatin 
Dignam buffer D 
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0.5 mM DTT, 0.5 mM PMSF, 1 µg/ml each of leupeptin and pepstatin 
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DNA Elution Buffer 
0.5 mM Ammonium Acetate 
10 mM Magnesium Acetate 
lmMEDTA 
Elution Buffer (nuclear run-on) 
1%SDS 
10 mM Tris-Cl (pH 7.5) 
5mMEDTA 
GITC Solution D 
4MGITC 
25 mM Sodium Citrate 
0.5% Sarkosyl 
Add 36µ12-Mercaptoethanol to 5 ml before use 
Glycerol Storage Buffer 




BBS (10 x) (transfections) (per 100 ml of distilled water) 
5.0 g Hepes 
8.0 g NaCl 
0.37 g KCl 
1. 0 g Dextrose 
0.103 g Na2HP04 (anhydrous - 1.45 mM) 
Materials and Methods I 171 
Chapter6 




10 mM Tris-Cl (pH 7.4) 




500 mM sodium pyrophosphate 
deionised formamide 
herring sperm DNA (10 mg/ml) 
10% SDS 
Incubation Buffer (EMSA) (5 x) 





20% Ficoll 400 
L-agar (per litre) 
10 g Tryptone 
5 g Yeast extract 
5 gNaCl 
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L-Broth (per litre) 
10 g Tiyptone 
5 g Yeast Extract 
5 gNaCl 
Lysogen Extraction Buffer 




PBS (pH 7.3) 
137mMNaCl 
2.7mMKCl 
4.3 mM Na2HP04.2H20 
1.4 mM KH2P04 
Protein Transfer Buffer 
25 mMTris 
192 mM Glycine 
20% Methanol 
Reaction Buffer without nucleotides (2 x) 
10 mM Tris-Cl (pH 8) 
5mMMgC12 
0.3 MKCl 
RNA Loading Buffer 
lmMEDTA 
0.25% Bromophenol Blue 
0.25% Xylene Cyanol 
50% Glycerol 
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RNA Running Buffer (10 x) 
200 mM Morpholinopropanesulfonic acid (MOPS) (pH 7.0) 
50 mM Sodium Acetate 
lOm.MEDTA 





SDS-PAGE Running Buffer (5 x) 
0.25 M Tris-Cl (pH 8.3) 




0.5 M Tris-Cl (pH 7.4) 
0.125 MEDTA 
SM A Diluent Buffer 
10 mM Tris-Cl (pH 7.5) 
lOm.MMgCli 
Solution 1 (Rapid plasmid prep) 
25 mM Tris-Cl (pH 8.0) 
lOm.MEDTA 
50 mM Glucose 
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Solution 2 (Rapid plasmid prep) 
200mMNaOH 
1%SDS 
Solution 3 (Rapid plasmid prep) 
3 M Potassium Acetate (pH 4.8) 
SSC (20 x) (per litre) 
3M NaCl 
0.3M sodium citrate.2H20 (pH 7.0) 
Stop Buffer 




T4 Polynucleotide kinase buffer (10 x) 
500 mM Tris-Cl (pH 7.6) 
lOOmMMgC}i 
50mMDTT 
1 mM Spermidine 
1 mM EDTA (pH 8.0) 
TAE Electrophoresis Buffer (1 x) 
40mMTris 
5 mM Sodium Acetate 
lmMEDTA 
pH 7. 8 with glacial acetic acid 
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TBE Electrophoresis Buffer (1 x) (pH 8.3) 
90mMTris 
90 mM Boric Acid 
2.5mMEDTA 
TE buffer (10 x) (pH 8.0) 
100 mM Tris-Cl 
lOmMEDTA 
TES Solution 
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Top agar (per litre) 
10 g Tryptone 
5 g Yeast extract 
5 gNaCl 
7 g Bacto-agar 
Treatment Buffer (2 x) 






Tris Buffered Saline (TBS) 
25 mM Tris (pH 7.5) 
0.9% w/v NaCl 
TTE (transfections) 
1 mM Tris-Cl (pH 8.0) 
0.025 mM EDTA 
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